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Abstract 
Hyperactivated microglia plays a key role in regulating neuroinflammatory responses 
which propagate damage to neurons. In recent years, substantial attention has been 
paid in identifying new strategies to abrogate neuroinflammation. Tiliroside, a dietary 
glycosidic flavonoid found in several medicinal and dietary plants is known to 
possess anti-inflammatory and antioxidant activities. This study is aimed at 
investigating the molecular mechanisms involved in the inhibition of 
neuroinflammation by the tiliroside.  
Neuroinflammation inhibitory effects of tiliroside (2-6 µM) were investigated in BV2 
microglia stimulated with a combination of LPS (100 ng/ml) and IFN (5 ng/ml). 
Results show that tiliroside significantly reduced the production of pro-inflammatory 
cytokines IL-6, TNFα, IL-1β while increasing the production of anti-inflammatory 
cytokine IL-10 in LPS/IFN-stimulated BV2 microglia. The compound reduced NO 
production in LPS/IFN-stimulated BV2 cells through inhibition of iNOS protein 
expression. Tiliroside also suppressed COX-2 protein expression and inhibited PGE2 
production in activated microglia. Western blotting and functional experiments 
revealed that inhibition of neuroinflammation by tiliroside was shown to be mediated 
through inhibition of NF-B and p38 MAPK signalling pathways. Also, the compound 
activated SIRT1 and inhibited the expression of acetylated-NF-B-p65 in LPS/IFN-
activated BV2 microglia. Further experiments revealed that inhibition of 
neuroinflammation by tiliroside is not dependent on SIRT1. Tiliroside increased the 
levels of Nrf2, HO-1 and NQO1 antioxidant proteins, indicating an activation of the 
Nrf2 protective mechanisms in the microglia. Furthermore, transfection of BV2 cells 
with Nrf2 siRNA resulted in the loss of anti-inflammatory activities of tiliroside. 
Results of neurotoxicity experiments showed that neuroinflammation-induced 
neurodegeneration, DNA fragmentation, ROS generation and calcium accumulation 
were significantly reduced in HT22 neurons when exposed to conditioned medium 
from BV2 microglia that were pre-treated with tiliroside prior to stimulation with 
LPS/IFN.  
Results from this study suggest that tiliroside inhibits neuroinflammation in 
LPS/IFN-activated BV2 microglia by targeting NF-B and p38 MAPK signalling 
pathways. Furthermore, the compound activated Nrf2 antioxidant mechanisms in the 
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microglia, which appears to contribute to its anti-inflammatory activity. The study also 
established that tiliroside protects HT22 neurons from neuroinflammation-induced 
toxicity.  
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Chapter 1. General introduction 
Inflammation is a physiological response that is triggered by the immune system, 
especially macrophages in the body to remove any harmful stimuli such as 
pathogens, damaged cells, local injury and irritants by releasing inflammatory 
mediators such as cytokines, platelets and chemokines. The word inflammation was 
derived from Latin "inflammo”, which means "I set a light or I ignite" (Didonato et al. 
2012). Such immediate or acute immune response by the body is beneficial; 
however, sustained or chronic production of inflammatory mediators like cytokines is 
thought to be the starting point for several fatal diseases like obesity, cancer, 
coronary artery diseases and neurodegenerative diseases (Zhang & An 2007). 
Tumour necrosis factor (TNF), interleukins (IL), interferon’s (IFN), haemopoietic 
growth factor (HGF) and growth factor (GF) are historically termed as cytokines. 
Moreover, these pro-inflammatory cytokines are critical in the initiation of various 
inflammatory responses in the body. 
1.1 Immunology of the central nervous system 
The mammalian central nervous system (CNS) is a vital organ that has been 
considered as ‘an immune privileged site’, protected from the influx of peripheral 
immune cells and inflammatory mediators by an intact blood-brain barrier (BBB) 
(Fonseca et al. 2014). However, evidence from recent studies suggests that during a 
variety of CNS pathologies the brain has shown to be interactive with the peripheral 
immune system (Wohleb & Godbout 2013). It has been well demonstrated and 
accepted that disruption of BBB leads to this effective interaction (Konczol et al. 
2013). Also, the presence of peripheral macrophages and immune cells in the CNS 
activates brain parenchymal cells such as microglia and astrocytes, which further 
initiate the production of inflammatory mediators like cytokines and chemokines. This 
acute inflammatory response by microglia seems to protect neurons in the CNS. 
However, uncontrolled release of cytokines could damage surveillance capacity of 
the microglia that eventually induces neuronal death (Abbott et al. 2010) and (Carvey 
et al. 2009). 
1.1.1 Neuroinflammation: a pathological perspective  
Inflammation is an acute or chronic reaction of tissues in the brain to the local injury 
(Streit et al. 2004). Acute inflammation is a defensive response specifically referred 
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to the accumulation of activated glial cells that comprises the immediate response to 
an injurious agent that resolves and repairs the damaged site. Chronic inflammation 
results from a broad spectrum of stimuli that are persistent or sustained cycles of 
injury and response. The deleterious effects of immunological microglia and 
astrocyte activation contribute to neurodestructive effects thus worsening the 
disease process through their actions (Streit et al. 2004) and (Peterson & Toborek 
2014).  
Microglia are the resident immune macrophages of the CNS that play a complex role 
in various immunological functions and neural activities. Under physiological 
conditions, ramified microglia are shown to regulate homoeostasis by controlling the 
production of cytokines, brain-derived neurotrophic factor (BDNF) and transforming 
growth factor (TGF) β in the brain (Miranda et al. 2015). In contrast, under 
pathological events, such as infection, local injury, ischemia, altered neuronal 
function, toxic insults and inflammation, ramified microglia becomes activated and 
changes to an amoeboid morphology and produce excess inflammatory mediators 
(Knott et al. 2000) and (Montgomery & Bowers 2012). In addition, microglia are 
known to recognise a variety of molecular targets, such as nucleotides, lipoproteins, 
abnormally processed, modified or aggregated proteins (e.g., Aβ) and various 
inflammatory cytokines which are considered as the strongest inducers (Michelle L. 
Block et al. 2007). Depending on the phenotype of the microglia, they can exert a 
variety of functional properties, which may be either neurotoxic or neuroprotective.  
However, under severe pathological circumstances, microglia become hyper-
activated and can induce uncontrolled detrimental neurotoxic effects by the excess 
production of a vast array of cytotoxic factors.  Such as pro-inflammatory cytokines, 
chemokines like MCP-1α, MIP-α and CXCL-8, nitric oxide (NO), prostaglandin E2 
(PGE2) and neurotoxic reactive oxygen species (ROS) (Hamadi et al. 2016), (Kim & 
Cho 2008) and (Zhang & An 2007). Furthermore, pro-inflammatory cytokines such 
as interleukin-1beta (IL-1β), interleukin 6 (IL-6), and tumour necrosis factor α (TNFα), 
primarily mediate and facilitate a broad spectrum of neural activities and 
inflammatory processes in the brain (Sahu et al. 2013), (Kaushik et al. 2013) and 
(Lynch et al. 2004). Particularly, during the early period of neurodegenerative 
disease development, the role of activated pro-inflammatory cytokines could be 
diverse, ranging from adjacent microglial activation to neuronal death or damage in 
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the CNS (Gibbons & Dragunow 2006). Due to these neurotoxic mediators, 
understanding the causes and defining the characteristics of deleterious microglial 
activation in neurodegenerative disease has become a recent focus of research. 
1.2 Role of neuroinflammation in neurodegenerative diseases  
Neuroinflammation has been identified as a primary suspect in the pathologies of 
several neurodegenerative CNS disorders. Such as Alzheimer's disease (AD), 
Parkinson's disease (PD), multiple sclerosis (MS), Huntington's disease (HD), 
amyotrophic lateral sclerosis (ALS), and tauopathies (Zecca et al. 2004), (Bal-Price 
& Brown 2001) and (Hsieh & Yang 2013). Due to the complexity of the events in 
neuroinflammation, it is unclear whether these responses from microglial activation 
and astrogliosis are beneficial, detrimental or neutral against neighbouring neurons. 
Studies in various animal models of neurodegenerative diseases revealed that 
chronic microglial activation and associated neuroinflammation is primarily involved 
in the progression of neuronal damage and death (Jurgens & Johnson 2012) and 
(Geller et al. 2001). In murine models of PD and ALS as well as in human AD brain 
tissue samples, upregulation of various microglial pro-inflammatory cytokines and 
other neurotoxic factors was observed. These studies further suggest that active 
microglia are the principle mediators of neurodegenerative conditions (Hamadi et al. 
2016), (Mitra et al. 2015) and (Trepanier & Milgram 2010).  
In adverse neurological diseases, neurons experience a primary insult that 
predisposes them to cell death, probably through elevated levels of pro-inflammatory 
cytokines and ROS-mediated oxidative stress (Zhang et al. 2016). Also, excess nitric 
oxide production during chronic inflammatory conditions by activated glia can induce 
neuronal death by causing selective inhibition of mitochondrial cytochrome C 
oxidase in neurons releasing high levels of ROS into the cytoplasm (Watanabe et al. 
2000) and (Uttara et al. 2009). Some epidemiological studies have also confirmed 
the presence of toxic inflammatory mediators like TNFα, IL-1β, IL-6, ROS and RNS 
in the cerebrospinal fluid (CSF) of patients with PD (Poloni et al. 2000). 
In addition, elevated levels of TNFα mRNA and its associated dopaminergic 
neuronal death were observed in the substantia nigra of rodent midbrain within the 
hours of administration of two neurotoxins, 6-hydroxydopamine (6-OHDA) and 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This study further highlights the 
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deleterious effects of inflammatory mediators on neuronal viability (Barcia et al. 
2005) and (Zhang et al. 2016). These studies also revealed the extent of TNFR1 and 
TNFR2 receptor expression on the neurons and it is assumed that excess TNFα 
produced during inflammation will bind to these receptors and induce neuronal death 
in the brain.  
It has been hypothesised that pro-inflammatory cytokines such as TNFα and IL 1β 
from hyperactive microglia are capable of causing redox imbalance and DNA strand 
breakage in neurons (Vauzour et al. 2015) and (Michelle L. Block et al. 2007). Also, 
elevated microglial activation in various regions of the brain such as basal ganglia, 
striatum, frontal and temporal cortical regions was observed from patients with 
idiopathic PD when compared to healthy age-matched controls (Gerhard et al. 
2006). These observations help to understand that persistent activation of microglia 
in the midbrain are due to the elevated levels of inflammatory cytokines and 
oxidative stress acting in an autocrine or paracrine manner to potentiate 
neurodegenerative responses. 
Additional evidence that neuroinflammation is intimately involved in neuronal 
degeneration is the blood-brain barrier studies. It is evident from several cell culture 
and animal studies that the permeability of the BBB increases with age and excess 
cytokine production (e.g. TNFα) during inflammation and the likelihood of peripheral 
immune cell infiltration into the CNS (Abbott et al. 2010) and (Tajes et al. 2014). This 
means that cytokines produced by brain-resident microglia may not be acting alone 
in mediating neuron cell death, but peripheral circulating neurotoxic factors may also 
involve in inducing neuronal dysfunction and in facilitating the development of 
various neurodegenerative diseases.   
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Figure 1.1 Self-propelling cycle of neuroinflammation and its associated neuronal 
death. Source:- (Frank-Cannon et al. 2009). RNS: Reactive nitrogen species, ROS: 
Reactive oxygen species. 
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1.4 Role of pro-inflammatory cytokines and other inflammatory mediators in 
neuroinflammation 
Cytokines released at low levels during normal physiological situations are shown to 
mediate survival signals between microglia and adjacent neurons/astrocytes in the 
CNS. These are divided into pro-inflammatory and anti-inflammatory cytokines, 
which facilitate and inhibit inflammatory responses, respectively. Among all the pro-
inflammatory cytokines TNFα, IL-1β and IL-6 are most widely investigated in 
neuroinflammation processes (Ramanan et al. 2008) and (McGeer & McGeer 2015). 
These have been shown to play a central role in initiating and regulating the cytokine 
cascade during an inflammatory response and have been shown to release 
consistently by activated microglia, along with other neurotoxic substances. 
Specifically, TNFα activates various pro-apoptotic signalling mediators such as 
caspases, MAPK (i.e. p38 MAPK, JNk1/2), NF-B and several other inflammatory 
genes, while IL-6 and IL-1β induce morphological alterations in the microglia 
(Hehlgans & Pfeffer 2005) and (Park & Bowers 2010).  
In addition, recent studies showed that when microglia stimulated with fibrillar Aβ, 
excess production of pro-inflammatory cytokines was observed and further studies 
show activated phagocytic oxidase (PHOX), that increased the levels of superoxide, 
peroxynitrite and damaged adjacent neurons (Chan et al. 2009) and (Brown & Neher 
2010). Also, these pro-inflammatory cytokines have shown to activate adjacent 
microglia and astrocytes in the CNS (Park & Bowers 2010). It appears from the 
studies conducted by various investigators that specific inhibition of cytokine 
production in the neuroinflammation by active microglia may serve as a better 
strategy to ablate neurodegenerative conditions. Pro-inflammatory cytokines that 
have attracted a lot of attention in recent years were discussed below. 
1.4.1 Tumour necrosis factor alpha (TNFα) 
Tumour necrosis factor alpha (TNFα) is one of the important pro-inflammatory 
cytokine released by microglia that has shown to employ both homeostatic and 
pathophysiological roles in the CNS (Olmos & Llad 2014). In the healthy brain, the 
broad spectrum of regulatory functions by TNFα involves food and water intake, 
memory and learning, synaptic plasticity, sleep and astrocyte-induced synaptic 
strengthening (Kim et al. 2016). However, hyperactivated microglia release 
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significant amounts of TNFα which is shown to be involved in several neurological 
disorders such as AD and PD (Zhang & An 2007).  
Initially, TNFα cytokine is synthesised as transmembrane protein (tmTNFα) which is 
later cleaved by matrix metalloprotease TNFα-converting enzyme (TACE) to release 
soluble TNFα (sTNFα) homotrimer (Idriss & Naismith 2000). The typical signal 
transduction of TNFα involves binding of sTNFα to two distinct surface receptors. 
Those are TNFα receptor 1 (TNFR1) and TNFα receptor 2 (TNFR2). These 
receptors are entirely different in their expression pattern and binding affinity for 
TNFα, however, the significant difference is the presence of cytoplasmic death 
domain tail on TNFR1, as this motif is entirely missing in TNFR2 (MacEwan 2002) 
and (Montgomery & Bowers 2012).  
Studies have shown that activation of TNFR1 signalling results in the induction of 
various intrinsic signal transduction pathways. Such as nuclear factor-kappa B (NF-
B), c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and 
p38 mitogen-activated protein kinase (p38 MAPK) (Adli et al. 2010) while TNFR2 
activation has shown to maintain homoeostasis functions of the CNS 
microenvironment (MacEwan 2002). Also, TNFR signalling pathways control the 
expressions of several inflammatory genes; particularly those regulated by the NF-
B signalling have shown to possess anti-apoptotic effects at low levels. Studies 
have demonstrated that cytokine interferon gamma (IFN) is a potent inducer of 
TNFα signalling along with other external stimuli such as LPS in the microglia (Ye et 
al. 2001) and (Merrill & Benveniste 1996).  
Although neurons and astrocytes can produce low levels of TNFα, it is assumed that 
microglia is the primary source of this cytokine during neuroinflammation (Figure 
1.2). The endogenous IFN induces microglial TNFα production and releases via 
activating IFN-surface receptors. TNFα that is released by microglia promotes the 
activation of TNFR1 signalling to induce excess pro-inflammatory cytokines and also 
shown to activate release of glutamate from hemi channels of microglial gap 
junctions (Olmos & Llad 2014). Furthermore, microglial TNFα activates TNFR 
signalling on astrocytes to induce glutamate exocytosis by blocking the glutamate 
uptake, thus increasing extracellular glutamate levels (McCoy & Tansey 2008). TNFα 
released from active microglia has both neuroprotective (at low concentrations) and 
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neurotoxic effects (high levels) related to the various signalling pathways activated 
by their receptors. 
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Figure 1.2 Tumour necrosis factor alpha (TNFα) signalling in the microglia. 
Source:- (Olmos & Llad 2014). 
 IFN: Interforns, TNFR1: Tumor necrosis factor receptor 1, mGLUR2: Metabotropic 
glutamate receptor 2, EAAT1: Excitatory amino acid transporter 1, GLAST: 
GLutamate ASpartate Transporter, GLT-1: Glutamate transporter 1, AMPA: α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, NMDA: N-methyl-D-
aspartate receptor, GABA: gamma-aminobutyric acid. 
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1.4.2 Interleukins 
Interleukins are pro-inflammatory cytokines, which are expressed at low levels in 
healthy CNS, but increases very rapidly in response to the pathogenic invasion in the 
CNS or when treated with exogenous LPS, IFN or TNFα (Rothwell & Luheshi 2000). 
These are particularly synthesised by glial cells, and astrocytes, as well as by 
neurons and has been shown to regulate various cellular functions in the brain. Out 
of several interleukins produced by active microglia during neuroinflammatory 
conditions, IL-6 and IL-1β are widely studied (Akdis et al. 2011). 
Accumulation of IL-6 and IL-1β are implicated in the progression of chronic 
neurological diseases including AD and PD, as well as acute neuroinflammatory 
conditions such as traumatic brain injury and stroke (Halle et al. 2008) and (Lynch et 
al. 2004). Also, these circulating interleukins upregulate the production of 
prostaglandins and other neurotoxic mediators in the CNS and are therefore 
considered as master regulators of neuroinflammation (Liu et al. 2012). Interleukin’s, 
once secreted from microglia and astrocytes, it can further stimulate its production in 
an autocrine or paracrine fashion via binding to IL-1 surface receptor superfamily (IL-
1Rs) (Araujo et al. 2009). 
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Figure 1.3 Association of various pro-inflammatory cytokines with 
neurodegenerative diseases (Yuste et al. 2015) .  
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1.4.3 Nitric oxide  
Nitric oxide (NO) is a potent signalling molecule, discovered nearly two decades ago 
and since then its vasodilator, neuromodulator and inflammatory mediator roles were 
continuously reported by various groups (Knowles & Moncada 1994) and (Calabrese 
et al. 2007). It has been suggested that upregulation in the NO signalling is involved 
in the pathogenesis of various neurodegenerative diseases such as AD, PD and MS, 
as well as ALS (Zecca et al. 2004), (Doherty 2011) and (Peterson & Toborek 2014).  
The actual problem starts with the imbalance in NO production during inflammatory 
insults, where microglia becomes hyperactivated. In mammals, NO is mainly 
synthesised by nitric oxide synthases (NOS) through the conversion of L-arginine to 
NO and L-citrulline. Traditionally, NO is synthesised by three forms of NOS in the 
CNS: neuronal NOS (nNOS) or NOS1, inducible NOS (iNOS) or NOS2, endothelial 
NOS (eNOS) or NOS3 (Figure 1.4). The activity of nNOS and eNOS typically depend 
on intracellular calcium (Ca2+-dependant) and are widely expressed in synaptic 
spines, astrocytes and the loose connective tissue surrounding blood vessels in the 
brain.  
Although, the expression of iNOS (Ca2+-independent) is not constitutive in the CNS, 
glial cells are shown to express this isoform in excess during pathological conditions 
such as in response to inflammatory stimuli (Alderton et al. 2001) and (Yuste et al. 
2015). Figure 1.4 shows various steps involved in the production of NO from different 
isoforms. High levels of nitric oxide were synthesised following the transcriptional 
expression of inducible NOS (iNOS) mediated by intrinsic signalling pathways in 
microglial cells and astrocytes after cytokine exposure (Yuste et al. 2015).The role of 
NO and its associated reactive nitrogen species (RNS) in neuroinflammation was 
well studied using various animal models (Uttara et al. 2009). It appears that excess 
NO released by active microglia during neuroinflammatory conditions blocks the 
reuptake of glutamate, and facilitate neuronal death (Rao et al. 2012) and (Kim et al. 
2009). The upregulation of iNOS isoform at the transcriptional level and its mediated 
NO production was observed during the neuroinflammatory process. Also it appears 
that several transcription factors are implicated in transactivation of iNOS gene 
during neuroinflammatory pathologies, among them NF-B and AP-1 are the most 
important (Hoesel & Schmid 2013) and (Kim et al. 2015).  
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In microglia, this NF-B-mediated iNOS expression triggers several intrinsic 
pathways related to RNS formation, caspase and nNOS signalling activities (Kim et 
al. 2009) and (Uttara et al. 2009). Several studies have demonstrated that inhibition 
of LPS-induced NF-B signalling and its mediated iNOS and NO production will 
ablate microglial activation in neuroinflammatory conditions (Fiebich et al. 2002), (Xu 
et al. 2014), (Onasanwo et al. 2016) and (Kao et al. 2010). 
  
Page | 34 
 
 
Figure 1.4 Nitric oxide signalling cascade. Source:- (Yuste et al. 2015). TBH: 
Tyramine beta-hydroxylase, NADPH: Nicotinamide adenine dinucleotide phosphate, nNOS: 
Neuronal nitric oxide synthase, iNOS: Inducible nitric oxide synthase , eNOS: Endothelial 
nitric oxide synthase, CAM: Calmodulin, sGC: Soluble Guanylate Cyclase, cGMP: Cyclic 
guanosine monophosphate, cGKI: cGMP-dependent protein kinase 1, PKG: cGMP-
dependent protein kinase or Protein Kinase G, CNG: Cyclic nucleotide-gated, PDE: 
phosphodiesterase. 
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1.4.4 Prostaglandins 
Two types of cyclooxygenases (COX) have been identified, COX-1 and COX-2. In 
which, COX-1 is a membrane-associated enzyme and constitutively expressed in 
most tissues of the brain and its mediated end products contribute to normal 
physiological functions. Interestingly, COX-2 is an inducible enzyme that is 
expressed in microglia, neurons, astrocytes and endothelia, which is responsible for 
the pathological production of prostaglandins (PGs) in response to pro-inflammatory 
stimuli such as endotoxins, cytokines, brain injury and other growth factors (Yang & 
Chen 2008) and (Maes 2012).  
It has been well documented that COX enzymes regulate the first step of the 
conversion of arachidonic acid (AA) into unstable intermediate PGG2/PGH2 
(Chattopadhyay et al. 2010), (de Oliveira et al. 2012) and (Calvello et al. 2012). 
Finally, in the presence of various cell-specific synthases, several biologically active 
prostaglandins (PGD2, PGE2, PGF2α, and PGI2), as well as thromboxane A2 (TXA2) 
are formed from PGH2 (Figure 1.5). It has been reported by Chen et al. that COX-2 
plays a vital role in regulating the production of PGE2 and PGI2 in the brain 
hippocampus, while COX-1 mediates the conversion of PGD2, TXA2 and PGF2α from 
PGH2 (Chen et al. 2002). This study also demonstrated for the first time that PGE2 is 
heavily involved in maintaining the synaptic transmission, membrane excitability, 
integration, and plasticity in the hippocampus. 
Three types of prostaglandin E synthases (PGESs) are involved in the conversion of 
PGE2 from PGH2, microsomal PGES-1 (mPGES-1), PGES-2 (mPGES-2) and 
cytosolic PGES (cPGES) (Breyer et al. 2001) and (Sugimoto & Narumiya 2007). 
While mPGES-1 is primarily coupled with COX-2 signalling, cytosolic PGES has 
been shown to be associated with the COX-1 pathway, and lastly, mPGES-2 is a 
constitutive enzyme released into the cytoplasm (Narumiya et al. 1999) and 
(Sugimoto & Narumiya 2007). When hippocampal slices are challenged with LPS 
and IL-1β, elevated COX-2 expression followed by mPGES-1 and PGE2 production 
was observed suggesting that mPGES-1 mediates neuroinflammatory process in the 
CNS (Yang et al. 2008) and (Yang & Chen 2008). Therefore, novel compounds 
targeting the mPGES may hold a great potential as alternatives to traditional non-
steroidal anti-inflammatory drugs (NSAIDs) and COX inhibitors for alleviating or 
treating neuroinflammation-associated neurodegenerative diseases.   
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Figure 1.5 Prostaglandins signalling pathway and its specific membrane 
receptors. Source:- (Yang & Chen 2008). AA: Arachidonic acid, COX: 
Cyclooxygenase, cPGES: Cytosolic prostaglandin E2 synthase, mPGES: 
Microsomal prostaglandin E synthase, EP: Prostaglandin E2 receptor, PIP2 : 
Phosphatidylinositol 4,5-bisphosphate, IP3 : Inositol trisphosphate, PKC: Protein 
kinase C, ATP: Adenosine triphosphate, PLC: Phospholipase C, PKA: Protein 
kinase A. 
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It has been well documented that four subtypes of PGE2 receptors (EPs) that belong 
to the family of seven-transmembrane-domain G-protein-coupled receptors (GPCRs) 
are identified. All receptors EP1, EP2, EP3 and EP4 with unique cellular actions and 
signal transduction profiles (Shibuya et al. 1999) and (Sugimoto & Narumiya 2007) 
(Figure 1.5). For example, activation of EP1 receptors increases intracellular calcium 
levels that are coupled with activation of inositol triphosphate (IP3) and protein kinase 
C (PKC) signalling cascades (Zonta et al. 2003). Studies have shown that in 
neuroinflammation these signalling pathways play a vital role in controlling the 
transcription of various inflammatory cytokines (Kumar et al. 2003) and (Wang et al. 
2014). On the other hand, activation of EP2 and EP4 receptors are shown to couple 
with cAMP and PKA pathways leading to an increase in the accumulation of cAMP 
(Streit et al. 2004) and (Shibuya et al. 1999). Animal studies conducted by Zhu et al. 
revealed that all four subtypes of PGE2 receptors are heterogeneously expressed in 
microglia, neurons and astroglial cells in the regions of hippocampus and cortex (Zhu 
et al. 2005). These studies explains the elevated microglial pro-inflammatory 
cytokines and it's mediated neuronal toxicity when stimulated with exogenous 
inflammatory stimuli. Further evidence from other studies shows that known PKC 
inhibitor completely blocked the expression of COX-2 and the production of PGE2 in 
LPS-treated rat hippocampal slices, strengthens the link between PKC signalling and 
ERK, p38MAPK and NF-B signal transduction pathways (Sang et al. 2005) and 
(Jazwa et al. 2011).  
Several epidemiological studies indicate that conventional anti-inflammatory 
therapies using NSAIDs can reduce the risk of developing neuroinflammation and its 
mediated neurotoxicity (Zhang & An 2007), (Trepanier & Milgram 2010), 
(Chattopadhyay et al. 2010) and (Vernieri et al. 2013). However, NSAIDs particularly 
COX-2 inhibitors (e.g. Celecoxib and Valdecoxib) have shown little or no therapeutic 
effect in the AD patients (Sano et al. 1997) and (Aisen et al. 2003). Also, long-term 
treatment with NSAIDs has been limited by gastrointestinal, cardiovascular or renal 
complications, as well as increased ability of the patient to tolerate the drugs 
(Minghetti et al. 2004) and (Chen et al. 2003). As an alternative, investigators are 
using different strategies to design new drugs that have been primarily focused on 
downstream targets of the COX-2 pathway (e.g., mPGES-1, EPs) respectively. 
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Figure 1.6 Table highlighting various prostaglandin receptors and their signalling 
pathways in the brain environment (Zecca et al. 2004). cPGES: Cytosolic 
prostaglandin E2 synthase, mPGES: Microsomal prostaglandin E synthase, EP: 
Prostaglandin E2 receptor, PIP2 : Phosphatidylinositol 4,5-bisphosphate, IP3 : Inositol 
trisphosphate, PKC: Protein kinase C, ATP: Adenosine triphosphate, PLC: Phospholipase 
C, PKA: Protein kinase A. 
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1.4.5 Reactive oxygen species (ROS) 
Microglial induction of reactive oxygen species (ROS) during neuropathological 
conditions was shown to be more predominant compared to other neurotoxic 
mediators (Lee & Yang 2012) and (Zhang et al. 2016). In general, mitochondrial 
ROS at low concentrations are widely recognised to perform physiological functions 
such as cell proliferation, apoptosis, cell survival and differentiation (Dröge 2002) 
and (Bernhardi & Eugenín 2012). Excessive production of ROS is termed as 
oxidative stress. The primary source of ROS production is mitochondria and other 
specialised enzymes such as Xanthine oxidase (Xox), NADPH oxidase (NOX), P450 
enzyme and inducible COX and NOS. ROS generated through these pathways were 
thought to be responsible for its deleterious effects on the CNS (Melo et al. 2011) 
and (Yuste et al. 2015). Also it is well established that generation of ROS is more 
predominant when inflammatory target proteins such as cytosolic phospholipase A2 
(cPLA2), matrix metalloproteinase-9 (MMP-9), inducible nitric oxide synthase (iNOS) 
and cyclooxygenase-2 (COX-2) are activated by various inflammatory stimulants 
(Wang et al. 2009), (Dröge 2002) and (Zhang & An 2007). 
Studies indicate that in response to oxidative stress, microglia and astrocytes further 
release various inflammatory mediators that in turn trigger severe pathological 
events in the brain (Uttara et al. 2009) and (Zecca et al. 2004). For example, 
accumulation of ROS has shown to induce redox-sensitive transcription factors such 
as NF-B and activator protein-1 (AP-1) in microglia, which further promotes more 
neuroinflammation and could be translated to functional deficits, such as cognitive 
impairment (Wang et al. 2014) and (Didonato et al. 2012).  
Reactive oxygen species that are mainly responsible for inducing oxidative stress 
are hydroxyl radical (∙OH-), singlet oxygen, superoxide anion (O2-), hypochlorous 
acid (HOCl) and hydrogen peroxide (H2O2). Furthermore, reactive nitrogen species 
(RNS) involve peroxynitrite (ONOO−) and nitric oxide (NO) (Bernhardi et al. 2015) 
and (Hsieh & Yang 2013). As shown in Figure 1.7, several pro-inflammatory factors 
released by activated microglia during inflammation reacts with molecular oxygen 
(O2) in the presence of various oxidase enzymes to produce highly reactive ROS 
and RNS. At low concentrations, these ROS and RNS are essential to perform 
physiological functions (e.g. killing invading microorganisms), however, they become 
detrimental at high levels (Chrissobolis & Faraci 2008) and (Melo et al. 2011). Apart 
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from neurodegenerative diseases, oxidative stress has also shown to mediate the 
pathogenesis of cardiovascular disorders such as stroke (Sandberg et al. 2014). 
  
Page | 41 
 
 
Figure 1.7 Generation and metabolism of reactive oxygen and nitrogen species. 
Source:- (Hsieh & Yang 2013). Nox: NADPH oxides, Xox: Xanthine oxidase, COX: 
Cyclooxygenase, NOS: Nitric oxide synthase, SOD: Superoxide dismutase, MPO: 
Myeloperoxidase, GPx: Glutathione peroxidase, L-Arg: L-arginine. 
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Also, it is widely accepted that the term oxidative stress defines an imbalance 
between the generation of ROS and the antioxidant systems that protect deleterious 
effects of ROS (Anand & Babu 2013) and (Halliwell 2006). Since mitochondria are 
the site of electron transport chain, it appears that defects in these physiological 
mechanisms induce excess ROS generation.  
In contrast, induction of several antioxidant systems and proteins such as superoxide 
dismutase (SOD), catalases or Nrf2-induced heme oxygenase-1 (HO-1) may reduce 
ROS generation and attenuate the inflammatory response, as well as DNA damage 
induced by oxidative stress (Figure 1.8) (W. Li et al. 2008), (X. Li et al. 2008) and 
(Martin et al. 2004). However, studies have shown that during neuroinflammation the 
balance appears to be tipped in favour of oxidative stress and therefore a reduction 
in the expression of antioxidant proteins was observed (Peterson & Toborek 2014). 
Glutathione (GSH) has been recognised as an important cellular antioxidant that is 
mainly produced by microglia during oxidative stress. Modulations in the levels of 
GSH have been implicated in various stress mediated neurodegenerative diseases 
(Roychowdhury et al. 2003) and (Kim et al. 2004). GSH is abundant in glial cells and 
is involved in scavenging ROS and peroxynitrite produced during neuroinflammation. 
Curcumin, a natural dietary compound has been shown to inhibit H2O2 induced 
oxidative stress via increasing the levels of GSH in mice (Kim et al. 2004). Also, a 
study on post-mortem brain of AD patients has revealed decreased levels of GSH in 
some regions of the brain when compared with control, which emphasises the pivotal 
role of GSH in neurodegenerative conditions (Gu et al. 1998). Thus strategies that 
target to activate antioxidant mechanisms could bring hyperactive microglia to 
resting state. 
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Figure 1.8 Balance between ROS/RNS mediated oxidative stress and antioxidant 
proteins. Source:- (Hsieh & Yang 2013). Nox: NADPH oxides, Xox: Xanthine oxidase, 
COX: Cyclooxygenase, NOS: Nitric oxide synthase, SOD: Superoxide dismutase, HO-1: 
Heme oxygenase 1, GPx: Glutathione peroxidase. 
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1.5 Anti-inflammatory cytokines 
Accumulating evidence has demonstrated that pro-inflammatory cytokines produced 
by hyperactive microglia are the key components involved in the pathogenesis of 
various neurodegenerative diseases (Kettenmann et al. 2011) and (Jurgens & 
Johnson 2012). On the other hand, microglia tends to release anti-inflammatory 
cytokines that have shown to control the deleterious effects of pro-inflammatory 
cytokines in the CNS (Kim et al. 2016) and (Guillot-Sestier et al. 2015). In general, 
the acute release of pro-inflammatory cytokines benefits CNS by attacking invading 
pathogens. However, a sustained increase of these cytokines damages surrounding 
tissues causing dysfunction and ultimately deterioration of healthy microglia and 
neurons. The primary functional role of the anti-inflammatory cytokines that includes 
interleukin (IL)-1 receptor antagonists such as IL-4, IL-10, IL-11, and IL-13, as well 
as transforming growth factor-β1 (TGF-β1) is to down-regulate the sustained 
inflammatory toxicity-induced by cytokines and initiate tissues reconstruction. It can 
be hypothesised that microglial anti-inflammatory cytokines possess protective 
effects against neuroinflammation by blocking the harmful effects of pro-
inflammatory cytokines. It also appears that deficiency of these anti-inflammatory 
cytokines in the brain may promote the risk of developing progressive 
neurodegenerative diseases like AD and PD (Richwine et al. 2009) and (Opal & 
DePalo 2000).   
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Figure 1.9 Various roles of anti-inflammatory cytokine IL-10 
Source:- (Guillot-Sestier et al. 2015) 
  
Page | 46 
 
Among all the anti-inflammatory cytokines, IL-10 is widely studied due to its potent 
anti-inflammatory, cellular survival and anti-apoptotic properties (Chakrabarty et al. 
2015) and (Richwine et al. 2009) (Figure 1.9). Studies have shown that IL-10 is 
capable of repressing various inflammatory cytokines such as TNF-α, IL-6 and IL-1β 
in LPS-activated microglia (Lynch et al. 2004). Also, IL-10 can upregulate 
endogenous anti-cytokines and down-regulate the expression of pro-inflammatory 
cytokine receptors in the brain (Park et al. 2007) and (McGeer & McGeer 2015). 
Moreover, acute administration of IL-10 protein in diverse animal models has been 
shown to suppress the development of spinally-mediated pain facilitation and also 
counter-regulated the function and production of various inflammatory mediators 
(Richwine et al. 2009) and (de Miranda et al. 2015). On the other hand blocking the 
production of IL-10 has shown to reverse the neuropathological behaviours in the 
murine models (Park et al. 2007). On top of that, recent clinical studies also indicate 
that low concentrations of IL-10 and IL-4 in the blood of patients with neuropathic 
pain highlights the pivotal roles of the anti-inflammatory cytokines (Zhang & An 2007) 
and (Chatterjee et al. 2014). From all these observations, it is understood that no 
direct evidence has been obtained about the other anti-inflammatory cytokines in the 
brain during neuroinflammatory conditions, where further investigation is required. 
1.6 Microglial nuclear factor kappa B (NF-B) signalling in neuroinflammation 
The nuclear transcription factor NF-B was first discovered by David Baltimore (Sen 
& Baltimore 1986). It was initially identified as an inducible transcription factor in 
peripheral lymphocytes. However, further research on NF-B signalling has revealed 
its essential role in the pathological process associated with chronic 
neuroinflammation and neurodegeneration (Didonato et al. 2012). In mammals, 
NF-B family typically comprises of several transcription factors that are equipped 
with Rel-homology domains (RHDs). These domain’s bind to specific DNA 
sequences in the promoter regions of inflammatory genes known as kappa B (B) 
sites (Adli et al. 2010) and (Hayden & Ghosh 2012). So far, five different NF-B 
transcription factors were discovered in mammalian cells: p65 (RelA), RelB, c-Rel, 
p50/p105 (NF-B1), and p52/p100 (NF-B2) (Chen & Greene 2004) and (Didonato 
et al. 2012) (Figure 1.10). Out of these, RelB, c-Rel, and p65 are known to contain 
C-terminal transcription activation domains that facilitate the recruitment of target 
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inflammatory gene expression, while p52 and p50 form heterodimers with p65, c-Rel, 
or RelB to activate the transcription of other target genes (Hayden & Ghosh 2011).  
In normal/resting cells, these NF-B complexes will be located mainly in the 
cytoplasm inhibited by inhibitory kinase protein complex (IB). So far, seven different 
types of IB inhibitors equipped with ankyrin repeats were identified: IBα, IBβ, 
IBε, IBζ, p100, p105 and IBns (Karin 2009) (Figure 1.10). With the help of these 
ankyrin repeats IB inhibitors can hold the NF-B dimers in the cytoplasm, which 
prevents the nuclear localisation of p65 subunit (Chen & Greene 2004). Upon 
activation of membrane TLR4 and innate receptors by inflammatory stimuli such as 
LPS, with the association of myeloid differentiation primary response 88 (MYD88), a 
signal transducing adaptor protein and TNF-receptor-associated factor 6 (TRAF6) 
becomes activated. This complex further triggers the induction/nuclear translocation 
of NF-B via rapid phosphorylation of specific serine residues of IB by a multi 
inhibitory kinase kinase protein complex (IKK) along with MAPK signalling (Kawai & 
Akira 2007) and (Takeda & Akira 2004). Ideally, these IKK complexes contain two 
subtypes of active kinases: IKKα and IKKβ, and a regulatory protein NEMO (NF-B 
essential modifier, also termed as IKKγ) (Lawrence et al. 2005) and (Kopitar-Jerala 
2015). Once IB becomes phosphorylated by the IKK complex, the remaining kinase 
protein gets degraded by cytoplasmic proteasomes followed by translocation of NF-
B dimers (p50/p65) into the nucleus (Karin 1999). Which means for NF-B to 
become fully active requires the phosphorylation and subsequent degradation of IB, 
hence, inhibiting the phosphorylation of this kinase ultimately inhibits NF-B’s 
transcriptional activity. 
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Figure 1.10 Members of the NF-B, IB and IKK protein families. Source:- (Hayden 
& Ghosh 2011). RHD: Rel homology domain, TAD: Topologically associating domain, 
ANK: Ankyrin repeat, DD: Death domain, PEST: proline glutamic acid, serine and threonine 
sequence, NBD: Cyclic nucleotide-binding domain, LZ: leucine zipper, HLH: helix-loop-helix 
domain, IB: inhibitor of kappa B , IKK; IB kinase, ZF: Zinc finger domain, CC1/2: coiled-
coil domain 1 and 2. 
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Once in the nucleus, NF-B enables the transcription of several genes that encode 
chemokines, pro-inflammatory cytokines, COX-2 and iNOS by binding to specific B 
sites on DNA (Wang et al. 2014). Another interesting aspect in this classical NF-B 
pathway is the transcription of IBα protein in the nucleus, as this newly synthesised 
kinase help to detach NF-B-p65 from the DNA and export the complex back to the 
cytoplasm (Didonato et al. 2012) and (Sun 2011). Studies conducted by Gupta et al. 
showed that NF-B is capable of activating around 500 genes that are implicated in 
the inflammatory responses (Gupta et al. 2010). This ability of NF-B signalling to 
control the transcription of multiple genes involved in various brain-related diseases 
makes it a novel target to block neuroinflammation and its associated 
neurodegenerative conditions. Due to the multiple steps involved in the regulation, 
NF-B signalling pathway can be potentially aimed at various levels such as toll-like 
receptors, inhibitory kinases, phosphatases, nuclear translocation and DNA binding, 
as well as post-translational modifications in the nucleus (Figure 1.11).  
Furthermore, these NF-B-dependent pro-inflammatory cytokines, such as TNFα 
and IL-1β tend to activate surface receptors on microglia and adjacent neurons. 
Also, studies have shown that cytokines activate astrocytes that in turn induce 
intracellular NF-B signalling; hence it turns into a vicious cycle that constantly 
produces neurotoxic mediators that induce neuronal death (Lawrence et al. 2005). In 
contrast, several cytokines like IL-10, TGFβ, glycogen synthase kinase-3 (GSK-3β) 
and IL-4 are shown to regulate NF-B signalling negatively via blocking peroxisome 
proliferator-activated receptor (PPAR)-γ-mediated mechanisms (Paintlia et al. 2006) 
and (Kaltschmidt et al. 2005). In the nucleus, p50/ p65 subunits of NF-B has to 
undergo several post-translational modifications like acetylation and methylation to 
regulate the transcription of the pro-inflammatory genes (Chen & Greene 2005) and 
(Zhu et al. 2011) which were discussed in detail in section 1.8. 
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Figure 1.11 Potential targets for inhibiting NF-B activation  
Source:-(Gupta et al. 2010) 
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1.7 Microglial p38 mitogen-activated protein kinase (MAPK) signalling in 
neuroinflammation 
Mitogen-activated protein kinases (MAPKs) are a family of serine/threonine protein 
kinases which are critical for regulation of the production of inflammatory cytokines. 
Some pathogenic, extracellular stimuli and bacterial products such as LPS are 
shown to activate MAPKs cascades via toll-like receptors or TNF receptor family and 
ultimately leading to the transcription of various inflammatory genes such as iNOS, 
TNFα and IL-1β (Cuadrado et al. 2010) and (Onyango et al. 2005). The use of 
MAPK inhibitors emerges as an attractive strategy in neuroinflammatory conditions 
because they are capable of reducing the transcription and synthesis of pro-
inflammatory cytokines in microglia (Zeng et al. 2010), (Xu et al. 2014) and (Zhu et 
al. 2014). 
In mammalian cells three major groups of MAP kinases were identified: ERK1/2, 
JNK, and p38 MAP kinase, where ERK1 and 2 are typically activated by MAP kinase 
kinase 1 (MKK1) and MKK2, JNK is activated by MKK4 and MKK7 and finally p38 
MAPK by MKK3 and MKK6. These kinases are critical regulators of various pro-
inflammatory cytokines in the pathologies of neuroinflammation related 
neurodegenerative diseases (Kaminska 2005) and (Munoz & Ammit 2010). Among 
these, p38 MAPK signalling has been shown to play a central role due to its 
importance in the activation and production of neurotoxic mediators that are involved 
in the progression of neuroinflammation (Kim et al. 2004).  
Activation of microglial membrane toll-like receptor 4 (TLR4) (e.g. by LPS) triggers 
p38 MAPK signalling (Didonato et al. 2012) and (Lawrence et al. 2005). This 
activation and expression of TLR4 further induce the phosphorylation of myeloid 
differentiation primary response gene 88 (MyD88) followed by TRAF6 activation. 
Studies have shown that in activated microglia, MyD88-dependent pathway is used 
by most TLRs to recruit IL-1R-associated kinase (IRAK)-1 and IRAK-4 and TRAF6 
(Yamamoto et al. 2003) and (Coban et al. 2007). Afterwards, the dissociation of this 
complex takes place leading TRAF6 to associate and activates transforming growth 
factor β-activated kinase (TAK1) via TAK1-binding protein 1. Further activates the 
transcription factors NF-B and activator protein 1 (AP-1) through the IKK complex 
and the MAPK pathway, respectively (Karin & Gallagher 2009). This activated TAK1 
complex further triggers phosphorylation of mitogen-activated protein kinase kinase 
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kinases (MAPKKKs). These MAPKKK serine/threonine kinases get phosphorylated 
and further activates MAPK kinases (MKKs) such as MKK3, MKK4 and MKK6 which 
in turn phosphorylate p38 MAPK at Thr180 and Tyr182 residues.  
Activated p38 further phosphorylates and activates serine and threonine residues of 
its kinase substrates, mitogen-activated protein kinase (MAPK)-activated protein 
kinases (MKs) such as MK2, MK3 and MK4 (Coban et al. 2007). Studies have 
shown that LPS-induced MK2 is involved in regulating the production of TNFα, IL-6 
and IL-8 and other cytokines in microglia (Duraisamy et al. 2008), (Fyhrquist et al. 
2010) and (Fyhrquist et al. 2010). When mouse models challenged with bacterial 
lipopolysaccharide showed excessive levels of endogenous MK2 in frontal cortex 
and hippocampus regions suggest the critical role of MK2 in the neuroinflammation 
(Corrêa et al. 2012). Moreover, targeted deletion of MK2 gene in mouse models 
resulted in a massive decrease in the production of TNFα when treated with LPS and 
D-galactosamine-induced shock (Kotlyarov et al. 1999). The intervention of these 
essential pathways may serve as a therapeutic approach for treating inflammatory 
neurological diseases. For example, the specific p38 MAPK inhibitor, SB203580 
markedly reduced NO, PGE2 production and iNOS protein expression in LPS-
induced BV2 microglia. Furthermore, orally administered p38 inhibitor abolished 
cerebral IL-1β release in LPS-challenged mice models (Xing et al. 2011b). Also, 
several other studies have found that inhibition of p38 MAPK and its associated 
kinases such as MKK3/6 and MK2 would resolve neuroinflammation.
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Figure 1.12 An overview of brain MAPK signalling cascades (Coban et al. 2007). 
MAPK: mitogen-activated protein kinase, Raf: Rapidly Accelerated Fibrosarcoma, MKK: 
Mitogen-activated protein kinase kinase, MLK: Mixed Lineage Kinase, JNK: c-Jun N-
terminal kinases, ERK: extracellular signal–regulated kinases. 
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1.8 Role of Sirtuin 1 (SIRT1) in the microglia 
The mammalian sirtuins are nicotinamide adenine dinucleotide (NAD+)-dependent 
deacetylases that have traditionally been linked with neuroinflammation and its 
mediated neurodegenerative conditions. In general, sirtuins are referred as class III 
histone deacetylases (HDACs) that play a significant role in mediating critical cellular 
and physiological processes such as ageing, senescence and low-grade 
inflammation.  
Among seven sirtuins, SIRT1 has been reported to be involved in promoting 
longevity in various species. Thus, pharmacological activation of sirtuins, particularly 
SIRT1 has shown to modulate neuroinflammatory conditions (Nimmagadda et al. 
2013). In neuroinflammation, NF-B complex has to undergo post-translational 
modifications to become fully active, which includes reversible acetylation of NF-
Bp65 subunit by CREB-binding acetyltransferases, p300 and phosphorylation by 
protein kinase A (Chen Lf et al. 2001) and (Chen et al. 2005). However, studies have 
shown that SIRT1 deacetylase negatively regulates NF-B signalling via 
deacetylation of Lys310 residue of RelA/p65 subunit (Chen et al. 2005) and (Jieming 
Ye et al. 2013), which means activation of SIRT1protein inhibits NF-B signalling by 
promoting deacetylation of the p65 subunit. In addition, SIRT1 has been shown to 
deacetylate histones (H3 and H4) as well as other transcription factors such as p53, 
FOXO and Ku70 in glial cells (Outeiro et al. 2008). Moreover, overexpression of 
SIRT1 has shown to prevent neuronal death in various cell culture models and 
reduces hippocampal degeneration in animal models of AD, PD and ALS (Cho et al. 
2015) and (Kim et al. 2007). Thus, compounds that pharmacologically promote the 
expression of SIRT1 could culminate deleterious effects of active microglia and 
ultimately protect neurons. For instance, resveratrol, a potent SIRT1 activator, has 
been shown to regulate immune responses in the LPS-stimulated microglia via NF-
B signalling by inhibiting the transactivation of NF-B complex. Further studies 
revealed resveratrol promotes deacetylation of Lysine 310 residue of NF-B -p65 
subunit (Cho et al. 2015), (Haigis & Sinclair 2011)and (Ye et al. 2013).  
Interestingly, chronic oxidative stress encountered during neuroinflammatory 
conditions apparently down-regulates the activity and expression of SIRT1 
(Salminen et al. 2013). While its activation has shown to inhibit pro-inflammatory 
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cytokines in LPS-activated microglia (Cho et al. 2015), (Li et al. 2015) and 
(Nimmagadda et al. 2013). In contrast, reduction of SIRT1 protein expression was 
observed when endothelial cells were incubated with LPS. This condition was 
accompanied by significant increase in the acetylation of NF-B-p65 and enhanced 
NF-B transcriptional activity (Yang et al. 2012) and (J Ye et al. 2013), this further 
highlights the role of SIRT1 during neuroinflammation. 
SIRT1 has been shown to be involved in a variety of pathophysiological processes 
like cell metabolism, inflammation and DNA repair, as well as cell growth. In 
macrophages, knockdown of SIRT1 gene lead to an increase of pro-inflammatory 
cytokines, whereas its activation has reversed the productions of TNFα, IL-1β and 
monocyte chemoattractant protein (MCP-1) (Rajendrasozhan et al. 2012), (Zhu et al. 
2011) and (Yang et al. 2007). Also, there is abundant literature indicating that the 
functional dysregulation of SIRT1 is associated with many age-related 
neurodegenerative diseases like AD and PD (Haigis & Sinclair 2011) and (Guarente 
2011), which means upregulating the activity of sirtuins could protect against 
damage from oxidative stress induced by inflammatory stimuli.  
1.9 Role of nuclear factor erythroid 2-related factor 2 (Nrf2) in the microglia 
Reduction of brain oxidative stress induced by neuroinflammatory conditions could 
be achieved by activation of various antioxidant mechanisms. The transcription 
factor nuclear factor erythroid 2-related factor 2 (Nrf2) and its associated antioxidant 
response element (ARE) pathway is a primary sensor and is known as a master 
regulator of oxidative stress via its ability to modulate the expression of several 
redox-regulated antioxidant and detoxifying genes such as HO-1 and NQO1.  
Activation of this pathway has been shown to be beneficial in several animal models 
of neuroinflammation and neurodegenerative disorders. In contrast, loss of these 
antioxidant defence systems has been observed in postmortem brains of patients 
with neurodegenerative conditions. For example, in regions of substantial nigra and 
dopaminergic neurons of AD and PD patients, lower levels of Nrf2 and its associated 
proteins were noticed, while increased load of free radicals was observed compared 
to age-matched controls (Bogdanov et al. 2008) and (Gan & Johnson 2014). 
Therefore, activating Nrf2 signalling provides a valuable target for the treatment of 
neuroinflammation associated neurological diseases. 
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Among the Nrf2 mediated stress proteins, heme-oxygenase 1 (HO-1) gained decent 
attention due to its pivotal role in modulating the phenotype of microglia during 
neuroinflammation. Genetically altered and dysregulated HO-1 protein have been 
associated with the susceptibility and pathogenesis of neurodegenerative diseases 
like AD, as well in brain ageing (Markesbery 1997) and (Pappolla et al. 1998). 
Interestingly, during tau abnormalities, clusters of microglia were observed around 
the neurons along with increased levels of Nrf2 and its mediated HO-1, suggesting 
that patient’s brain is attempting to limit microgliosis by activating antioxidant 
mechanisms (Wakabayashi et al. 2010). In line with these findings, anti-inflammatory 
compounds like schizandrin C and several other small molecules have been shown 
to activate HO-1 protein in the microglia (Zeng et al. 2012), (Foresti et al. 2013), 
(Jazwa et al. 2011) and (Motohashi & Yamamoto 2004).  
It has been well documented that Nrf2 activity is mainly regulated by cellular inhibitor 
Keap1. Further research on this antioxidant protein showed that disruption of 
Nrf2/Keap1 interaction is an essential process to push Nrf2 into nucleus (Hancock et 
al. 2012) and (Turpaev 2013). This crucial step is primarily targeted by medical 
interventions to produce specific Nrf2 inducers. Surprisingly, cancer is an exception 
to the benefits that are associated by Nrf2. In cancer cells, cytoprotective mechanism 
induced by Nrf2 has shown to be hijacked and used against gaining resistance to 
radiotherapy and chemotherapy. Levels of Nrf2 have proved to be elevated in 
several types of cancers such as endometrial, lung, breast and pancreatic cancer 
(Soini et al. 2014), (Hartikainen et al. 2012) and (Liu et al. 2013). 
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Figure 1.13 The dual role of Nrf2 and its mediated antioxidant proteins (Zeng et al. 
2012). Nrf2: nuclear factor erythroid 2 related factor 2, HO-1: Heme oxygenase 1, NQO1: 
NAD(P)H dehydrogenase [quinone] 1, ARE: antioxidant response element, ROS: Reactive 
oxygen species.  
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1.10 BV2 microglia as an invitro experimental model for neuroinflammation  
Mammalian microglia are the brain resident phagocyte-like cells with an important 
role in immunity, toxicology and inflammatory neuropathologies. As 
neuroinflammation is an expanding area of biomedical research, the role of microglia 
in the inflammatory pathologies has been extensively studied in various animal 
models and primary cell cultures. Due to the limited proliferation capacity of rodent 
primary microglia, they have to be freshly prepared for each experiment. For 
example, to assess various signalling or disease mechanisms in neuroinflammation, 
at least 15-30 new rodent’s brains are required to yield enough cells to perform the 
desired experiments, which have a large impact on animal consumption. To 
overcome this challenge, a cell line that can be subcultured routinely would be highly 
desirable to save animals, expensive consumables and preferably time (Chan et al. 
2007) and (Krause & Muller 2010). 
Several studies have shown that immortalised murine microglial cell line BV2 could 
accelerate research on neuroinflammation and its mediated neurological diseases, 
provided that this particular cell line reduces the necessity of animal experiments and 
continuous fresh cell preparations (Lund et al. 2005) and (Henn et al. 2009). In an 
extension of these studies, it has been demonstrated that BV2 cell line is capable of 
reproducing the in vivo situation with high fidelity (Vehmas et al. 2003) and (Giulian & 
Baker 1986). Immortalised BV2 cells are generated by infecting mouse microglial 
cells with v-raf/v-myc (J2 virus) carrying retrovirus (Blasi et al. 1985). BV2 microglia 
cells when stimulated with LPS and other inflammatory stimuli, shown to induce the 
release of nitric oxide via upregulation of iNOS and superoxide anions via activation 
of NADPH oxidase (NOX) systems (Boje & Arora 1992) and (Ramanan et al. 2008). 
Interestingly, when rat primary microglia are treated with LPS, secreted lesser but 
substantial production of NO and iNOS protein expression, as well as reduced 
NADPH oxidase activation was observed (Colton & Gilbert 1987) and (Chan et al. 
2007). This data introduced bias against usage of rat primary microglia in 
neuroinflammation research as iNOS induced NO production is considered as an 
important mediator in the pathologies of inflammation.  
Further experiments to test the expression levels of Iba-1, a glial activation marker 
revealed that BV2 microglia are capable of producing high levels of Iba-1(Horvath et 
al. 2008). Since then, BV2 microglia have been used for several pharmacological 
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and toxicological studies, in phagocytosis, as well as for many immunological related 
discoveries (Lund et al. 2005) and (Hirt & Leist 2003). In addition, Henn et al. and his 
group examined the phenotypes of BV2 cells and confirmed that these cells are the 
perfect alternative for primary cultures (Henn et al. 2009). They also found that in 
response to LPS, 90% of inflammatory genes induced by BV2 cells were also 
produced by primary microglia; however, the upregulation of genes in the primary 
microglia were far less pronounced than in BV2.  
N9 microglia cells are another popular retroviral-immortalised cell line that shares 
similar phenotypical characteristics with primary mouse microglia (Hickman et al. 
2008). Also, when challenged with LPS, these cells have shown to upregulate the 
pro-inflammatory genes similar to BV2, including iNOS, IL-6, COX-2, TNFα and IL-
1β (Stansley et al. 2012). In line with these invitro models, human immortalised 
microglia (HMO6) are rarely used in the neuroscience research; as it is harder to 
obtain these cells. They have to be derived from human embryos and can be difficult 
to get access as these will develop ethical and legal issues (Nagai et al. 2001). 
HMO6 cells were shown to express IL-1β, IL-6, IL-8, IL-10, IL-12, IL-15 and TNFα 
when challenged with various inflammatory or bacterial stimuli similar to BV2 
microglial phenotype (Stansley et al. 2012). Out of all the invitro models, 
immortalised BV2 microglia appear to be the perfect model to study the 
neuroinflammation inhibitory effects of the novel compounds using various 
inflammatory stimuli. 
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Figure 1.14 Table summarizing various in vivo and in vitro models to study 
neuroinfoammation inhibitory effects of the novel small molecules. Aβ: amyloid β, 
ER: endoplasmic reticulum, ERK: extracellular signal-regulated kinase, HO-1: heme 
oxygenase-1, IL-1β: interleukin 1β, iNOS: inducible nitric oxide synthase, JAK: Janus 
Kinase, JNK: c-Jun N-terminal kinase, MAPK: mitogen-activated protein kinase, NO: nitric 
oxide, SAMP8: senescence-accelerated prone mouse 8, TNF-α: tumor necrosis factor-α, 
WT: wild type. 
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1.11 Pharmacology of flavonoids 
Flavonoids belong to a broad class of secondary polyphenolic natural compounds 
that are widely distributed in the seeds, fruits, leaves, and flowers, as well as stem 
barks of plants. Till date, over 4000 flavonoids were identified with significant 
chelating and antioxidant properties (Heim et al. 2002) and (Christensen et al. 2008). 
In plants, these hydroxylated phenolic substances are likely to be synthesised by 
phenylpropanoid pathway in response to herbivores, ultraviolet radiation and 
microbial infection (Middleton 1998). The health benefits of these flavonoids were 
reported by various epidemiological studies (Calderon-Montano et al. 2011) and 
(Hartman et al. 2006). Flavonoids that predominantly exist in different fruits, wines, 
cocoa, tea and vegetables are known to exhibit free radical scavenging activity. 
Along with these effects, flavonoids were also shown to possess antioxidant 
activities, anti-inflammatory activities, coronary heart disease prevention, 
hepatoprotective, anticancer and antiviral activities (Xi et al. 2012), (Ishige et al. 
2001) and (Zafrilla et al. 2001). Since the uptake of these dietary ingredients that 
contains flavonoids is a part of human diet, there is a need to evaluate the biological 
activity, bioavailability and metabolism of these flavonoids. So far several studies 
have highlighted that the pharmacological actions exert by the flavonoids are 
structure dependent (Hisashi Matsuda et al. 2002) and (Kumar et al. 2013).  
Chemically, flavonoids are a large group of compounds having a benzo-γ-pyrone 
structure in common. However they are differentiated based on the arrangements of 
hydroxyl, methoxy, and glycosidic side groups on a fifteen carbon skeleton that 
contains two benzene rings (A and B) linked to heterocyclic pyrone ring (C) (Figure 
1.15) (Rice-Evans et al. 1996). They can be further divided into various classes such 
as flavones (e.g. fruit skins, red wine, red pepper and tomato skin), flavonols (e.g. 
black tea, berry fruits, linden, rose hip, olive oil and broccoli), flavanones or 
dihydroflavons (e.g. grape fruits, citrus fruits, lemons and oranges), flavanols (e.g. 
tea) and isoflavones (e.g. soya bean) (Figure 1.16) (Ishige et al. 2001), (Xi et al. 
2012) and (Kumar et al. 2013). All these subtypes of flavonoids occur in food as O-
glycosides, aglycones and methylated derivatives that primarily differ in the levels of 
oxidation and substitution of A, B and C rings. Being phytochemicals, flavonoids are 
impossible to be synthesised my humans and animals (Sun et al. 2010). However, 
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once consumed, human intestinal microbiota hydrolysis these glycosidic units of 
dietary flavonoids.  
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Figure 1.15 Basic nuclear structure of flavonoid 
Source:- (Heim et al. 2002) 
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Figure 1.16 Classification and basic structure of flavonoids with examples 
Source:- (Kumar et al. 2013) 
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Several in vitro and in vivo investigations have revealed the plausible biological 
properties exhibited by dietary flavonoids to confer neuroinflammation and other 
brain-related diseases such as dementia, AD, ALS and PD (Heim et al. 2002). 
Among these, the flavonoid kaempferol (highlighted in the Figure 1.16) gained 
attention in recent years due to its health benefits and existence in a wide variety of 
dietary supplements such as strawberries, rose hip, leek, onion, sweet potato and so 
forth (Kim & Choi 2013). Numerous evidence prove that kaempferol and its 
glycosides like tiliroside possess anti-inflammatory activities both invitro and in 
animals (Kim et al. 2010), (Medeiros et al. 2009), (Roth et al. 1999) and (S. Park et 
al. 2011). 
1.11.1 Tiliroside 
Tiliroside (kaempferol 3-O-β-D-(6″-O-coumaroyl) glucopyranoside) (Figure 1.17) is a 
dietary glycosidic flavonoid derived from kaempferol and is found in several 
medicinal and nutritional plants such as linden, olive oil, broccoli, rose hip and 
strawberry. Several studies have shown that tiliroside could be extracted from 
various plants, flowers and seeds (Table 1). For example, ethanolic extract of 
Agrimonia pilosa Ledeb (Rosaceae; AP) has shown to contain tiliroside as a major 
component (Jin et al. 2016).  
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Figure 1.17 Chemical structure of tiliroside  
Source :- (Jin et al. 2016) 
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Also, pharmacological research on this compound revealed that it exhibits excellent 
anti‑diabetic properties via enhancing the consumption of glucose by insulin‑
resistant HepG2 cells (Qiao et al. 2011) and (Zhu et al. 2010). In addition to these 
effects, tiliroside also possesses vasorelaxant and anti-hypertensive effects. 
However, the exact mechanism of action is not known. Tiliroside has been shown to 
inhibit mouse ear inflammation induced by 12‑O‑tetradecano and mouse paw 
oedema when challenged with phospholipase A. These observations seem to 
suggest that tiliroside possess anti-inflammatory effects that warrant further 
research. Most recent studies on LPS-stimulated macrophages revealed the anti-
inflammatory activities of tiliroside (Jin et al. 2016), although its precise mechanism 
of action in LPS/IFN-induced neuroinflammation is not studied yet. From all the 
previous studies on tiliroside it appears that the inhibitory effects are investigated 
when it is in the form of extract; however, this is the first study to examine its 
inhibitory activity of neuroinflammation directly. 
Several reports have suggested the possible mechanisms of action of dietary 
flavonoids in various cellular models, however to what extent these beneficial effects 
can be extrapolated to humans is yet to understood (Holiman et al. 2001.). To fully 
comprehend the biological fate of the flavonoids, it is vital to have a thorough 
understanding of its bioavailability, absorption, metabolism and pharmacokinetics. 
Studies on humans conducted by Hollman et al. revealed that quercetin glucosides 
in the onions were readily absorbed in the small intestine via sodium-dependent 
glucose transporters (SGLT) (Hollman et al. 1995). Also, the same group has 
reported high levels of oxidatively metabolised quercetin in the blood plasma levels. 
Another study conducted by Oliveira et al. on quercetin and kaempferol revealed that 
both flavonoids were extensively metabolised into glucuronides and absorbed in the 
small intestine via UDP-glucuronosyltransferase isoform UGT1A9 (Oliveira et al. 
2002). However, the extent of absorption and metabolism of tiliroside, a glycosidic 
derivative of kaempferol was not clear. Therefore, further studies were required to 
assess the bioavailability, metabolism and absorption of tiliroside in humans. 
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 Species Family Tiliroside Reference 
Agrimonia pilosa 
Ledeb 
Rosaceae Kaempferol 3-O-β-D-
glucopyranoside-6-p-coumaril 
ester 
(Jin et al. 
2016) 
Helichrysum 
italicum 
Asteraceae Kaempferol 3-O-β-D -(6"-E-p-
coumaroyl)-glucopyranoside  
(Sala et al. 
2003) 
Magnolia fargesii Magnoliaceae 
 
Kaempferol 3-O-β-D-(6"-O-
coumaroyl)glucopyranoside 
(Jung et al. 
1998) 
Rosa canina Rosaceae Kaempferol 3-O-β-D-(6"-E-p-
coumaroyl)-glucopyranoside 
(Ninomiya et 
al. 2007) 
Rubus idaeus Rosaceae Kaempferol, kaempferol 3-O-
β-D-galactosides, kaempferol 
3-O-β-L-arabinopyranoside 
and kaempferol 3-O-β-D-(6''-
E-p-coumaroyl)- glucoside 
(Zafrilla et al. 
2001) 
Tilia argentea Tiliaceae Kaempferol 3,7-O-β-di-
rhamnoside and kaempferol 
3-O-β-D-(6"-E-p-coumaroyl)-
glucopyranoside 
(H Matsuda et 
al. 2002) 
Waltheria indica Sterculiaceae Kaempferol 3-O-β-D-(6"-O-
coumaroyl)glucopyranoside 
(Rao et al. 
2005) 
Table 1 Plant species that contain tiliroside (glycoside of kaempferol) 
Source:- (Calderon-Montano et al. 2011) 
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1.12 Gap in knowledge 
So far, very few studies have shown the anti-inflammatory effects of the dietary 
flavonoid tiliroside, although those investigations were very preliminary. Till now 
precise mechanism of action of tiliroside against neuroinflammation is not known. 
1.13 Objectives of this study 
This study is aimed at investigating neuroinflammation inhibitory activities of tiliroside 
in LPS/IFN-stimulated BV2 microglia 
1.13.1 Specific Aims 
1. To examine the neuroinflammation inhibitory activity of tiliroside in BV2 microglia 
that are stimulated with the combination of LPS and IFN. 
2. To evaluate whether inhibitory actions of the compound on LPS/IFN-induced 
neuroinflammation are due to interference with NF-B and p38 MAPK signalling in 
microglia. 
3. Investigate the effects of tiliroside on Nrf2/HO-1/NQO1 activation and examine 
whether this antioxidant mechanism is involved in the anti-neuroinflammatory activity 
of the compound. 
4. To examine whether tiliroside blocks the HT22 neuronal toxicity induced by 
neuroinflammation. 
  
Page | 70 
 
Chapter 2. Materials and methods 
2.1 BV2 mouse microglia 
Mouse microglia has shown high functional plasticity when activated with external 
inflammatory stimuli such as lipopolysaccharide (LPS) and gamma interferon. BV2 
cells have been widely used to study molecular mechanisms in immunity, 
neuroinflammation, neurodegeneration and toxicology studies. The most important 
feature is, BV2 cells have an excellent inflammatory related gene expression pattern, 
which makes it appropriate for the current research. BV2 microglia cell line ICLC 
ATL03001 obtained from Interlab Cell Line Collection, Banca Biologicae Cell 
Factory, Italy. BV2 microglia are immortalised murine cell lines cultured in Roswell 
Park Memorial Institute medium 1640 (RPMI) supplemented with 10% foetal bovine 
serum (FBS) (Sigma), 2 mM L-glutamine (Sigma), 100 mM sodium pyruvate 
(Sigma), 100 U/ml penicillin and 100 mg/ml streptomycin (Sigma) in a 5% CO2 
incubator at 37ºC. Cells were passaged twice a week in 75 cm2 filter-capped vented 
flasks. Once confluent, flasks were washed with phosphate-buffered saline (PBS) 
and trypsinised with 2 ml of 0.25% trypsin-EDTA solution. Trypsinisation was 
terminated by adding 8 ml of complete RPMI medium, followed by centrifugation at 
1200 rpm for 5 minutes. Once the BV2 cell pellet was formed, the medium was 
aspirated and resuspended in fresh complete medium. Cells were then seeded out 
at a concentration of 2 × 105 cells /ml in various cell culture plates respectively. 
2.1.1 Drugs and treatment 
Tiliroside was purchased from Sigma and prepared in DMSO (Sigma). Primary stock 
of 100 mM of the compound was made and stored in small aliquots at -80°C. A 
working stock of 10 mM was prepared from aliquots of the original stock. The 
combination of (lipopolysaccharide) LPS (100 ng/ml) and (interferon gamma) IFN 
(5 ng/ml) was used to stimulate BV2 microglia in all neuroinflammation associated 
experiments. LPS was derived from Salmonella enterica serotype Typhimurium 
SL118, purchased from Sigma. IFN was derived from Escherichia coli, obtained 
from R & D systems. A working stock of 100 µg/ml was prepared from the primary 
stock of LPS (1 mg/ml) using sterile deionised double distilled water and aliquots 
were stored in 4ºC. These were discarded after one month of use. Sterile PBS was 
used to prepare aliquots of 10 µg/ml of IFN from the provided primary stock and 
Page | 71 
 
stored in -80°C. Before the addition of LPS and IFN, aliquots were vortexed for at 
least 15 minutes. 
2.1.2 XTT assay 
The XTT assay (Invitrogen) was used to determine the sensitivity of tiliroside in BV2 
microglia. There are several inherent advantages of this assay over other cell 
viability methods such as MTT assay. For example, exposure to the large quantities 
of dimethyl sulphide (DMSO) while performing MTT assay was considered as a 
safety hazard. Also, the deleterious effects of DMSO on laboratory equipment 
prompted to look for other alternative methods (Scudiero et al. 1988). Unlike other 
dyes, XTT reagent 2, 3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide) cannot diffuse into the cell. However, the reduction reaction of XTT 
dye occurs at the cell surface facilitated by plasma membrane electron transporters 
and mediated by mitochondrial oxidoreductases (Figure 2.1). An intermediate 
electron acceptor such as N-methyl dibenzopyrazine methyl sulphate (PMS) was 
used to improve the XTT results. PMS is an activation reagent that has been shown 
to mediate XTT reduction by picking up electrons from the cell surface and then 
further reduces XTT to brightly orange formazan derivative. Resulting colorimetric 
change can be measured using plate reader. 
BV2 microglia were seeded at a density of 2 × 105 cells/ml in a 96-well cell culture 
plate and incubated at 37°C. At confluence, cells were stimulated with various 
concentrations of LPS and IFN and incubated for 24 hours. Stimulation was 
terminated by adding 25 µl of XTT/PMS solution. The plate was then further 
incubated for 2 hours at 37°C and resulting colour change was read at 450 nm with a 
plate reader (Infinite F50, Tecan). Later, BV2 cells were incubated with tiliroside 
(6 µM) for various time points followed by stimulation with the combination of LPS 
(100 ng/ml) and IFN (5 ng/ml). XTT/PMS solution was added and the orange colour 
was read at 450 nm with a plate reader. 
BV2 microglia were seeded at a density of 2 × 105 cells/ml in a 96-well cell culture 
plate and incubated at 37°C. At confluence, cells were treated with tiliroside (2-6 µM) 
for 30 minutes followed by stimulation with the combination of LPS and IFN for a 
further 24 hours. Stimulation was terminated by adding 25 µl of XTT/PMS solution. 
The plate was incubated for 2 hours at 37°C, followed by gentle shaking for few 
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seconds to distribute the orange colour before absorbance was read at 450 nm with 
a plate reader (Infinite F50, Tecan). 
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Figure 2.1 Colorimetric reduction of XTT dye by cellular enzymes in the presence 
of N-methyl dibenzopyrazine methyl sulphate (PMS). 
Source:- (Scudiero et al. 1988) 
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2.1.3 Nitrite production 
Nitric oxide (NO) is an important signalling molecule that plays a vital role in the 
pathogenesis of neuroinflammation. It serves as anti-inflammatory under normal 
physiological conditions, while large amounts are shown to be neurotoxic in the brain 
(Dheen, Kaur, & Ling, 2007). Since NO is volatile in nature, levels of nitrite (NO2-), a 
stable and non-volatile breakdown product of nitric oxide can be measured using 
Griess assay (Griess 1879). The main principle of this assay relies on a diazotisation 
reaction that is formed when nitrite in the cell culture supernatant reacts with 
sulphanilamide in the dark. The resulting diazonium salt reacts with N-1-
napthylethylenediamine dihydrochloride (NED) under acidic (phosphoric acid) 
conditions to produce a pink colour (Figure 2.2). The absorbance of the colour 
change is then measured using a plate reader. 
BV2 cells were seeded at a density of 2 × 105 cells/ml and cultured until confluent. 
After that, cells were pre-treated with tiliroside (2-6 μM) for 30 minutes before 
stimulation with LPS (100 ng/ml) and IFN (5 ng/ml) for 24 hours. Levels of nitrite in 
culture media were measured using a Griess reagent kit (Promega, Southampton). 
Supernatants were collected and centrifuged for 5 minutes at 2500 rpm to remove 
cell debris. Sulphanilamide solution was added to 50 µl of culture supernatants in a 
microplate and incubated in the dark for 10 minutes. Thereafter, N-1-
napthylethylenediaminedihydrochloride (NED) was added followed by incubation in 
the dark for further 10 minutes. Absorbance was measured within 30 minutes at 540 
nm in a microplate reader (Infinite F50, Tecan). 
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Figure 2.2 Chemical reactions that are involved in the measurement of NO2- using 
the Griess reagent system. 
Source:- (Griess 1879) 
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2.1.4  Prostaglandin E2 (PGE2) production 
Prostaglandin E2 (PGE2) is an arachidonic acid derivative released by activated 
microglia through the enzymatic action of cyclooxygenase-2 (COX-2), a rate-limiting 
pro-inflammatory enzyme. Studies have revealed that high levels of PGE2 modulate 
the production of inflammatory cytokines during neuroinflammation (Kim et al. 2015) 
and (Loane et al. 2014). This observation, in turn, suggests that inhibition of PGE2 
production in the activated microglia may be beneficial in the treatment of 
neuroinflammation and its associated neurodegeneration.  
Enzyme immune assay (EIA) is a reliable method for measuring the levels of PGE2 
in culture supernatants. EIA uses basic concept of an antigen binding to its specific 
antibody, which allows detection of tiny quantities of antigens (PGE2) in the culture 
supernatants. Antigens are allowed to bind with specific pre-coated antibody that is 
subsequently detected by an enzyme-coupled secondary antibody. A chromogenic 
substrate then binds to the enzyme and yields a visible colour change that can be 
measured using plate reader.  
BV2 cells were seeded in a 24-well plate (2 × 105 cells /ml) and incubated at 37°C 
until confluence. Later, cells were pre-treated with tiliroside (2-6 µM) for 30 minutes 
followed by stimulation with LPS and IFN and incubated at 37°C for further 24 
hours. Levels of PGE2 secretion in culture supernatants was measured with 
commercially available PGE2 EIA kit (Arbor Assays, Michigan). Firstly, contents of 
the kit were brought to room temperature from -20°C. In the first step, standards 
were prepared and added to the 96-well strip plate that has been pre-coated with 
monoclonal capture antibody. Later, 100 µl of centrifuged culture supernatants were 
added, followed by 25 µl of PGE2 conjugate solution (prostaglandin E2-peroxidase 
conjugate in stabilising solution) and 25 µl of mouse detection monoclonal antibody. 
The plate was covered with a sealer and shaken at room temperature for 2 hours at 
300 rpm. Then, contents of the plate were discarded and washed with freshly 
prepared washing buffer to remove non-specifically bound proteins or antibodies. 
Thereafter, 100 µl of 3,3’,5,5’-tetramethylbenzidine (TMB) substrate was added to 
each well and incubated at room temperature for 30 minutes without shaking. The 
reaction was stopped by adding stop solution (0.16M sulphuric acid), and 
absorbance was read at 450 nm using microplate reader (Infinite F50, Tecan). 
Concentrations of PGE2 were calculated from standards (6.25-1000 pg/ml).  
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2.1.5  Enzyme-linked immunosorbent assay (ELISAs)  
In neuroinflammation, pro-inflammatory cytokines such as TNFα, IL-6 and IL-1β are 
considered as significant neurotoxic factors released by activated microglia. Studies 
have shown that these cytokines further activate chemokines and other additional 
inflammatory mediators that induce neuronal apoptosis signalling cascades in the 
hippocampus regions of the brain (Bernhardi et al. 2015) and (Spencer et al. 2012). 
On the other hand, the progression of neuroinflammation was blocked by anti-
inflammatory cytokine production like IL-10 by microglia (Park et al. 2007). 
Therefore, cytokine production in the microglia remains an important target in 
reducing neuroinflammation. 
The ELISA is a specific analytical assay technique used to quantify inflammatory 
cytokines in cell supernatants. The critical step in the assay is the direct detection of 
antigen in the sample by immobilising antigen-specific capture antibody directly onto 
the 96-well surface. This is followed by addition of a specific primary antibody. The 
antigen is thus “sandwiched” between such capture antibody and a detection primary 
antibody. Wells are thoroughly washed to remove unbound antibody. In the next 
step, enzyme-linked secondary antibody is applied, which then binds to the primary 
antibody, followed by addition of enzymatic substrate solution. The resulting colour 
change (reflecting the antigen concentration in the sample) is then quantified.  
BV2 microglia cells were seeded in a 24-well plate (2 × 105 cells /ml) and incubated 
at 37°C. Once confluent, cells were pre-treated with tiliroside (2-6 µM) for 30 minutes 
followed by stimulation with LPS and IFN and incubated at 37°C for further 24 
hours. Stimulation was terminated, and culture supernatants were collected and 
centrifuged for 5 minutes at 2500 rpm. Concentrations of TNFα, IL-6, IL-1β and IL-10 
were measured with commercially available ELISA kits (Biolegend). This method 
uses a 96-well strip plate that is pre-coated with specific target capture monoclonal 
antibody. Firstly, 50 µl of assay buffer was added to each well. Later, 50 µl of freshly 
prepared standard dilutions were added, followed by 50 µl of culture supernatants. 
The plate was then sealed and incubated at room temperature with shaking at 200 
rpm. After 2 hours, the contents of the wells were discarded, and the plate was 
washed four times with at least 300µl of wash buffer and dried by tapping firmly on 
absorbent paper. Specific detection antibody solution was added and incubated for 
60 minutes at room temperature while shaking at 200 rpm. The washing process 
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was repeated, followed by addition of 100µl avidin-horseradish peroxidase enzyme 
(HRP) solution to the wells and incubated for 30 minutes at room temperature while 
shaking at 200 rpm. Contents in the plate were discarded, washed and substrate 
solution was added to the each well and incubated for 15 minutes in the dark. 
Subsequently, the reaction was terminated by adding 100 µl of stop solution (0.16M 
sulphuric acid). The resulting colour change was read at a wavelength of 450 nm 
using plate reader (Infinite F50, Tecan). The concentration of cytokines present in 
the samples was calculated from the absorbance compared to the relevant standard 
curve. 
2.1.6  Isolation of cytoplasmic lysates 
One way to study the extent of protein expression inside the cell is to prepare lysates 
by disrupting and extracting the cytoplasmic cellular contents. This was achieved by 
washing cells with cold PBS, followed by addition of ~25 µl of 
radioimmunoprecipitation assay buffer (RIPA) lysis buffer (Cell signalling) that 
contains 2 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma) and incubated for 15 
minutes. Subsequently, cells were scraped, and lysates were further centrifuged at 
4°C for 15 minutes at 13500 rpm. The resulting cytoplasmic lysates in the 
supernatants were collected, quantified and stored away at -80°C.  
2.1.7 Isolation of nuclear lysates 
Nuclear lysates were prepared to study the behaviour of some transcription factors 
(e.g., NF-B and Nrf2) inside the nucleus of the cell. This was performed using 
EpiSeeker Nuclear Extraction Kit (Abcam). Cells were washed with cold PBS, 
followed by addition of 20 µl of pre-extraction buffer (ENE1 buffer) and incubated on 
ice for 10 minutes. After that, cells were centrifuged at 12000 rpm for 1 minute. 
Supernatants were discarded, and 10 µl of nuclear extraction buffer (ENE2 buffer) 
was added to the pellet and incubated on ice for further 15 minutes with occasional 
vortexing (every 5 minutes). This was followed by centrifugation at 13500 rpm for 15 
minutes at 4°C. The resulting nuclear lysates in the supernatants were collected, 
quantified and stored away at -80°C. 
2.1.8  Protein quantification 
Protein concentrations from cytoplasmic and nuclear lysates were quantified using 
Coomassie (Bradford) protein assay kit (Thermo Fisher). The main principle of this 
assay relies on the calorimetric reaction between the proteins in lysates with 
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Coomassie dye in acidic medium. The resulting colour change (brown to blue) was 
measured at 540 nm using a plate reader. In this assay, bovine serum albumin 
(BSA) was used as standard (125-2000 µg/ml). Lysates and specific standards were 
diluted with de-ionized double distilled water, 5 µl of both samples and standards 
were pipetted into a 96-well microplate. Later, 250 µl of Coomassie reagent was 
added, and the plate was incubated for 10 minutes at room temperature. 
Absorbance was measured at 540 nm using microplate reader (Infinite F50, Tecan). 
Later, protein concentrations of the samples are calculated from the standard curve.  
2.1.9  Western blot analysis 
Western blotting is an important technique used to separate and identify cellular 
proteins based on their molecular weights. Following protein quantification, 25 µg of 
protein was denatured by heating with 5 µl of lithium dodecyl sulphate (LDS) 
(Invitrogen) and 2 µl sample reducing agent (500 mM dithiothreitol (DTT)), 
(Invitrogen) at 70°C for 10 minutes. Electrophoresis was performed using Bolt™ 4-
12% Bis-Tris Plus pre-cast polyacrylamide gels (Invitrogen) with running buffer 
(Invitrogen) at a constant voltage of 200 V for 35 minutes. Running buffer contains a 
mixture of Tris base, glycine, SDS in H2O and pH was adjusted to 8.3. Later, 
separated proteins were transferred from the gel onto a polyvinylidene fluoride 
(PVDF) membrane (Millipore) using transfer buffer (Invitrogen) for 2 hours at 25 V. 
Transfer buffer contains a mixture of 25 mM Tris, 190 mM glycine, 20% methanol 
and finally pH was adjusted to 8.3. Membranes were then washed three times (5 
minutes each wash) with Tris-buffered saline (TBS-T) and blocked for 60 minutes at 
room temperature using non-fat dry milk. Later, membranes were washed and 
incubated with primary antibodies overnight at 4°C. Primary antibodies used in this 
research are listed in Table 1. The next day, membranes were washed three times 
with TBS-T (5 minutes each wash) and then incubated with anti-rabbit Alexa Fluor 
680 goat secondary antibody (Invitrogen) for 60 minutes in the dark (fluorophore 
attached to the secondary antibody are light sensitive). Later, membranes were 
washed briefly, and band detection was done using Licor Odyssey image station. 
Molecular weight determination was done by comparing bands to the Precision Plus 
Protein™ unstained standards (Bio-Rad). The relative density of the protein 
expressions was measured using Image J (National Institutes of Health, USA) and 
was normalised by comparing to anti-actin (cytoplasmic proteins) or Lamin B 
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(nuclear proteins) antibodies. All antibodies and buffers are prepared in TBS-T to 
reduce background signal.  
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Antibodies Supplier Host Type Dilution 
iNOS Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
COX-2 Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
p-IB-α Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
Total-IB-α Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
p-IKK-α Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
Total-IKK-α Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
p-NF-B-p65 Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
Total-NF-B-p65 Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
p-p38 Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
Total-p38 Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
p-MK2 Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
Total-MK2 Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
p-MKK3/6 Cell signalling Rabbit Polyclonal 1:1000 
TRAF6 Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
TLR4 Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
HO-1 Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
NQO1 Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
Nrf2 Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
SIRT1 Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
Acetyl-NF-B-p65 Cell signalling Rabbit Polyclonal 1:1000 
Beta-actin Sigma Aldrich Rabbit Polyclonal 1:1000 
Lamin B Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
MAP2 Santa Cruz Biotechnology Rabbit Polyclonal 1:500 
Table 2 Primary antibodies used in the western blot analysis. 
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2.1.10  Transient transfection and luciferase reporter gene assays 
Over the past few years, research has focused on studying the role of various 
transcription factors such as NF-B and Nrf2 in neuroinflammatory conditions. It is 
imperative to explore the roles of these transcription factors in neuroinflammation 
due to their crucial role in controlling the transcription of various inflammatory 
mediators (Didonato et al. 2012), (Lee & Johnson 2004) and (Kim et al. 2010b). In 
general, genetic reporters are used in studying gene expressions and other 
intracellular events coupled to gene expression at transcriptional level. Typically, in 
luciferase-based reporter assays, luciferase reporter gene is cloned with a DNA 
sequence of interest into an expression vector which is then transferred into cells 
using a transfection reagent. Once cells are activated, reporter protein (luciferin) is 
converted to oxyluciferin in the presence of firefly luciferase enzyme along with high 
efficient light which is further quantified using luminometer (Figure 2.3). The 
efficiency of the gene reporters typically depends on the type of vector used during 
transfection. Luciferase reporter assay system uses pGL4.32 vectors to deliver 
luciferase reporter gene [luc2P] into cells. The pGL4 Vectors are engineered in a 
way to facilitate high-end gene expression and reduced anomalous transcription. 
The pGL4.32 [luc2P/ NF-B-RE/Hygro] (Promega) vector was used to study the NF-
B-mediated gene expression at the transcriptional level in the microglia. This vector 
contains five copies of NF-B response elements (NF-B-RE) that drive transcription 
of luciferase reporter gene luc2P. Also, to understand antioxidant response element 
(ARE)-mediated gene expression in microglia, pGL4.37 [luc2P/ARE/Hygro] 
(Promega) vector was used, which contains four copies of ARE that drive 
transcription of the luciferase reporter gene luc2P.  
The day before the transfection BV2 cells were subcultured at a ratio of 1:3. The next 
day, cells were harvested and seeded at a density of 4 x 105 cells/ml in a solid white 
96-well plate using Opti-MEM® (modified Eagle's Minimum Essential Media) 
(Invitrogen) mixed with 5% FBS. The pGL4.32 [luc2P/ NF-B -RE/Hygro] vector was 
used for NF-B at a concentration of 1 ng DNA/µl, mixed with Fugene 6 (Promega) 
transfection reagent. This mixture was later added to the cells in the 96-well plate 
and incubated for a further 16 hours at 37°C in 5% CO2 incubator. After that, media 
was changed to Opti-MEM® (without 5% FBS) and incubated for a further 8 hours. 
To determine NF-B-mediated gene expression, transfected cells were pre-treated 
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with tiliroside for 30 minutes followed by stimulation with LPS and IFN for 60 
minutes at 37°C. At the end of the stimulation, 100 µl of luciferase assay buffer 
containing luminescence substrate was added to each well and luminescence was 
read with FLUOstar OPTIM reader (BMG LABTECH). 
A different vector was used to investigate the effects of tiliroside on ARE-associated 
gene expression in BV2 microglia. Cells were seeded at a density of 4 x 105 cells/ml 
in a white 96-well plate using Opti-MEM® that contains 5% FBS. Later, the pGL4.37 
[luc2P/ARE/Hygro] vector (1 ng DNA/µl) was mixed with Fugene 6 and added to the 
cells followed by incubation for 16 hours at 37°C. Thereafter, media was changed to 
Opti-MEM® (without 5% FBS) and incubated for a further 8 hours. Transfected cells 
were treated with tiliroside (2-6 µM) alone for 24 hours (for time point experiments 
refer to the section 3.2.11, 5.2.1 and 5.2.2) to investigate ARE-associated gene 
expression. At the end of the stimulation, 100 µl of luciferase assay buffer containing 
luminescence substrate was added to each well and luminescence was read with 
FLUOstar OPTIM reader (BMG LABTECH).  
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Figure 2.3 Chemical reaction involved in the luciferase reporter assay 
Source:- (Alam & Cook 1990) 
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2.1.11 Nrf2 and SIRT1 siRNA transfections  
Small interfering RNAs (siRNAs) are short non-coding double-stranded RNAs with 
high efficacy and excellent specificity to inhibit or shut down target gene expression 
prior to translation. These siRNAs are widely used to investigate the individual 
contributions of specific genes of interest to an assortment of cellular processes. 
siRNAs mainly consist of two RNA strands, an antisense or guide strand and a 
sense or passenger strand. This small double-stranded siRNAs are transfected into 
cells with the help of polymer based transfection reagents, where the guide strand is 
loaded into RNA-induced Silencing Complex (RISC) (Figure 2.4). This activated 
protein, and nucleic acid complex can then elicit gene silencing by binding, through 
perfect complementarity, to a single target mRNA sequence, thereby targeting it for 
cleavage and degradation (Reynolds et al. 2004). 
Several studies have highlighted the roles of transcription factors Nrf2 and SIRT1 in 
neuroinflammation (Lee & Johnson 2004) and (Shen et al. 2009). Compounds that 
have shown to activate these transcription factors blocked LPS-induced 
neuroinflammation in the microglia (Y. Li et al. 2015) and (Onasanwo et al. 2016). 
Therefore, to further determine the neuroinflammation inhibitory activity of tiliroside in 
the absence of Nrf2, siRNA technique was used. Nrf2 gene was knocked out in BV2 
microglia using Nrf2 siRNA (Santa Cruz Biotechnology). BV2 cells were cultured and 
seeded in a 6-well plate at a density of 2 × 105 cells/ml using antibiotic-free (penicillin 
and streptomycin) RPMI 1640 growth medium and incubated at 37°C in a 5% CO2 
incubator until 50% confluent. In tube A, 2 µl of Nrf2 siRNA duplex (Santa Cruz 
Biotechnology) was diluted into 100 µl of siRNA transfection medium (Santa Cruz 
Biotechnology). In tube B, 2 µl of transfection reagent (Santa Cruz Biotechnology) 
was diluted into 100 µl of siRNA transfection medium. The contents of tube A were 
transferred gently to tube B to prepare transfection cocktail and incubated for 45 
minutes at room temperature. Next, 200 µl of Nrf2 siRNA transfection cocktail was 
added to the cells in the plate and further incubated for 6 hours at 37°C. Control BV2 
microglia were transfected with control siRNA. Following transfection, media was 
changed to RPMI 1640 growth media and incubated for a further 18 hours at 37°C. 
Effects of tiliroside (6 µM) on nitrite, PGE2, TNFα and IL-6 production in LPS 
(100 ng/ml)/IFN (5 ng/ml)-stimulated control siRNA and Nrf2-siRNA-transfected BV2 
cells were then determined. Also, iNOS and COX2 protein expressions were 
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evaluated using western blots. NF-B DNA binding assays were conducted for both 
control siRNA and Nrf2 siRNA-transfected BV2 cells treated with tiliroside (6 µM). 
Transfection efficiency was determined by subjecting nuclear lysates from both 
control siRNA and Nrf2 siRNA-transfected BV2 microglia to western blotting to detect 
levels of Nrf2 protein. 
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Figure 2.4 The mechanism of RNA interference using siRNA. 
Source:- (Agrawal et al. 2003) 
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To further determine the neuroinflammation inhibitory activity of tiliroside in the 
absence of SIRT1, siRNA technique was used. SIRT1 gene was knocked out in BV2 
microglia using SIRT1 siRNA (Santa Cruz Biotechnology). BV2 cells were cultured 
and seeded in a 6-well plate at a density of 2 × 105 cells/ml using antibiotic-free 
(penicillin and streptomycin) RPMI 1640 growth medium and incubated at 37°C in a 
5% CO2 incubator until 50% confluent. In tube A, 2 µl of SIRT1 siRNA duplex (Santa 
Cruz Biotechnology) was diluted into 100 µl of siRNA transfection medium (Santa 
Cruz Biotechnology). In tube B, 2 µl of transfection reagent (Santa Cruz 
Biotechnology) was diluted into 100 µl of siRNA transfection medium. The contents 
of tube A were transferred gently to tube B to prepare transfection cocktail and 
incubated for 45 minutes at room temperature. Next, 200 µl of SIRT1 siRNA 
transfection cocktail was added to the cells in the plate and further incubated for 6 
hours at 37°C. Control BV2 microglia were transfected with control siRNA. Following 
transfection, media was changed to RPMI 1640 growth media and incubated for a 
further 18 hours at 37°C. Effects of tiliroside (6 µM) on nitrite, PGE2, TNFα and IL-6 
production in LPS/IFN-stimulated control siRNA and SIRT1-siRNA-transfected BV2 
cells were then determined. Transfection efficiency was determined by subjecting 
nuclear lysates from both control siRNA and SIRT1 siRNA-transfected BV2 microglia 
to western blotting to detect levels of SIRT1 protein. 
2.1.12  Immunofluorescence 
Immunofluorescence is an imaging technique that is widely accepted as a robust 
method to assess localisation and expression of proteins of interest in cells. The 
principle mainly relies on the direct or indirect antigen-antibody reaction, which 
allows the end user to observe the changes under fluorescence or confocal 
microscope. BV2 microglia were seeded at a density of 2 × 105 cells /ml in 24-well 
plates. At confluence, cells were pre-treated with tiliroside (2-6 µM) for 30 minutes 
followed by stimulation with the combination of LPS (100 ng/ml) and IFN (5 ng/ml) 
for various time points (see chapters 3, 4 and 5 for details of time points). Cells were 
fixed with ice-cold methanol (100%) for 15 minutes at -20°C and later washed three 
times for 5 minutes with phosphate buffer saline (PBS). Non-specific binding sites 
were blocked by incubating cells with 5% bovine serum albumin (BSA) blocking 
solution (containing 10% horse serum) in 1X TBS-T) for 60 minutes at room 
temperature followed by washing with PBS. Thereafter, cells were incubated with 
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primary antibodies (Table 3) for overnight at 4°C. Following overnight incubation, 
cells were washed 3 times with PBS and incubated for 2 hours in the dark with Alexa 
Fluor 488-conjugated donkey anti-rabbit IgG (Life Technologies) secondary antibody 
(1:500). Later, cells were washed with PBS and counterstained with 4', 6 diamidino-
2-phenylindole dihydrochloride (50 nM, DAPI; Invitrogen) for 5 minutes. After rinsing 
cells with PBS, the excess buffer was removed, and gold antifade reagent 
(Invitrogen) was added to prevent the signal from fading. All staining procedures 
were performed at room temperature. Representative fluorescence images were 
obtained using EVOS® FLoid® cell imaging station (Invitrogen). 
 
Antibodies Supplier Host Type Dilution 
p-NF-B-p65 Santa Cruz Biotechnology Rabbit Polyclonal 1:100 
Total-NF-B-p65 Santa Cruz Biotechnology Rabbit Polyclonal 1:100 
TLR4 Santa Cruz Biotechnology Rabbit Polyclonal 1:100 
HO-1 Santa Cruz Biotechnology Rabbit Polyclonal 1:100 
Nrf2 Santa Cruz Biotechnology Rabbit Polyclonal 1:100 
SIRT1 Santa Cruz Biotechnology Rabbit Polyclonal 1:100 
Acetyl-NF-B-p65 Santa Cruz Biotechnology Rabbit Polyclonal 1:100 
MAP2 Santa Cruz Biotechnology Rabbit Polyclonal 1:100 
Table 3 Primary antibodies used in immunofluorescence experiments. 
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2.1.13  Electrophoretic mobility shift assays (EMSA) 
In neuroinflammation, transcription factors play a crucial role in regulating several 
pro-inflammatory genes by controlling their transcription. However, these gene 
expressions are tightly controlled by the transcriptional protein-DNA interactions 
inside the nucleus. EMSA is an important technique used to study these protein-DNA 
interactions in mammalian tissues and nuclear cell lysates. 
ELISA-based EMSA 
Activation of NF-B transcription factor has been shown to increase the production of 
pro-inflammatory cytokines and other mediators involved in the neuroinflammation. 
Studies have demonstrated that LPS alone can predominantly induce transcription of 
several inflammatory genes via nuclear NF-B-DNA interactions in the microglia 
(Hanamsagar et al. 2012), (Zhou et al. 2014), (Xu et al. 2014) and (Takeda & Akira 
2004). Therefore, it is important to study the interactions between NF-B-DNA in the 
activated microglia during neuroinflammatory conditions. Commercially available 
non-radioactive TransAM® NF-B transcription factor EMSA kit, (Active Motif, 
Belgium) was used to determine the effects of tiliroside on DNA binding of NF-B in 
BV2 microglia. This kit contains a 96-stripwell plate in which a specific double-
stranded oligonucleotide that contains multiple copies of the consensus-binding site 
has been immobilised on the well surface. The transcription factor that is present in 
the nuclear extract binds specifically to this oligonucleotide, which is further 
quantified by adding a specific primary antibody, secondary antibody and a 
developing solution. The resulting colorimetric outcome can be easily quantified 
using a plate reader at a wavelength of 450 nm (Figure 2.5). Gel based EMSA or 
conventional EMSA involves several steps such as preparation of DNA complexes 
using various buffers, pre-annealed nucleotides and most importantly the binding 
reaction. In addition, only a limited number of samples can be subjected to 
electrophoresis, as these issues prompted to look for other alternative methods. In 
ELISA based EMSA is a straightforward assay and does not require any additional 
steps or reaction mixtures. Moreover, 96-stripwell format enables to run a high 
number of samples at a time. 
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Figure 2.5 Flow chart for the TransAM® NF-B transcription factor ELISA based 
EMSA kit. 
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BV2 microglia were pre-treated with increasing concentrations of the compound for 
30 minutes and later, cells were stimulated with LPS (100 ng/ml)/IFN (5 ng/ml). 
After 60 minutes, nuclear lysates were prepared using EpiSeeker Nuclear Extraction 
Kit (Abcam), as explained previously in section 2.1.7. The EMSA kit employs a 96-
well plate to which an oligonucleotide containing the NF-B consensus site (5’ 
GGGACTTTCC-3’) has been immobilised. Later, 30 µl of complete binding buffer 
was added to each well, followed by 20 µg nuclear extract samples. The plate was 
covered and shook (100 rpm) for 60 minutes at room temperature. This was followed 
by discarding contents of the plate and washing it for three times with 200 µl/well of 
wash buffer, followed by addition of 100µl of NF-B antibody (1:1000). The plate was 
sealed and incubated for further 60 minutes at room temperature while shaking, 
followed by washing three times. Later, 100 µl of HRP-conjugated antibody (1:1000) 
was added and incubated for 60 minutes at room temperature followed by washing. 
In the end, 100 µl of developing solution was added and incubated in the dark for 15 
minutes, and the reaction was stopped by adding 100 µl of stop solution. 
Absorbance was read on a Tecan F50 microplate reader at 450 nm. 
To investigate DNA binding of Nrf2, BV2 microglia were treated with tiliroside (2-
6 µM) for 24 hours and nuclear lysates were prepared using EpiSeeker Nuclear 
Extraction Kit (Abcam), as explained previously in section 2.1.7. Later, 20 µg of 
nuclear lysates were added to 96-well plates on which oligonucleotide containing the 
ARE consensus binding site (5’ GTCACAGTGACTCAGCAGAATCTG-3’) has been 
immobilised. After that, 30 µl of complete binding buffer was added to each well and 
incubated for 60 minutes at room temperature while shaking. This was followed by 
discarding contents of the plate and washing it for three times with 200 µl/well of 
wash buffer, followed by addition of 100µl of Nrf2 antibody (1:1000). Cover the plate 
and incubate it for further 60 minutes at room temperature while shaking, followed by 
three times washing. Later, 100 µl of HRP-conjugated antibody (1:1000) was added 
and incubated for further 60 minutes at room temperature followed by washing. In 
the end, 100 µl of developing solution was added and incubated in the dark for 15 
minutes and the reaction was terminated by adding 100 µl of stop solution. 
Absorbance was read on a Tecan F50 microplate reader at 450 nm. 
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2.1.14 Measurement of intracellular reactive oxygen species (ROS)  
A series of studies has revealed the crucial role of ROS in neuroinflammatory 
processes and its mediated neurodegeneration in the CNS (Ray & Lahiri 2009). 
Microglia was shown to produce ROS in response to the inflammatory stimuli. This 
intracellular accumulation of ROS triggers the release of various inflammatory 
mediators through activation of downstream signalling pathways like MAPKs and 
NF-B in microglia (Rojo et al. 2014). Several lines of evidence show that 
antioxidants inhibit NF-B activation and block inflammatory cytokines production by 
modulating the generation of ROS (Zhang et al. 2016). Intracellular ROS production 
was measured using 2’, 7’-dichlorofluorescein diacetate DCFDA-cellular reactive 
oxygen species detection assay kit (Abcam). This assay system uses the cell 
permeant reagent 2’, 7’ –dichlorofluorescein diacetate (DCFDA), a fluorogenic dye 
that measures the activity of ROS within the cell. DCFDA dye diffuses into the cell 
and gets deacetylated into to a non-fluorescent compound by cellular esterases, 
which is later oxidised by intracellular ROS into 2’, 7’ –dichlorofluorescein (DCF). As 
DCF is a highly fluorescent compound that can be detected by fluorescence with 
maximum excitation of 495 nm and emission of 529 nm respectively (Figure 2.6).  
BV2 microglia were seeded in non-transparent white bottomed 96-well plates at a 
density of 2 × 105 cells/ml. Once confluent, the cells were washed with PBS and 
stained with 20 μM DCFDA for 30 minutes at 37°C. After incubation, the cells were 
washed with PBS and further incubated for 30 minutes with or without tiliroside (2-
6 μM) prior to stimulation with LPS (100 ng/ml) and IFN (5 ng/ml) for 24 hours. 
Intracellular production of ROS was measured by the fluorescence detection of 
dichlorofluorescein (DCF) as the deacetylated product of DCFDA in a Polar Star 
Optima microplate reader (BMG LABTECH) at an excitation wavelength of 485 nm 
and an emission wavelength of 535 nm. 
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Figure 2.6 Formation of fluorescent compound DCF from DCFDA dye by ROS. 
Source:- (Held 2008) 
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2.1.15 Measurement of glutathione (GSH) 
Depletion of glutathione (GSH) levels has been identified as an early event in the 
progression of neuroinflammation and its mediated neurodegenerative diseases. 
Reduced GSH levels are shown to promote oxidative stress and potentially leading 
to the death of microglia in the brain (Lee et al. 2010). Concentrations of GSH in the 
BV2 cell culture supernatants were measured using GSH-Glo™ Glutathione assay 
kit (Promega). This luminescence assay is based on the conversion of a luciferin 
derivative into luciferin in the presence of glutathione, catalysed by glutathione S-
transferase enzyme (GST). The stable luminesce signal generated during this 
coupled reaction in the presence of firefly luciferase (Figure 2.7) was measured 
using luminometer and is proportional to the amount of glutathione present in the 
supernatants. 
BV2 microglia were harvested in a 96-well plate (2 × 105 cells/ml). When cells 
reached confluence, the culture medium was changed to serum-free medium, pre-
treated with tiliroside (2-6 µM) for 30 minutes and later stimulated with a combination 
of LPS (100 ng/ml) and IFN (5 ng/ml) for 24 hours. At the end of the experiment, the 
culture medium was removed, and 100 μl of 1X GSH-Glo™ reagent was added to 
each well and incubated with shaking at room temperature for 30 minutes. 
Thereafter, 100μl of luciferin detection reagent was added to each well and 
incubated with shaking at room temperature for 15 minutes. Luminescence was then 
read with FLUOstar OPTIM reader (BMG LABTECH). 
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Figure 2.7 Chemical reactions that are involved in the measurement of GSH using 
GSH-Glo assay kit. 
Source:- (Sies 1999) 
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2.2 HT22 mouse hippocampal neurons 
HT22 neuronal cells were a kind gift from Dr Jeff Davis. These are immortalised 
mouse hippocampal neuronal cell lines that were derived from HT4 cells (Davis & 
Maher, 1994). HT22 neuronal cells were cultured in DMEM supplemented with 10 % 
FBS, 100 mM sodium pyruvate (Sigma), 100 U/ml penicillin and 100 mg/ml 
streptomycin in a 5 % CO2 incubator at 37 °C. Cells were cultured in 75 cm2 flasks. 
Confluent monolayers were washed with PBS and trypsinised with 2 ml of 0.25% 
trypsin-EDTA solution. Trypsinisation was terminated by adding 8 ml of complete 
DMEM medium, followed by centrifugation at 1200 rpm for 5 minutes. Once cells 
were pelleted, the medium was aspirated and resuspended in fresh complete 
medium. Cell count was performed using a haemocytometer and seeded at a 
concentration of 2 × 105 cells /ml in various cell culture plates respectively. 
2.2.1  Microglial conditioned medium 
BV2 cells were seeded at a density of 2 × 105 cells/ml in a 6-well plate and incubated 
at 37°C. Once confluent, cells were pre-treated with tiliroside (2-6 µM) for 30 minutes 
and stimulated with LPS (100 ng/ml)/IFN (5 ng/ml) for 24 hours. Stimulation was 
terminated by removing supernatants (conditioned medium) from the cells and 
centrifuged at 2500 rpm for 5 minutes to remove cellular debris, aliquoted and then 
stored at -80°C. 
2.2.2  Determination of HT22 cell viability using conditioned medium 
The effect of conditioned medium obtained from microglia on the viability of HT22 
cells was measured using the XTT assay (Invitrogen). BV2 cells were pre-treated 
with tiliroside (2-6 µM) for 30 minutes and stimulated with LPS (100 ng/ml)/IFN 
(5 ng/ml) for 24 hours. Stimulation was terminated by collecting conditioned medium 
from the cells and centrifuged and stored at -80°C. HT22 hippocampal neurons were 
seeded at a density of 2 × 105 cells /ml in 96-well cell culture plates and incubated at 
37°C. When cells reach confluence, the culture medium was removed and replaced 
with 100 μl of conditioned medium and further incubated for 24 hours. Stimulation 
was terminated by adding 25 µl of XTT/PMS solution and incubated for 2 hours at 
37°C, followed by gentle shaking for few seconds to distribute the orange colour 
before absorbance was read at 450 nm with a plate reader (Infinite F50, Tecan). 
2.2.3  Measurement of ROS in neuronal cells 
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The effect of conditioned medium on levels of intracellular ROS in HT22 neuronal 
cells was investigated using DCFDA-cellular reactive oxygen species detection 
assay kit, (Abcam) that uses a cell permeable fluorogenic dye DCFDA. Conditioned 
medium was obtained from BV2 cells that were pre-treated with tiliroside (2-6 µM) for 
30 minutes and stimulated with LPS (100 ng/ml)/IFN (5 ng/ml) for 24 hours. HT22 
hippocampal neurons were seeded at a density of 2 × 105 cells /ml in 96-well cell 
culture plates and incubated at 37°C. After 48 hours, cells were washed with PBS 
and stained with 20 μM DCFDA followed by further incubation at 37°C for 30 
minutes. After incubation, the cells were washed with PBS and thereafter treated 
with 200 μl of microglia conditioned medium and incubated for further 24 hours at 
37°C. Intracellular production of ROS was measured by the fluorescence detection 
of dichlorofluorescein (DCF) using Polar star Optima microplate reader (BMG 
LABTECH) at an excitation wavelength of 485 nm and an emission wavelength of 
535 nm.  
2.2.4  Immunofluorescence in HT22 neuronal cells 
HT22 neuronal cells were seeded at a density of 2 × 105 cells /ml in 24 well plates. 
Once confluent, cells were treated with conditioned medium for 24 hours (for MAP2). 
Cells were then fixed with ice-cold methanol (100%) for 15 minutes at -20°C and 
later washed 3 times for 5 minutes with PBS. Non-specific binding sites were 
blocked by incubating cells with 5% BSA blocking solution (containing 10% horse 
serum) in 1X TBS-T) for 60 minutes at room temperature followed by washing with 
PBS. Thereafter, the cells were incubated with 1:100 dilution of rabbit anti-mouse 
MAP2 (Santa Cruz) antibody for overnight at 4°C. Following overnight incubation, 
cells were washed 3 times with PBS and incubated for 2 hours in dark with Alexa 
Fluor 488-conjugated donkey anti-rabbit IgG (Life Technologies) secondary antibody 
(1:500). Later, cells were washed with PBS and counterstained with 4', 6 diamidino-
2-phenylindole dihydrochloride (50 nm, DAPI; Invitrogen) for 5 minutes. After rinsing 
cells with PBS, the excess buffer was removed and gold antifade reagent 
(Invitrogen) was added. All staining procedures were performed at room 
temperature. Representative fluorescence images were obtained using EVOS® 
FLoid® Cell imaging station (Invitrogen). 
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2.2.5  DNA fragmentation assay in HT22 neuronal cells 
In neurodegeneration, inflammation-induced DNA fragmentation is considered as 
one of the important biomarkers that feature neuronal apoptosis (Park et al. 2000) 
and (Koh et al. 2008). Modulations of the chromatin DNA fragmentation in neuronal 
cells by means of compounds or treatment strategies have the potential to eliminate 
the neuroinflammation-associated toxicity. An ELISA based non-radioactive cellular 
DNA fragmentation assay kit (Roche Diagnostics) was used to measure the DNA 
fragmentation of HT22 neuronal cells treated with conditioned medium. The principle 
of this assay is based on a simple enzymatic reaction between the pre-coated 
immobilised anti-DNA antibody and 5-bromo-2’-deoxyuridine (BrdU) labelled DNA 
fragments in the supernatants. Firstly, cells are labelled with BrdU dye and later 
stimulated with conditioned medium. The cell-mediated cytotoxicity is mainly 
characterised by cleavage of the DNA into fragments because DNA cleavage is an 
important hallmark of apoptosis. Subsequently, cells that are pre-labelled with BrdU 
are lysed and resulting BrdU-complexed DNA fragments were analysed by ELISA. 
HT22 neurons were seeded at a density 2 x 105 cells /ml and allowed to become 
confluent. Thereafter, cells were labelled with 5-bromo-2’-deoxyuridine (BrdU) for 12 
hours. Later, the BrdU-containing culture medium was removed and conditioned 
medium was added and incubated for 24 hours. Next day, cells were collected and 
centrifuged at 2500 rpm for 10 minutes and supernatants were discarded. Later, 
cells were lysed by adding 200 µl of incubation buffer (a non-ionic detergent) and 
incubated for 30 minutes at room temperature, followed by centrifugation at 2500 
rpm for 10 minutes. 100 µl of the supernatants were pipetted into anti-DNA pre-
coated 96-well plate and incubated for 90 minutes at room temperature. Contents of 
the plate were removed and washed three times with 250 µl of wash buffer. Later, 
100 µl/well of exonuclease III solution was added and further incubated at 37°C for 
30 minutes. The solution in the plate was discarded and washed for three times with 
250 µl of wash buffer, followed by addition of anti-BrdU peroxidase conjugate 
solution and incubated for 90 minutes at room temperature. Contents of the plate 
were emptied and washed. Later, 100 µl of substrate solution was added and 
incubated in the dark for 30 minutes. The reaction was terminated by adding 25 µl of 
stop solution and absorbance was measured at 450nm using microplate reader 
(Infinite F50, Tecan).  
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2.2.6  Calcium quantification in HT22 neuronal cells 
Calcium is an essential intracellular messenger that mediates several signalling 
processes in all cell types of the CNS. High intracellular levels of calcium were 
observed in adjacent neurons during neuroinflammatory conditions which could 
damage DNA, cell membranes, enzyme dysfunctions and could lead to neuronal 
death (Ceulemans et al. 2010). Levels of calcium in the cell cytoplasm were 
measured using Calcium Detection assay kit (Abcam). Calcium ions in the sample 
react with the o-cresolphthalein reagent to form a chromogenic complex with a 
colour change that can be measured at a wavelength of 575 nm. HT22 neuronal 
cells were seeded into 24-well at a density of 2 x 105cells/ml and allowed to settle. At 
confluence, the medium was replaced with conditioned medium as explained 
previously and incubated for 24 hours at 37°C. Later, lysates were collected using 
RIPA lysis buffer followed by centrifugation at 4°C, 13500 rpm for 15 minutes. Fifty 
microliters of the lysates were pipetted into 96-well plate followed by 90 µl of 
chromogenic reagent along with 60 µl of calcium assay buffer, incubated in the dark 
for 15 minutes at room temperature. Output was measured using Tecan F50 
microplate reader at a wavelength of 575 nm. Concentrations of calcium in the 
cytoplasmic lysates were calculated by comparing to the standard curve (0-2.0 
µg/ml).  
2.2.7 Statistical analysis 
Statistical analysis was done by one-way analysis of variance (ANOVA) with post-
hoc Student-Newman-Keuls test (multiple comparisons). The ANOVA compares the 
mean between the groups and will determine whether those means are significantly 
different from each other. To determine the specific groups that are significantly 
different from each other were evaluated by using post-hoc Student-Newman-Keuls 
test with multiple comparisons. Calculations for statistical analysis were performed 
with Graph Pad Prism software version 5 (San Diego, US). Differences were 
considered significant at p < 0.05. For neuroinflammation experiments designations 
include: &p<0.05, &&p<0.01, &&&p<0.001 compared with untreated control and 
*p<0.05, **p<0.01, ***p<0.001 in comparison with LPS/IFN control. 
For siRNA experiments: ᶿp< 0.05, ᶿᶿp<0.01, ᶿᶿᶿp<0.001 in comparison within the 
groups of the untreated control. $p< 0.05, $$p<0.01, $$$p<0.001 as compared within 
the groups stimulated with LPS/IFN and #p<0.05, ##p<0.01, ###p<0.001 as compared 
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within the groups pre-treated with tiliroside (6 μM). At least three independent 
experiments were performed for analysis. Where necessary original data were 
converted into % values of control or LPS/IFN and mean ± S.E.M. was calculated. 
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Chapter 3. Tiliroside inhibited LPS/IFN-induced neuroinflammation 
in BV2 microglia 
3.1 Introduction 
Neuroinflammation is a defence mechanism aimed at protecting against pathogens 
and infections in the central nervous system (CNS) through activation of microglia. 
Excessive neuroinflammatory responses in the microglia have been shown to cause 
neuronal damage in neurodegenerative diseases such as Parkinson’s disease (PD), 
Alzheimer’s disease (AD), multiple sclerosis (MS), and amyotrophic lateral sclerosis 
(ALS) (Lehnardt 2010). Activated microglia secretes a variety of pro-inflammatory 
cytokines, neurotoxic factors, reactive oxygen mediators and arachidonic acid 
derivatives, which are considered to be a major hallmark of brain inflammation, and 
plays a key role in regulating neuroinflammatory responses (Ray & Lahiri 2009) and 
(Lyman et al. 2013).  
In general, brain inflammation may be divided into three phases, (1) acute phase (2) 
chronic and (3) resolution phase. The acute phase is an initial stage where ramified 
microglia is found at resting state with a small static cell body and processed 
branches that actively monitor their microenvironment for pathogens or infections in 
the brain. Cell wall components, DNA/RNA of the bacteria or pathogens, damaged 
host cells and heat shock proteins are recognised by pattern recognition receptors 
(PRRs), such as toll-like receptors (TLRs), NOD-like receptors (NLRs) on microglia. 
Once these receptors are activated, microglia produces several pro-inflammatory 
cytokines such as IL-1β, TNF α and IL-6 via different intracellular signalling 
cascades. This activation is also accompanied by partial rounding up and mobility of 
adjacent glial cells and astrocytes that ultimately creates a vicious cycle by releasing 
various neurotoxic factors. Microglia at this phase is termed as chronically active. 
The resolution phase, where microglia exhibit amoeboid, highly phagocytic, and 
produce anti-inflammatory cytokines such as IL-4, IL-6, IL-10, IL-11, IL-13 and TGFβ, 
in order to resolve the local inflammation and clear up the bacteria or pathogens 
(Morales et al. 2014), (Opal & DePalo 2000) and (Halliday et al. 2000). However, in 
neuroinflammatory conditions, microglia become hyperactive and release excess 
neurotoxic factors in the brain. For instance, increased microglial activation was 
observed in early stages of AD and PD (Vehmas et al. 2003) and (Krause & Muller 
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2010). Therefore, therapies that target microglial activation and its mediated 
neuroinflammatory factors gained a decent attention in recent years. 
Hyperactive microglia facilitates the activation of several intracellular signalling 
pathways; however in-depth understanding of these pathways is very limited. 
Prostaglandin E2 (PGE2) is an arachidonic acid derivative, the production of which is 
catalysed by cyclooxygenase enzymes in activated microglia. Cyclooxygenases are 
two subtypes, cyclooxygenase-1 (COX-1) and cycloxygenase-2 (COX-2). COX-1 is 
constitutively expressed in most cell types, whereas expression of COX-2 is induced 
by various factors including inflammatory cytokines, and is mainly responsible for the 
production of PGE2 (Lima et al. 2012). Sustained upregulation of COX-2 and its 
mediated PGE2 in microglia contributes to the progressive damage in 
neurodegenerative diseases. In cultured rat brain microglia, bacterial 
lipopolysaccharide (LPS) has been shown to induce COX-2 expression, and this is 
prevented in the presence of inhibitors of NF-B (Zhou et al. 2014). Also, COX-2 and 
PGE2 are highly expressed in glial cells of substantia nigra of post-mortem AD 
patients, and specific inhibitors of COX-2 has been found to exert neuroprotective 
effects (Peterson & Toborek 2014) and (Knott et al. 2000). Recent epidemiological 
studies clearly suggest that COX inhibitors reduce the risk of AD and PD (Krause & 
Muller 2010). Therefore, inhibition of COX-2 and its mediated PGE2 production 
would be an effective therapeutic approach in alleviating the progression of 
neuroinflammation. 
In addition to PGE2, the cellular messenger, nitric oxide (NO) has been widely 
implicated in neuroinflammation and neurodegenerative processes. Elevated levels 
of NO have been reported in both microglia and astrocytes, which are activated 
during the neuroinflammatory response (Morales et al. 2014). A significant body of 
evidence also suggests that the release of large amounts of NO from activated 
astrocytes and microglia, mediated by the inducible nitric oxide synthase (iNOS) 
enzyme, is important in the pathogenesis of neurodegenerative disorders. Research 
evidence suggests that iNOS is not commonly expressed in brain cells. However, 
inflammatory mediators such as LPS and cytokines can induce its expression 
(Brown & Neher 2010) and (Ghasemi & Fatemi 2014). High levels of NO have been 
shown to induce neuronal toxicity by causing mitochondrial depolarisation by 
targeting cytochrome oxidase in neurons. This further facilitates glutamate release 
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from neuronal cells and causes excitotoxicity in adjacent astrocytes via calcium 
release from intracellular stores, thus inducing toxicity in both neurons and 
astrocytes in the brain (McGeer & McGeer 2015) and (Spencer et al. 2012). Also, 
this is evident in the induction of neuronal death through both necrotic and apoptotic 
pathways (Doherty 2011). Consequently, both COX-2-mediated PGE2 and iNOS-
mediated NO production in the microglia remain important targets for reducing 
neuroinflammation in the microglia. 
Along with COX-2 and PGE2, activated microglia release a variety of 
proinflammatory cytokines such as IL-1β, TNF α, IL-6 and low levels of anti-
inflammatory cytokines like IL-10, TGF-β and IL-1 receptor antagonist (IL-1Ra) 
during chronic inflammatory conditions in neurodegenerative diseases. Pathogen 
components such as LPS can readily induce IL-1β, TNF α and IL-6 in both rodent 
models and cultured microglial cells (Kim & Joh 2006), (Morales et al. 2014) and 
(Olajide et al. 2013). In particular, IL-1β and TNFα have been shown to be involved 
in the development of CNS inflammation through the disruption of BBB, which further 
facilitates the infiltration of peripheral immune cells such as leukocytes and other 
foreign bodies into CNS. Also, recent studies on TNFα overexpressing mice 
demonstrated that TNFα might directly initiate brains tissue destruction via 
autoimmune inflammation (Akassoglou et al. 1998) and (Park & Bowers 2010). 
Together these cytokines play a critical role in neuronal damage in various 
neurodegenerative disorders. Therefore, the inhibition of these inflammatory 
mediators is essential in preventing escalation of the inflammatory process in 
microglia. On the other hand, anti-inflammatory cytokine IL-10 inhibits microglia 
activation through modulation of pro-inflammatory cytokines, chemokines and 
oxidative species in microglia. Thus substances activating IL-10 would be beneficial 
in targeting neuroinflammatory conditions (Heyen et al. 2000). 
During neuroinflammation, the transcription factor, nuclear factor-B (NF-B) has 
been shown to regulate cytokines production, COX-2 and iNOS-mediated NO and 
PGE2 production, respectively. A diverse spectrum of activators such as LPS, ROS 
and heat shock proteins, has been shown to activate this pleiotropic transcription 
factor, which further facilitates the transcription of inflammatory genes in 
neuroinflammation (Bozic et al. 2015), (Cuaz-Pérolin et al. 2008) and (Olajide et al. 
2013). In general, mammalian NF-B consists of five subunits, which can form homo 
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and heterodimers in any combination; RelA (p65), RelB, c-Rel, p50 and p52. As 
each of these proteins consists of a prototypical amino-terminal sequence known as 
Rel homology domain (RHD), that facilitates cytoplasmic retention by IB, DNA-
binding and nuclear localisation. In neuroinflammation, specific phosphorylation and 
degradation of IB are critical in regulating NF-B DNA-binding activity in brain cells. 
The cytosomal IB binds to the nuclear localisation signal (NLS) of NF-B to form an 
inactive complex (Ghosh & Hayden 2012). However, upon stimulation, intracellular 
signalling cascades phosphorylates IKK complex, which mediates phosphorylation of 
IB at specific amino acid residues. For instance, Serine-32 and Serine-36 in IB. 
This phosphorylation of IB further liberates NF-B for nuclear translocation and bind 
to related sites in inflammatory target genes (Didonato et al. 2012). In the nucleus, 
NF-B has to undergo several post-translational modifications to regulate the 
transcription of pro-inflammatory genes to become fully active. One such 
modification is reversible acetylation of NF-B-p65 subunit. Studies have shown that 
compounds that inhibit acetylation of NF--p65 blocked the production of various 
inflammatory cytokines that are controlled by NF-B signalling (Chen & Greene 
2005) and (Zhu et al. 2011). Therefore, it is crucial to investigate for the compounds 
that target NF-B signalling pathway, which is essential in controlling the escalation 
of the inflammatory process during neuroinflammation in microglia. 
Mitogen-activated protein kinases (MAPKs) are a family of serine/threonine protein 
kinases which are critical in regulating the production of inflammatory mediators 
(Fyhrquist et al. 2010). Pro-inflammatory cytokine-driven neuroinflammation is a 
persistent pathological hallmark in several neurodegenerative diseases. The MAPKs 
have been shown to be critical regulators of various inflammatory cytokines in the 
neurodegenerative process. Four types of MAPKs are identified in mammalian cells: 
the extracellular signal-related kinases (ERKs), the c-jun N-terminal kinases (JNKs), 
the atypical MAPKs (ERK3, ERK5, and ERK8), and the p38 MAPKs.(Cuadrado et al. 
2010) and (Neininger et al. 2002). Among these, the p38 MAPK has been shown to 
play a central role in mediating the production of the pro-inflammatory cytokines and 
other neurotoxic factors (Culbert et al. 2006). In the light of neuroinflammation, the 
general role of p38 MAPK was extensively studied in external stimuli-treated glia and 
blocking of this kinase expression has shown to resolve microglial activation (Xing et 
al. 2011a) and (Kim et al. 2004). Studies demonstrate that, in brain cells, p38 MAPK 
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has to undergo dual phosphorylation at Thr-180 and Tyr-182 residues by MAP 
kinase kinase 3/6 (MKK 3/6) (Herlaar & Brown 1999). In the cultures of microglia, 
astrocytes and neurons, activation of p38 MAPK were induced through upstream 
activation of MKK3/6, which further produced cytokines and other neurotoxic factors 
respectively (Kim et al. 2004). Activation of p38 MAPK signalling and production of 
its mediated IL-1β and other cytokines was observed in Aβ-stimulated microglia and 
neuroblastoma cell cultures. Similar observations were noted in other animal models 
of neuroinflammation when treated with LPS (Savage et al. 2002), (Haddad et al. 
2001), (Olajide et al. 2014) and (Corrêa et al. 2012).  
Also, in response to extracellular stress, phosphorylated p38 shown to activate 
mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MK-2) in the 
microglia (Duraisamy et al. 2008). MK-2 is one of the several kinases that are 
regulated by p38 MAPK, which makes it an important target in neuroinflammatory 
and neurodegenerative pathologies. The activation of MK-2 was increased in 
microglial cells when stimulated with LPS and gamma interferon, resulting in the 
expression and production of inflammatory mediators such as IL-1β, TNF α, IL-6, 
NO, iNOS and PGE2 (Ramanan et al. 2008) and (Culbert et al. 2006). Mice lacking 
MK-2 gene showed low levels of TNFα and other cytokines when exposed to 
endotoxic shock, supports that MK-2 is involved in the production of cytokines during 
inflammation (Gaestel et al. 1999) and (Fyhrquist et al. 2010). Thus, there is a 
desperate need to investigate for compounds that inhibit p38 MAPK signalling and its 
associated inflammatory cytokines in neuroinflammation. 
Toll-like receptor 4 (TLR4) signalling has been well established in the pathologies of 
neuroinflammation. During innate immunity, TLR4 receptor modification has been 
identified to play a central role in the activation of various intracellular signalling 
pathways (Hanamsagar et al. 2012). The stimulation of TLR4 by external stimuli, 
such as LPS, activates NF-B and p38 MAPK signalling pathways, leading to the 
production of critical pro-inflammatory cytokines that are necessary to induce potent 
immune responses (Nguyen et al. 2013) and (Park et al. 2011). Also, studies from 
the researchers confirmed that, blocking LPS-induced TLR4 activation in the glial 
cells resulted in the significant inhibition of neuroinflammation (Nguyen et al. 
2013),(Lei et al. 2015) and (Takeda & Akira 2004). Also, evidence from the literature 
demonstrates the involvement of tumour necrosis factor-receptor-associated factor 6 
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(TRAF 6) in the induction of pro-inflammatory cytokines triggered by TLR4 activation. 
TRAF 6 has been shown to mediate the activation of p38 MAPK and NF-B 
signalling via TGF-β-activated kinase 1 (TAK1) (Maeda 2010). For this reason, 
inhibiting the activation of TLR signalling is thought to be an effective strategy in 
neuroinflammation and its associated neurological disorders. 
In activated microglia, NF-B signalling has to undergo several post-translational 
modifications to regulate the transcription of pro-inflammatory genes. One such 
modification is reversible acetylation of NF-B-p65 subunit. Studies have shown that 
sirtuins negatively regulate NF-B signalling via deacetylation of Lys310 residue of 
RelA/p65 subunit (Chen et al. 2005) and (Jieming Ye et al. 2013). Sirtuins belong to 
class III histone deacetylases (HDACs), which plays a significant role in regulating 
ageing, inflammatory diseases, and senescence by targeting histones, coregulators 
and inflammatory transcription factors like NF-B, p53 and Nrf2 in brain cells (Haigis 
& Sinclair 2011) and (Kim et al. 2007). Among seven sirtuins, SIRT1 has been 
reported to be involved in promoting longevity in various species. Thus activation of 
SIRT1 inhibits NF-B signalling by promoting deacetylation of the p65 subunit. Also, 
reports have shown that inhibition of SIRT1 protein expression by LPS in endothelial 
cells significantly increased the expression of acetylated-NF-B-p65 and further 
enhanced NF-B transcriptional activity (Yang et al. 2012). Moreover, microglia 
treated with LPS has significantly increased the production of inflammatory cytokines 
like IL-1β and TNFα, coinciding with the inhibition of SIRT1, suggesting that SIRT1 is 
involved in regulating pro-inflammatory cytokines (S. H. Cho et al. 2015) and (J Ye et 
al. 2013). Thus, there is an urgent need to investigate for compounds that activate 
SIRT1 expression in neuroinflammation driven neurological diseases.  
Reactive oxygen species (ROS) are produced for the maintenance of many 
physiological functions and act as second messengers. Accumulating evidence has 
suggested that the pathogenesis of neurodegenerative disorders, including AD, is 
related to excessive production of ROS and the resultant increased oxidative stress 
(Zhang et al. 2016). However, the exact role of redox signalling cascade and its 
associated crosstalk with inflammatory mediators during neuroinflammation is yet to 
be understood. Increased ROS production has been shown to control the expression 
of several critical inflammatory mediators such as COX-2, iNOS and the adhesion 
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molecules induced by cytokines, infections and neurotoxic substances during 
neuroinflammation (Lee & Yang 2012), (Hsieh & Yang 2013) and (Gu et al. 1998). 
Alternatively, there is increasing evidence that ROS triggers the activation of redox-
sensitive transcription factors such as NF-B and AP-1 in the microglia (Zhang et al. 
2016) and (Lee et al. 2015). Recently, Kim and his team demonstrated that 
apocynin, a known NOX inhibitor showed potent antioxidant activities and inhibitory 
effects on TNFα-induced NF-B and AP-1 signalling in animal models of asthma 
(Kim et al. 2012). In addition, several other researchers showed that blocking ROS 
production in LPS-induced in vitro models will reverse detrimental pathologies 
involved in neuroinflammation (Lee & Yang 2012), (Wang et al. 2011), (Lee et al. 
2015) and (Zeng et al. 2012). Depletion of endogenous levels of GSH was also 
observed during oxidative stress which is implicated in the pathogenesis of 
neuroinflammation and associated neurotoxicity (Lee et al. 2010). Animal studies 
showed the unique capacity of GSH to preserve, protect and rescue human 
microglial and neuronal cells from cytokines induced neurotoxicity (Zhu et al. 2014). 
Therefore, targeting ROS production and GSH activation in microglia would be an 
efficient therapeutic strategy for the treatment of neuroinflammation and its 
associated neurotoxicity. 
Tiliroside is a glycosidic flavonoid found in several medicinal and dietary plants, such 
as linden, rose hip and strawberry (Matsuda et al. 2002). This compound has been 
shown to exhibit anti-inflammatory, antioxidant, anticarcinogenic, and 
hepatoprotective activities (Tsukamoto et al. 2004). However, the anti-
neuroinflammatory effects of the compound are not yet studied; therefore the effects 
of tiliroside are investigated in LPS/IFN-induced neuroinflammation in BV2 
microglia. Further experiments were done to assess the effects of the compound on 
SIRT1 activation in BV2 microglia. 
.
Page | 109 
 
3.2 Results 
3.2.1 Tiliroside reduced production of pro-inflammatory cytokines in LPS/IFN-
activated BV2 microglia without affecting the  BV2 cell viability at the concentrations 
used in pharmacological experiments 
The cytotoxic effect of various concentrations of tiliroside (2-6 µM) was determined 
using XTT assay. BV2 microglia were pre-treated with the compound for 30 minutes 
before stimulation with a combination of LPS (100 ng/ml) and IFN (5 ng/ml) for 24 
hours. Results showed that there was no significant difference in the viability of cells 
treated with various concentrations of tiliroside when compared with control 
(untreated) cells (Figure 3.1). 
Hyperactive microglia are known to release pro-inflammatory cytokines such as IL-
1β, TNF α and IL-6, which are considered as most significant neurotoxic factors that 
contributes to neuroinflammation (MacEwan 2002). Therefore, cytokines production 
in the activated microglia remains an important target in reducing neuroinflammation. 
The levels of IL-1β, TNF α and IL-6 in the supernatants were analysed using ELISA. 
Upon stimulation with LPS (100 ng/ml)/IFN (5 ng/ml), a marked increase (p<0.001) 
in the release of IL-1β (~7-fold increase, ~900 pg/mL), TNF α (~45-fold increase, ~ 
950pg/mL) and IL-6 (~6-fold increase, ~890 pg/mL) was observed in microglia when 
compared to untreated cells. However, tiliroside (2 M, ~1.3-fold [~800 pg/mL]; 
4 M, ~ 1.4-fold [~750 pg/mL]; 6 M, ~ 1.8-fold [~450 pg/mL] reduction) significantly 
(p<0.01) inhibited IL-1β production in the activated microglia. In addition, the 
compound reduced the release of TNF α (4 M, ~ 1.4-fold [~760 pg/mL]; 6 M, ~ 
1.7-fold [~600 pg/mL] reduction) (p<0.001) in the microglia (Figure 3.2 a and b). 
However, at 2 M, the inhibitory effect of tiliroside on TNF α production was not 
significant. As expected, tiliroside exhibited a similar effect on IL-6 levels when 
microglia were pre-incubated with the compound (2 M, ~1.3-fold [~850 pg/mL]; 
4 M, ~ 1.4-fold [~780 pg/mL]; 6 M~1.6-fold [~600 pg/mL] reduction p<0.01) (Figure 
3.2c). These results indicate that selected concentrations of tiliroside reduced 
LPS/IFN-induced proinflammatory cytokines released by microglia. 
Several reports have shown that the combination of LPS and IFN is capable of 
inducing pro-inflammatory cytokines along with other chemokines via activating toll-
like receptors in microglia  (TLRs) (Xu et al. 2014). However, the precise effective 
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concentrations that can induce pro-inflammatory parameters in the microglia are yet 
to be evaluated. In the current research, the effective concentrations of LPS and 
IFN were determined using XTT cell viability assay. BV2 microglia were stimulated 
with various concentrations of LPS and IFN and incubated for 24 hours. Results 
revealed that the combination of LPS at 100 ng.ml and IFN 5ng.ml exhibited 
maximal cytotoxic effects compared to other concentrations (Figure 3.3a). The 
incubation time of the tiliroside with BV2 cells was assessed using XTT assay. 
Figure 3.3b shows that tiliroside (6µM) at 30 minutes in the presence of LPS 
(100 ng/ml) and IFN (5 ng/ml) was less cytotoxic compared to other time points. 
Therefore, the incubation time of 30 minutes was adopted in all neuroinflammation 
experiments.  
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Figure 3.1 Pre-treatment with tiliroside did not affect the viability of BV2 
microglia 
Cells were stimulated LPS/IFN in the presence or absence of tiliroside (2-6 μM) for 24 
hours. At the end of the incubation period, XTT assay was carried out on cells. Results show 
that tiliroside did not affect the viability of microglia cells. All values are expressed as mean ± 
SEM for three independent experiments. Data were analysed using one-way ANOVA for 
multiple comparisons with post hoc Student Newman-Keuls test. *p < 0.05, **p<0.01, 
***p<0.001 compared with LPS/IFN control. 
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Figure 3.2 Tiliroside reduced IL-1β, TNFα and IL-6 production in LPS/IFN-
activated BV2 microglia. 
Cells were stimulated with LPS/IFN in the presence or absence of tiliroside (2–6 μM) for 24 
hours. Stimulation was terminated, and supernatants were collected and levels of (a) IL-1β, (b) 
TNF-α and (c) IL-6 were measured using ELISA. Tiliroisde inhibited the production of IL-1β 
,TNF-α and IL-6 in LPS/IFN-stimulated BV2 cells. All values are expressed as mean ± SEM 
for three independent experiments. Data were analysed using one-way ANOVA for multiple 
comparisons with post hoc Student Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 
compared with untreated control and *p<0.05, **p<0.01, ***p<0.001 compared to LPS/IFN. 
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Figure 3.3 Pre-tretament with tilrioside (6µM) did not effect the viability of BV2 
cells at 30 min when stimulated with LPS and IFN. 
(a) BV2 cells were stimulated with various concentrations of LPS and IFN and incubated for 
24 hours. Stimulation was terminated by adding 25 µl of XTT/PMS solution. Results show that 
the combination of LPS (100 ng/ml) and IFN (5 ng/ml) were cytotoxic. (b) BV2 microglia were 
incubated with tiliroside (6 µM) for various time points followed by stimulation with the 
combination of LPS (100 ng/ml) and IFN (5 ng/ml). Cell vibility assay revelaed that tilroside at 
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30 min did not effect the vaibility of Bv2 cells compared to other time points. All values are 
expressed as mean ± SEM for three independent experiments. Data were analysed using one-
way ANOVA for multiple comparisons with post hoc Student Newman-Keuls test. &p<0.05, 
&&p<0.01, &&&p<0.001 compared with untreated control and *p<0.05, **p<0.01, ***p<0.001 
compared to LPS/IFN. 
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3.2.2 Tiliroside increased the production of IL-10 in LPS/IFN-activated BV2 microglia 
In chronic neuroinflammation, prolonged exposure to inflammatory stimuli leads to 
increased inflammatory cytokines and inhibition in the production of anti-
inflammatory cytokines like IL-10 and TGFβ was observed (Ha et al. 2012). Since 
tiliroside has blocked the production of cytokines, the effect of the compound on IL-
10 production was further evaluated. Cells were pre-incubated for 30 minutes with 
tiliroside (2-6 M) and then stimulated with LPS/IFN for 24 hours. Thereafter, IL-10 
production was determined using ELISA. Stimulation with a combination of LPS and 
IFN significantly (p<0.001) reduced IL-10 levels (~3.4-fold reduction, ~200 pg/mL) 
compared to unstimulated microglia. Interestingly, tiliroside (2 M, ~1.3-fold [~300 
pg/mL], 4 M, ~2-fold [~450 pg/mL] and 6 M, ~3.3-fold [~800 pg/mL] increase) 
significantly (p<0.001) and dose-dependently reversed LPS/IFN-mediated IL-10 
reduction in the microglia (Figure 3.4). 
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Figure 3.4 Tiliroside increased IL-10 production in LPS/IFN-activated BV2 
microglia 
Cells were stimulated with a combination LPS/IFN in the presence or absence of tiliroside 
for 24 hours. At the end of the incubation, supernatants were collected, and levels of IL-10 
were measured using ELISA. All values are expressed as mean ± SEM for three 
independent experiments. Data were analysed using one-way ANOVA for multiple 
comparisons with post hoc Student Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 
compared with untreated control and *p<0.05, **p<0.01, ***p<0.001 compared to LPS/IFN. 
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3.2.3 Suppression of iNOS protein expression and its mediated nitrite production by 
tiliroside in LPS/IFN-activated BV2 microglia 
This experiment was conducted to investigate the effects of the compound on iNOS 
protein expression and it’s mediated NO release in LPS/IFN-stimulated microglia. 
Nitric oxide (NO) is an important mediator for regulating chronic inflammation in 
microglia and high concentrations of NO has been shown to be neurotoxic to 
adjacent neurons (Cao et al. 2010) and (Spencer et al. 2012). Therefore, the effect 
of tiliroside (2-6 M) on nitrites, a breakdown product of NO, was assessed using 
Griess assay. Results show that there was a marked increase (~13-fold, ~90 µM]) in 
nitrite production (p<0.001) when cells were stimulated with LPS (100 ng/ml)/IFN 
(5 ng/ml) alone, compared with unstimulated cells. However, pre-treatment with 
tiliroside (2 μM, ~1.6-fold [~60 µM], 4 μM, ~2.1-fold [~55 µM] and 6 μM, ~3.6-fold 
[~30 µM] reduction) significantly inhibited nitrite production (Figure 3.5a).  
In activated microglia, NO production is directly proportional to the expression of 
iNOS protein. Encouraged by the nitrite results, further investigation was done to 
assess the effect of the compound on iNOS protein expression. BV2 microglia were 
pre-incubated with tiliroside for 30 minutes, followed by stimulation with LPS/IFN for 
24 hours. Cytoplasmic lysates were collected and subjected to western blotting. 
Results showed that tiliroside (4 M~1.5-fold and 6 M~1.8-fold reduction) produced 
significant (p<0.001) suppression of iNOS protein expression (Figure 3.5b), however, 
at 2 M, compound exhibited a sharp inhibition of iNOS (2 M~1.1-fold reduction), 
which was not significant. These results indicate that tiliroside regulated NO 
production in LPS/IFN-stimulated BV2 cells through inhibition of iNOS protein 
expression. 
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Figure 3.5 Tiliroside inhibited nitrite production and iNOS protein expression in 
LPS/IFN-activated microglia.  
Cells were stimulated with LPS (100 ng/ml)/IFN (5 ng/ml) in the presence or absence of the 
compound for 24 hours. Subsequently, culture supernatants and cytoplasmic lysates were collected 
and analysed for nitrite production and iNOS protein expression. (a) Tiliroside reduced NO 
production in LPS/IFN-activated BV2 cells. (b) Tiliroside inhibited levels of iNOS protein in 
LPS/IFN-activated BV2 cells. Cytoplasmic lysates were analysed for iNOS protein expression using 
western blot. Actin was used as a loading control. All values are expressed as mean ± SEM for 
three independent experiments. Data were analysed using one-way ANOVA for multiple 
comparisons with post hoc Student Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 compared 
with untreated control and *p<0.05, **p<0.01, ***p<0.001 compared to LPS/IFN. 
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3.2.4 Tiliroside suppressed PGE2 production by inhibiting COX-2 protein expression in 
LPS/IFN-activated BV2 microglia 
Encouraged by results showing the effects of tiliroside on iNOS expression and it’s 
associated NO production, its effects on PGE2 and COX-2 expression in the 
activated microglia were further assessed. In neuroinflammation, uncontrolled 
activation of microglia are shown to produce high levels of neurotoxic factors like 
COX-2-mediated PGE2 (Dargahi et al. 2011). As shown in Figure 3.6a, LPS/IFN-
treated BV2 cells produced detectable levels of PGE2 (~10-fold increase, ~950 
pg/mL) compared to the untreated microglial cells. Tiliroside produced a significant 
(p<0.001) reduction of PGE2 production by ~1.5-fold (~690 pg/mL) at 4 μM and at 
6 μM by ~ 2.2-fold (~400 pg/mL) in a concentration-dependent manner. However, at 
2 μM (~ 1.1-fold [~850 pg/mL] reduction) the inhibition was not significant.  
To understand the mechanism further, the effect of tiliroside on COX-2 expression 
was investigated. Results in Figure 3.6b show marked expression of the COX-2 
protein (~63.1-fold increase) in LPS/IFN stimulated cells compared to untreated 
microglia. This effect was significantly (p<0.001) counteracted through pre-incubation 
with compound (2 μM, ~1.3-fold, 4 μM, ~2-fold and 6 μM, 2.7-fold reduction). These 
results suggest that tiliroside inhibits LPS/IFN-induced PGE2 production by inhibiting 
COX-2 protein expression in BV2 microglia. 
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Figure 3.6 Tiliroside inhibited PGE2 production and COX-2 protein expression in 
LPS/IFN-activated microglia. 
Cells were stimulated with LPS (100 ng/ml)/IFN (5 ng/ml) in the presence or absence of the 
compound for 24 hours. Subsequently, culture supernatants and cytoplasmic lysates were 
collected and analysed. (a) Tiliroside reduced PGE2 production in LPS/IFN-activated BV2 
cells. (b) Tiliroside inhibited levels of COX-2 protein in LPS/IFN-activated BV2 cells. 
Cytoplasmic lysates were analysed for COX-2 protein expression using western blot. Actin 
was used as a loading control. All values are expressed as mean ± SEM for three independent 
experiments. Data were analysed using one-way ANOVA for multiple comparisons with post 
hoc Student Newman-Keuls test. using one-way ANOVA for multiple comparisons with post 
hoc Student Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 compared with untreated 
control and *p<0.05, **p<0.01, ***p<0.001 compared to LPS/IFN. 
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3.2.5  Tiliroside inhibited LPS/IFN-induced neuroinflammation through NF-B 
signalling in BV2 microglia 
The transcription factor NF-B, plays a central role in regulating the production of 
proinflammatory cytokines and the expression of genes like COX-2 which mediates 
PGE2 production and iNOS which control nitrite production in stimulated microglia 
(Ghosh & Hayden 2012). Since tiliroside inhibited the release of pro-inflammatory 
cytokines and levels of iNOS and COX-2 proteins, its effects on NF-B signalling 
was examined in BV2 microglia. Firstly, a luciferase reporter gene assay was used to 
evaluate the effect of the compound on nuclear transactivation of NF-B in microglia. 
BV2 cells were transfected with a vector containing NF-B regulated luciferase 
reporter construct. The experiment revealed that tiliroside (2 μM, ~1.1-fold, 4 μM, 
~1.7-fold and 6 μM ~3.8-fold reduction) significantly (p<0.001) inhibited NF-B 
regulated luciferase reporter gene expression following stimulation with LPS/IFN 
(Figure 3.7a). Once it was confirmed that tiliroside inhibited transactivation of NF-B, 
its effects on NF-B-DNA binding activity was further investigated using ELISA 
based EMSA. Figure 3.7b show that LPS/IFN induced (~9.1-fold increase) the DNA 
binding of NF-B compared to untreated cells, following 60-minute incubation. 
However, this nuclear DNA binding of NF-B was significantly suppressed when pre-
treated with tiliroside (2 μM~1.3-fold, 4 μM~1.8-fold and 6 μM ~3.9-fold reduction) in 
the microglia. 
Based on the above results, the effect of tiliroside on the nuclear-phosphorylated p65 
subunit, which is critical in the activation of NF-B pathway, was further examined. 
BV2 microglia were pre-treated with tiliroside for 30 minutes and later incubated with 
LPS and IFN for 60 minutes. Western blotting results show that treatment with 
LPS/IFN remarkably increased phosphorylation of p65. In contrast, levels of p-p65 
was significantly (p<0.01) inhibited (4 M, ~1.7-fold and 6 M, ~3-fold reduction) 
upon pre-treatment with the compound, (Figure 3.8a) while at 2 M (~1.4-fold-
reduction) there was no significant inhibition. In addition, immunofluorescence 
experiments were done to further examine the effects of the compound on 
phosphorylation of p65 in microglia. Figure 3.8b show that p-p65 was highly 
expressed in the microglia when challenged with LPS and IFN compared to 
untreated cells. However, pre-treatment with tiliroside resulted in suppression of p-
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p65 activation. Collectively, these results together suggest that tiliroside alleviates 
LPS/IFN-induced neuroinflammation through inhibition of NF-B signalling in the 
microglia.  
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Figure 3.7 Tiliroside inhibited neuroinflammation by targeting NF-B signalling in 
activated BV2 microglia. 
(a) Transfected BV2 cells were treated with LPS/IFN in the presence or absence of the 
tiliroside (2-6 µM) for 6 hours. At the end of the stimulation, luciferase assay buffer containing 
luminescence substrate was added, and luminescence was read. Tiliroside suppressed NF-B 
activity in transfected BV2 cells stimulated with LPS/IFN. (b) Increasing concentrations of 
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tiliroside inhibited DNA binding of NF-B in LPS (100 ng/ml)/IFN (5 ng/ml)-stimulated BV2 
microglial cells. All values are expressed as mean ± SEM for three independent experiments. 
Data were analysed using one-way ANOVA for multiple comparisons with post hoc Student 
Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 compared with untreated control and 
*p<0.05, **p<0.01, ***p<0.001 compared to LPS/IFN. 
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Figure 3.8 Tiliroside inhibited neuroinflammation by targeting NF-B signalling 
pathway in BV2 microglia 
(a) Cells were treated with LPS (100 ng/ml)/IFN (5 ng/ml) in the presence or absence of the 
tiliroside for 60 minutes. Later, nuclear lysates were collected, and western blot was done for 
p-p65 and Total-p65 protein detection. Tiliroside inhibited p-p65 translocation in LPS/IFN-
activated microglia compared to total-p65. Lamin B was used as a loading control. (b) 
Immunofluorescence experiments were done to investigate the effects of various 
concentrations of tiliroside on p-p65 protein expression in activated microglia at 60 minutes. 
Cells were labelled with p-p65 antibody and counterstained with DAPI and fluorescence 
images acquired with an EVOS® FLoid® cell imaging station (scale bar=100 μm) and 
processed using image J. Tiliroside treatment decreased the LPS/IFN-induced p-p65 
expression in microglia. Experiments were repeated at least three times All values are 
expressed as mean ± SEM for three independent experiments. Data were analysed using one-
way ANOVA for multiple comparisons with post hoc Student Newman-Keuls test. ᶿ p< 0.05, ᶿᶿ 
p<0.01, ᶿᶿᶿ p<0.001 in comparison with untreated control. using one-way ANOVA for multiple 
comparisons with post hoc Student Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 
compared with untreated control and *p<0.05, **p<0.01, ***p<0.001 compared to LPS/IFN. 
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3.2.7 Tiliroside inhibited phosphorylation of IKK and IB in LPS/IFN-induced 
neuroinflammation in microglia 
In response to an inflammatory stimulus, IB/NF-B complex become 
phosphorylated by IKK. As a result, active NF-B-p65 subunit is translocated to the 
nucleus thereby regulating the expression of target genes. Cytoplasmic proteasomes 
further degrade free IB. Based on the outcome of the experiments on NF-B, an 
attempt was made to further understand the effect of tiliroside on upstream proteins 
in LPS/IFN-stimulated microglia. BV2 cells were pre-treated with tiliroside for 30 
minutes, followed by LPS/IFN stimulation for 60 minutes. Western blotting results 
show that the combination of LPS and IFN significantly upregulated (~3.1-fold 
increase) the expression of p-IB in the microglia, compared to control cells. 
However, this inhibition was significantly (p<0.05 and p<0.001) counteracted by the 
tiliroside (2 M, ~1.2-fold, 4 M, ~1.3-fold and 6 M, ~2-fold reduction) (Figure 3.9a). 
A western blot experiment was performed to detect the levels of total-IB in 
LPS/IFN-stimulated microglia. High levels of total-IB protein (~2.6-fold increase) 
was observed in the untreated cells compared to LPS/IFN treated. Interestingly, 
tiliroside (2 M, ~1.3-fold, 4 M ~2-fold and 6 M, ~3.3-fold increase) inhibited the 
proteasomal degradation of IB (Figure 3.9b).  
Later, the effect of the compound on the phosphorylation of IKKα was investigated in 
LPS/IFN-activated microglia. As shown in Figure 3.9c, LPS (100 ng/ml)/IFN (5 
ng/ml) combination have induced IKK phosphorylation compared to control cells. 
Interestingly, compound (6 M, ~2-fold decrease, p<0.01) suppressed IKK 
phosphorylation in the microglia, while 2 M and 4 M of the compound had no 
significant inhibitory effect. These results seem to suggest that tiliroside prevents 
LPS/IFN-induced neuroinflammation by interfering with IKK/IBα/NF-B signalling 
in BV2 microglia. 
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Figure 3.9 Tiliroside inhibited phosphorylation of IB and IKKα in LPS/IFN-
stimulated BV2 microglia 
Cells were stimulated with a combination of LPS/IFN in the presence or absence of the 
tiliroside for 60 minutes. Subsequently, cytoplasmic lysates were collected and analysed for 
phosphorylation of IB, as well as IKK and degradation of IB protein using western blot. 
(a) Tiliroside abrogated IB phosphorylation in LPS/IFN-activated BV2 cells. (b) Tiliroside 
inhibited degradation of IB in LPS/IFN-activated BV2 microglia. (c) Tiliroside inhibited IKKα 
phosphorylation in LPS/IFN-activated BV2 cells compared to Total-IKKα expression. Actin 
was used as a loading control. All values are expressed as mean ± SEM for three independent 
experiments. Data were analysed using one-way ANOVA for multiple comparisons with post 
hoc Student Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 compared with untreated 
control and *p<0.05, **p<0.01, ***p<0.001 compared to LPS/IFN. 
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3.2.8 Tiliroside inhibited LPS/IFN-induced p38 MAPK signalling pathway 
Increasing evidence suggests that p38 mitogen-activated protein (MAP) kinase 
regulates NF-B-dependent transcription and controls the production of inflammatory 
mediators such as IL-1β, TNF α, IL-6, NO, iNOS, PGE2 and COX-2 (Cuadrado et al. 
2010) and (Didonato et al. 2012). Consequently, an attempt was made to investigate 
whether compound interferes with p38 signalling in LPS/IFN-activated BV2 
microglia. Firstly, the effect of tiliroside on phosphorylation of p38 following activation 
of BV2 microglia with a combination of LPS and IFN was evaluated. This was 
achieved by pre-incubating microglia with tiliroside (2-6 M) for 30 minutes, followed 
by stimulation with LPS (100 ng/ml)/IFN (5 ng/ml) for 60 minutes. Upregulation of p-
p38 protein expression (~2-fold increase) was observed in LPS and IFN-treated 
microglia compared to control microglia. Interestingly, pre-incubation with compound 
significantly suppressed phosphorylation of p38 (4 M, ~1.3-fold decrease, p<0.05 
and 6 M, ~1.8-fold decrease, p<0.01), while at 2 M the inhibition was insignificant 
(Figure 3.10a).  
Further investigations on the downstream substrate of p38, MK2 showed an 
inhibition of its phosphorylation by tiliroside (4 and 6 M), following activation of BV2 
microglia with LPS/IFN (Figure 3.10b). Tiliroside followed a similar pattern in the 
inhibition of LPS/IFN-induced MK2 compared to p-p38 results. At 4 and 6 M (4 M, 
~1.4-fold decrease, p<0.05 and 6 M, ~1.9-fold decrease, p<0.001) the inhibition 
was efficient and at 2 M the effect of tiliroside was minimal. After observing the 
inhibitory effects of the compound on phosphorylation of p38 and its downstream 
target MK2 its effect on MKK3/6, an upstream kinase of p38 MAPK signalling was 
investigated. Results show that MKK3/6 was activated at 60 minutes in the microglia 
(Figure 3.11a). From Figure 3.11b, it appears that LPS/IFN strongly activated MKK 
3/6 in microglia. However, tiliroside at 4 M (~1.3-fold decrease, p<0.05) and 6 M 
(~2-fold decrease, p<0.001) significantly inhibited MKK 3/6 phosphorylation, 
suggesting that compound inhibits LPS/IFN-induced neuroinflammation via p38 
MAPK signalling pathway. 
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Figure 3.10 Tiliroside inhibited phosphorylation of p38 and MK2 in LPS/IFN-
activated microglia 
Microglia were treated with LPS and IFN for 60 minutes in the presence or absence of 
tiliroside. Subsequently, cytoplasmic lysates were collected and western blot was done for 
p38α and MK2 protein detection. (a) Tiliroside inhibited p38α phosphorylation compared to 
total-p38 in LPS/IFN-activated BV2 cells. (b) The compound also reduced MK2 
phosphorylation compared to total-MK2 in activated BV2 cells. Actin was used as a loading 
control. All values are expressed as mean ± SEM for three independent experiments. Data 
were analysed using one-way ANOVA for multiple comparisons with post hoc Student 
Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 compared with untreated control and 
*p<0.05, **p<0.01, ***p<0.001 compared to LPS/IFN. 
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Figure 3.11 Tiliroside inhibited phosphorylation of MKK3/6 in response to LPS/IFN 
(a) Cells were treated with LPS/IFN for several time points. Later, cytoplasmic lysates were collected 
and subjected to western blot to determine the phosphorylation of MKK 3/6. This experiment showed 
that MKK3/6 was phosphorylated at 60 minutes in LPS/IFN-activated microglia. (b) Microglia were 
challenged with LPS and IFN in the presence or absence of tiliroside for 60 minutes. Subsequently, 
cytoplasmic lysates were collected and western blot was done for MKK 3/6 protein detection. Tiliroside 
inhibited MKK3/6 phosphorylation in LPS/IFN-treated BV2 cells. Actin was used as a loading control. 
All values are expressed as mean ± SEM for three independent experiments. Data were analysed using 
one-way ANOVA for multiple comparisons with post hoc Student Newman-Keuls test. &p<0.05, 
&&p<0.01, &&&p<0.001 compared with untreated control and *p<0.05, **p<0.01, ***p<0.001 compared to 
LPS/IFN. 
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3.2.9 Tiliroside inhibited LPS/IFN-induced neuroinflammation by targeting TLR4 and 
TRAF6 in BV2 microglia 
Studies have shown that microglia upon stimulation with LPS, can predominantly 
induce NF-B and MAPK activation through TLR4 receptor by activatingTRAF-6 
protein (Hanamsagar et al. 2012), (Zhou et al. 2014), (Xu et al. 2014) and (Takeda & 
Akira 2004).Western blotting was used to show that TRAF6 protein was maximally 
expressed within 10 minutes of LPS (100 ng/ml)/IFN (5 ng/ml) stimulation and its 
expression was significantly inhibited by tiliroside 4 M (~1.3-fold decrease, p<0.001) 
and 6 M (~1.9-fold decrease, p<0.001) (Figure 3.12a and b). The effect of the 
compound was further investigated against LPS/IFN-induced TLR4 activation in 
microglia. As shown in the Figure 3.13a, when microglia was exposed to LPS 
(100 ng/ml)/IFN (5 ng/ml) for 10 minutes, the TLR4 expression was upregulated 
(~3.4-fold increase) compared to untreated cells. Notably, this activation was 
abrogated by tiliroside (6 M, ~2-fold decrease, p<0.01) treatment, while 2 M and 
4 M has minimal effect. In addition, immunofluorescence was used to examine 
whether TLR4 activation is involved in LPS/IFN-induced neuroinflammation. Figure 
3.13b shows that TLR4 was highly expressed in the microglia when incubated with 
LPS/IFN compared to untreated cells. However, pre-treatment with tiliroside 
resulted in suppression of TLR4 activation, suggesting that TLR4 pathway is 
primarily involved in the inhibitory effects of the compound in activated microglia. 
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Figure 3.12 Tiliroside inhibited activation of TRAF6 in LPS/IFN-induced microglia 
(a) Cells were treated with a combination of LPS and IFN for several time points. Later, cytoplasmic 
lysates were collected and subjected to western blot to determine the expression of TRAF6. This 
experiment showed that TRAF6 was activated at 10 minutes in activated microglia. (b) Microglia were 
treated with LPS and IFN in the presence or absence of the tiliroside (2-6 µM) for 10 minutes. 
Subsequently, cytoplasmic lysates were collected and western blot was done for TRAF6 protein 
detection. Tiliroside inhibited TRAF6 activation in LPS/IFN-treated BV2 cells. Actin was used as a 
loading control. All values are expressed as mean ± SEM for three independent experiments. Data 
were analysed using one-way ANOVA for multiple comparisons with post hoc Student Newman-Keuls 
test. &p<0.05, &&p<0.01, &&&p<0.001 compared with untreated control and *p<0.05, **p<0.01, ***p<0.001 
compared to LPS/IFN. 
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(b) 
 
Figure 3.13 Tiliroside inhibited TLR4 activation in LPS/IFN-activated microglia 
(a) Cells were treated with the combination of LPS and IFN in the presence or absence of the 
tiliroside for 10 minutes. Subsequently, cytoplasmic lysates were collected and western blot 
was done for TLR4 protein detection. Tiliroside inhibited TLR4 activation in LPS/IFN-activated 
BV2 cells. Actin was used as a loading control. (b) BV2 microglia was pre-treated with tiliroside 
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for 30 minutes and later stimulated with LPS/IFN for 10 minutes. Subsequently, cells were 
labelled with TLR4 antibody and counterstained with DAPI and fluorescence images acquired 
with an EVOS® FLoid® cell imaging station (scale bar=100 μm) and processed using image J. 
Tiliroside treatment decreased the LPS/IFN-induced TLR4 activation in microglia. All values 
are expressed as mean ± SEM for three independent experiments. Data were analysed using 
one-way ANOVA for multiple comparisons with post hoc Student Newman-Keuls test. 
&p<0.05, &&p<0.01, &&&p<0.001 compared with untreated control and *p<0.05, **p<0.01, 
***p<0.001 compared to LPS/IFN. 
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3.2.10 Tiliroside suppresses acetylation of NF-B-p65 in LPS/IFN-activated microglia 
Compounds that inhibit the activation of NF-B signalling pathway in hyperactive 
microglia have been shown to block the expression of acetylated-NF-B-p65 (Chen 
& Greene 2005) and (Cao et al. 2010). Since tiliroside blocked the 
neuroinflammation via NF-B signalling, its effect on LPS/IFN-induced acetyl-NF-
B-p65 was investigated in microglia. The combination of LPS and IFN markedly 
increased the expression of acetyl-NF-B-p65 (~52-fold increase, p<0.001) in 
microglia when compared to unstimulated cells. Interestingly, this upregulation of 
acetyl-NF-B-p65 was significantly attenuated by tiliroside (4 M, ~1.4-fold, p<0.01 
and 6 M, ~2.1-fold reduction, p<0.001) treatment, while at 2 M compound did not 
show any effect (Figure 3.14).  
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Figure 3.14 Tiliroside inhibited acetylation of NF-B-p65 in LPS/IFN-activated BV2 
microglia. 
BV2 Cells were treated with LPS/IFN in the presence or absence of the tiliroside for 60 minutes. 
Later, nuclear lysates were collected and western blotting was done for Acetyl- NF-B-p65 and 
Total-NF-B-p65 protein detection. Tiliroside inhibited acetylation of NF-B-p65 in LPS/IFN-
activated microglia compared to Total-p65. Lamin B was used as a loading control. All values are 
expressed as mean ± SEM for three independent experiments. Data were analysed using one-way 
ANOVA for multiple comparisons with post hoc Student Newman-Keuls test. &p<0.05, &&p<0.01, 
&&&p<0.001 compared with untreated control and *p<0.05, **p<0.01, ***p<0.001 compared to 
LPS/IFN. 
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3.2.11 Tiliroside activates SIRT1 signalling in BV2 microglia 
SIRT1 is a class III histone deacetylase enzyme that has been shown to inhibit NF-
B signalling by deacetylation of NF-B-p65 subunit at Lysine 310 (Salminen et al. 
2013) and (Yeung et al. 2004). Activation of SIRT1 protein could resolve 
neuroinflammation by downregulating the expression of NF-B-mediated 
inflammatory genes (Jieming Ye et al. 2013). Tiliroside was shown to block the 
accumulation of LPS/IFN-induced acetyl-NF-B-p65 in microglia. Therefore, it was 
thought to investigate the effects of the compound on SIRT1 activation in microglia. 
BV2 cells were pre-incubated with a most effective concentration of tiliroside (6 M) 
and the levels of SIRT1 were measured at various time points using western blotting. 
Figure 3.15a shows time-dependent activation of SIRT1 in the presence of tiliroside 
(6 M), however, highest expression (~3.1-fold increase, p<0.001) was observed at 
24 hours, compared to untreated cells. 
Based on the above results, the expression of SIRT1 was further investigated using 
various concentrations of tiliroside. Consequently, microglia was incubated with the 
compound (2-6 M) for 24 hours. Western blotting results show that SIRT1 was 
significantly (p<0.001) and dose-dependently activated by tiliroside in the microglia 
(Figure 3.15b). Immunofluorescence experiments were done to investigate the 
nuclear accumulation of SIRT1 in microglia. As shown in Figure 3.15c, there was no 
fluorescence observed in untreated cells, which shows no expression of SIRT1. 
However, when BV2 cells were incubated with tiliroside (2-6 M), there was a dose-
dependent increase in the expression of SIRT1, suggests that tiliroside activated 
SIRT1 in microglia. 
There is an abundant literature indicating that the functional dysregulation of SIRT1 
during neuroinflammation is associated with many age-related neurodegenerative 
diseases (Haigis & Sinclair 2011) and (Guarente 2011). Consequently, the effect of 
the tiliroside was investigated against SIRT1 expression in LPS/IFN-treated 
microglia. Stimulation of BV2 microglia with the combination of LPS and IFNγ 
resulted in marked decrease in the expression of SIRT1 (Figure 3.16). With 2 M of 
tiliroside, there was no significant effect on SIRT1 expression. However, pre-
treatment with tiliroside (4 M and 6 M) resulted in a significant activation (~2.4-fold 
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increase, p<0.01 and ~3.6-fold increase, p<0.001) of SIRT1 protein was observed 
when compared with LPS/IFN control. 
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(c) 
 
Figure 3.15 Tiliroside upregulated SIRT1 expression in BV2 microglia 
Time point experiments was done by treating BV2 microglia with tiliroside 6 µM and incubated 
for different time points. Later, nuclear lysates were collected and subjected to western 
blotting.(a) Tiliroside upregulated SIRT1 expression in microglia. (b) Also, western blot results 
showed that tiliroside dose-dependently increased the expression of SIRT1 in microglia. Lamin 
B was used as a loading control. (c) BV2 cells were treated with increasing concentrations of 
tiliroside for 24 hours. Later, cells were fixed, blocked and stained with SIRT1 antibody for 
overnight. Following day, cells were washed and incubated with secondary antibody for 2 
hours in the dark. Cells were counterstained with DAPI and fluorescence images acquired with 
an EVOS® FLoid® cell imaging station (scale bar=100 μm) and processed using image J. All 
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values are expressed as mean ± SEM for three independent experiments. Data were analysed 
using one-way ANOVA for multiple comparisons with post hoc Student Newman-Keuls test. 
&p<0.05, &&p<0.01, &&&p<0.001 compared with untreated control and *p<0.05, **p<0.01, 
***p<0.001 compared to LPS/IFN. 
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Figure 3.16 Tiliroside activated SIRT1 protein expression in LPS/IFN-treated BV2 microglia. 
BV2 cells were pre-incubated with tiliroside (2-6 µM) for 30 minutes, following stimulation with LPS/IFN for 
24 hours. Nuclear lysates were collected and subjected to western blotting to detect SIRT1 expression. 
Results show that the SIRT1 expression was downregulated in neuorinflammation, where tiliroside 
significantly reversed this inhibition. Lamin B was used as a loading controlAll values are expressed as 
mean ± SEM for three independent experiments. Data were analysed using one-way ANOVA for multiple 
comparisons with post hoc Student Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 compared with 
untreated control and *p<0.05, **p<0.01, ***p<0.001 compared to LPS/IFN. 
 
  
Page | 155 
 
3.2.12 Anti-neuroinflammatory effects of tiliroside are independent of SIRT1 activity in 
LPS/IFNγ-activated BV2 microglia 
To further confirm the contributions of nuclear SIRT1 to the suppressive effects of 
tiliroside on LPS/IFN-activated inflammatory responses, BV2 cells were transiently 
transfected with control siRNA and SIRT1 siRNA. Following transfection, cells were 
pre-treated with tiliroside (6 μM) and stimulated with LPS (100 ng/ml)/IFN (5 ng/ml) 
for 24 hours. Later, supernatants were collected and levels of cytokines were 
measured using ELISA. Figure 3.17 shows that in control siRNA cells, the 
combination of LPS and IFN produced a marked increase in TNF α (a), IL-6 (b) and 
IL-1β (c) production, while in SIRT1 silenced cells a further increase in the 
production of the cytokines was observed. As expected, tiliroside significantly 
inhibited the production of cytokines in control siRNA cells, interestingly, in SIRT1 
silenced cells, the inhibitory activity of the compound was not reversed suggesting 
that the activity of the compound is independent of SIRT1 in microglia.  
Encouraged by this outcome, the effect of the compound on the production of NO 
and PGE2 is further investigated in SIRT1 silenced LPS/IFN-treated BV2 microglia. 
Cells were transfected with control siRNA and SIRT1 siRNA and pre-incubated with 
tiliroside (6 μM) followed by stimulation with LPS and IFN for 24 hours. Microglial 
SIRT1 deficiency elevated nitrites (a by-product of NO) and PGE2 production, 
however, no reversal of this upregulation was observed in the presence of tiliroside. 
These results seem to be consistent with data on cytokines suggesting that anti-
neuroinflammatory activities of the compound are not SIRT1 mediated (Figure 3.18). 
The efficiency of SIRT1 gene knockdown in BV2 cells was assessed using western 
blotting experiments. Results show that cells that are transfected with control siRNA 
significantly expressed SIRT1. However, following transfection of microglia with 
SIRT1 siRNA, there was a marked deletion of nuclear SIRT1 protein in the cells 
(Figure 3.19). Tiliroside (6 μM) has significantly upregulated SIRT1 expression in 
control siRNA transfected cells compared to SIRT1 gene silenced microglia, which 
shows that SIRT1 gene was knocked out efficiently in microglia. 
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Figure 3.17 SIRT1 gene knockdown in BV2 microglia did not affect 
neuroinflammation inhibitory effects of tiliroside 
SIRT1 siRNA and control siRNA transfected BV2 cells were pre-treated with tiliroside for 30 
minutes prior to stimulation with LPS/IFN for 24 hours. Subsequently, culture supernatants 
were analysed for TNF α (a), IL-6 (b) and IL-1β (c) production using ELISA. Results revealed 
that tiliroside significantly inhibited the production of pro-inflammatory cytokines in control 
siRNA cells. However, the inhibitory effects of the compound are not reversed in SIRT1 siRNA 
BV2 cells. All values are expressed as mean ± SEM for at least 3 independent experiments. 
Data were analysed using one-way ANOVA for multiple comparisons with post-hoc Student 
Newman-Keuls test. ᶿp< 0.05, ᶿᶿp<0.01, ᶿᶿᶿp<0.001 as compared within the groups of the 
untreated control. $p< 0.05, $$p<0.01, $$$p<0.001 as compared within the groups stimulated 
with LPS/IFN and #p<0.05, ##p<0.01, ###p<0.001 as compared within the groups pre-treated 
with tiliroside (6 μM). 
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Figure 3.18 Neuroinflammation inhibitory effects of tiliroside are independent of SIRT1 
activation in BV2 microglia 
SIRT1 siRNA and control siRNA transfected BV2 cells were pre-treated with tiliroside (6 µM) for 30 minutes 
prior to stimulation with LPS/IFN for 24 hours. Subsequently, culture supernatants were analysed for 
nitrites using Griess assay and PGE2 by EIA assay. Results revealed that tiliroside significantly inhibited 
nitrite and PGE2 production in control siRNA cells. However, the inhibitory effects of the compound are not 
reversed in SIRT1 siRNA BV2 cells. All values are expressed as mean ± SEM for at least 3 independent 
experiments. Data were analysed using one-way ANOVA for multiple comparisons with post-hoc Student 
Newman-Keuls test. ᶿp< 0.05, ᶿᶿp<0.01, ᶿᶿᶿp<0.001 as compared within the groups of the untreated control. 
$p< 0.05, $$p<0.01, $$$p<0.001 as compared within the groups stimulated with LPS/IFN and #p<0.05, 
##p<0.01, ###p<0.001 as compared within the groups pre-treated with tiliroside (6 μM). 
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Figure 3.19 SIRT1 protein was knocked out efficientley in SIRT1 siRNA transfected BV2 
microglia 
Control siRNA and SIRT1 siRNA-transfected BV2 microglia were treated with tiliroside (6 µM) for 30 
minutes prior to stimulation with LPS/IFN for 24 hours. Nuclear lysates were collected and assessed 
for SIRT1 expression using western blot. SIRT1 protein was successfully knocked out compared to 
control siRNA in the microglia. All values are expressed as mean ± SEM for at least 3 independent 
experiments. Data were analysed using one-way ANOVA for multiple comparisons with post-hoc 
Student Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 compared to untreated control. 
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3.2.13 Tiliroside prevents LPS/IFN-induced ROS production and GSH inhibition in 
BV2 microglia 
Chronic activation of microglia generates excess cellular ROS, which ultimately 
damages adjacent neurons. This intracellular accumulation of ROS in microglia 
triggers the release of various inflammatory mediators through activation of 
downstream signalling pathways like MAPKs and NF-B (Zhang et al. 2016). The 
effect of tiliroside on LPS/IFN-activated ROS production in BV2 microglia was 
investigated. BV2 cells were challenged with the combination of LPS and IFN for 24 
hours in the presence and absence of the compound. Results show that tiliroside (2-
6 M) produced significant (p<0.01) reduction of ROS following activation by 
LPS/IFN in microglia. Compound at 2 M significantly inhibited ROS generation by 
~1.3-fold, 4 M ~1.4-fold and at 6 M by ~1.8-fold in the activated microglia (Figure 
3.20a).  
Glutathione (GSH) is a major cellular protectant against ROS and has been shown to 
be dysregulated during neuroinflammatory conditions (Roychowdhury et al. 2003) 
(Ray et al. 2011), (Barger et al. 2007) and (Cho et al. 2012). Consequently, tiliroside 
was investigated for its effect on the levels of GSH in LPS/IFN-activated microglia. 
Stimulation with LPS and IFN resulted in a significant decrease in GSH levels 
compared to untreated cells (Figure 3.20b). However, when pre-treated with tiliroside 
(2-6 M), there was a significant (p<0.001) and dose-dependent increase (~1.7-fold 
increase, ~2.2-fold increase and ~2.5-fold increase) in the levels of GSH. 
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Figure 3.20 Tiliroside inhibited ROS generation and increased GSH levels in 
LPS/IFN-stimulated microglia 
(a) BV2 microglia were pre-treated with tiliroside (2-6 M) for 30 minutes and later stimulated 
with LPS (100 ng/ml)/IFN (5 ng/ml)-incubated for 24 hours. (a) Cells were washed with PBS 
and stained with 20 µM DCFDA for 30 minutes at 37C, and then stimulated with LPS /IFN for 
24 hours in the presence or absence of the compound. Fluorescence detection of ROS 
production was done using Polar star Optima plate reader. Tiliroside inhibited ROS production 
in the microglia. (b) Cells were pre-treated with compound for 30 minutes and later stimulated 
with LPS/IFN-incubated for 24 hours. Subsequently, the culture medium was replaced with 
GSH-Glo™ reagent and incubated at room temperature for 30 minutes. Thereafter, luciferin 
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detection reagent was added to each well and luminescence was then read. All values are 
expressed as mean ± SEM for three independent experiments. Data were analysed using one-
way ANOVA for multiple comparisons with post hoc Student Newman-Keuls test. &p<0.05, 
&&p<0.01, &&&p<0.001 in comparison with untreated control and *p<0.05, **p<0.01, ***p<0.001 
in comparison with LPS/IFN. 
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3.3 Discussion 
Neuroinflammation is a critical component of a diverse range of neurodegenerative 
diseases. Furthermore, increasing evidence suggests that hyperactive microglia is a 
key causative factor in this process. In this research, neuroinflammation inhibitory 
actions of the dietary flavonoid tiliroside were investigated in LPS/IFN-activated BV2 
microglia. 
As expected, stimulation of microglia with a combination of bacterial 
lipopolysaccharide (LPS) and gamma interferon (IFN) resulted in an increase in the 
production of pro-inflammatory cytokines like TNFα, IL-1β and IL-6. Several reports 
have shown that LPS is capable of inducing pro-inflammatory cytokines along with 
other chemokines via activating toll-like receptors (TLRs) (Xu et al. 2014). Further 
studies revealed that IFN can be used to prime macrophages derived from bone 
marrow to enhance the inflammatory response to TLRs (Schroder et al. 2006) and 
(Ye et al. 2001). Interestingly, when these macrophages were challenged with IFN 
alone, there were no effects on the induction of pro-inflammatory cytokines like 
TNFα, IL-6 and IL-1β. However, when combined with LPS high levels of pro-
inflammatory cytokines were observed (Southworth et al. 2012). In other studies, this 
combination of LPS and IFN has been shown to increase the expression of MYD88 
and TRAF6 in macrophages (Mita et al. 2001) and (Southworth et al. 2012). In the 
current research, tiliroside suppress the production of TNFα in LPS/IFN-activated 
BV2 microglia, suggesting that the compound is capable of inhibiting 
neuroinflammation. Studies have demonstrated that TNFα released from activated 
microglia during neuroinflammation binds to the TNFR superfamilies’ on adjacent 
microglia and neurons (Didonato et al. 2012) and (Opal & DePalo 2000). This further 
triggers the release of excess TNFα into the brain environment and in turn 
exacerbates neuroinflammatory conditions leading to neuronal toxicity. In addition to 
TNFα, excess levels of IL-1β and IL-6 released from activated microglia are shown 
to induce neuronal death via activating several intrinsic pathways in neurons (Aïd & 
Bosetti 2011) and (Chatterjee et al. 2014). Tiliroside suppressed IL-1β release from 
LPS/IFN-stimulated microglia. Furthermore, the effect of tiliroside was investigated 
against LPS/IFN-induced IL-6 release in microglia. Results show that the compound 
significantly blocked the production of IL-6 in microglia, suggesting that tiliroside is 
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capable of inhibiting interleukins in neuroinflammation. Several lines of studies have 
shown that anti-inflammatory cytokines like IL-10 and TGF-β are capable of blocking 
the binding of TNFα to its receptors on the microglia and could resolve 
neuroinflammation (Park et al. 2007) and (Zhou et al. 2012). Tiliroside in this study 
reversed the inhibition of IL-10 production in activated microglia. All these results 
seem to suggest that tiliroside blocked the progression of neuroinflammation by 
inhibiting the production of pro-inflammatory and activating anti-inflammatory 
cytokines in microglia.  
The combination of LPS and IFN increased the production of nitric oxide and the 
expression of iNOS protein in the microglia. Tiliroside reduced these events 
suggesting another mechanism for inhibiting neuroinflammation in activated BV2 
cells. Stimulation of glial cells has been proposed to lead to the generation of large 
quantities of nitric oxide through iNOS protein expression and can contribute to 
neurodegeneration (Knott et al. 2000), (Calvello et al. 2012) and (Liu et al. 2008). 
The role of iNOS and its mediated nitric oxide in neuroinflammation is well 
documented. Excess nitric oxide has shown to induce ROS production in microglia 
via targeting mitochondrial electron transport chain function (Doherty 2011). 
Furthermore, excessive nitric oxide production has proved to be detrimental, as it is 
capable of inducing protein misfolding during post-translational modifications such as 
S-nitrosylation in the microglia. Dysregulated S-nitrosylation will hyperactivate 
transcription factors like NF-B and further enhances inflammatory conditions in the 
brain (Chattopadhyay et al. 2010) and (Vauzour et al. 2015). Studies have shown 
that blocking iNOS protein expression and its mediated nitric oxide production will 
inhibit neuroinflammation in glial cells (Xing et al. 2008), (Choi & Park 2012) and 
(Bozic et al. 2015).  
Tiliroside significantly suppressed LPS/IFN-induced PGE2 production in activated 
microglia. Also, compound reduced COX-2 protein expression at all the 
concentrations investigated in microglia following stimulation with LPS and IFN. 
These results indicate that the activity of tiliroside is more pronounced at the level of 
COX-2 protein expression. Activated microglia are shown to generate eicosanoids 
like prostaglandins that are under control of cyclooxygenase (COX-2) enzyme 
pathway (Morales et al. 2014). Prostaglandin E2 (PGE2) is a major eicosanoid found 
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in many CNS related inflammatory diseases and is a primary target for non-steroidal 
anti-inflammatory drugs (Doherty 2011) and (Wang et al. 2015). 
The transcription factor NF-B (nuclear factor -light-chain-enhancer of activated B 
cells), plays a major role in regulating immune responses, inflammation and cell 
survival in the microglia. Out of five members of NF-B family, heterodimers of the 
p50 and p65 subunits are widely studied in neuroinflammation, as they are 
considered as potent activators of inflammatory gene transcription (Hayden & Ghosh 
2012). Several lines of evidence suggest that binding of translocated NF-B to the 
promoter region of chemokines, pro-inflammatory cytokines (TNFα, IL-1β and IL-6), 
COX-2 and iNOS expressing gene is required for the target gene transcription 
(Lyman et al. 2013), (Didonato et al. 2012) and (Yamamoto et al. 1995). Moreover, 
hyper-activation of NF-B signalling and its associated inflammatory mediators has 
been linked to the broad range of brain immune diseases such as AD and PD (Kawai 
& Akira 2007). Consequently, targeting NF-B signalling in neuroinflammation could 
ablate the transcription and release of inflammatory mediators in the brain. NF-B is 
coupled to IB to form an inactive complex in the cytoplasm. However, when 
challenged with inflammatory stimuli or during endogenous inflammatory conditions, 
phosphorylation by active IKKα results in further phosphorylation and subsequent 
degradation of IBα by proteasomes, followed by NF-B translocation into the 
nucleus. In the nucleus, NF-B undergo phosphorylation and binds to the promoter 
regions of inflammatory genes to initiate the transcription of inflammatory genes 
(Didonato et al. 2012). Therefore, the effect of tiliroside on phosphorylated-p65 in 
LPS/IFN-activated microglia was studied. Results revealed that the p-p65 
suppressive effect of tiliroside was not efficient at 2 µM. However, as the 
concentration was increased to 4 and 6 µM, a dose-dependent inhibition of p65 
phosphorylation was observed. To induce transcription, p-p65 has to bind to the 
DNA of the inflammatory genes. Therefore, further investigation was carried out to 
know the effect of the tiliroside on DNA binding of NF-B. Surprisingly, tiliroside 
significantly blocked LPS/IFN-induced NF-B-DNA binding in the microglia. These 
NF-B-DNA binding inhibitory actions further support the anti-neuroinflammatory 
effects of tiliroside on LPS and IFN-induced TNFα, iNOS, COX-2 and IL-1β 
production in microglia. During neuroinflammation, transactivated NF-B will be 
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translocated to the nucleus and will bind to the respective genes to drive the 
transcription. The compound was shown to produce a significant inhibition of NF-B-
dependent gene expression, through suppression of LPS/IFN-induced activation of 
the NF-B-driven luciferase expression in microglia. These inhibitory effects further 
suggest that tiliroside can inhibit transactivation of NF-B in activated microglia. 
From all these results, it appears that tiliroside inhibit neuroinflammation by targeting 
NF-B signalling in BV2 microglia. 
After confirming that tiliroside inhibited NF-B signalling events in activated 
microglia, its effect on upstream kinases were investigated next. Results showed that 
tiliroside inhibited phosphorylation and subsequent degradation of IB in LPS/IFN-
activated microglia. In addition to its inhibitory effects on IB phosphorylation, 
tiliroside also blocked phosphorylation of IKK following stimulation with a 
combination of LPS and IFN in the microglia. Blocking these events during 
neuroinflammation could inhibit nuclear translocation of NF-B and further 
transcription of inflammatory mediators (Xu et al. 2014), (Kang, Choi, et al. 2013) 
and (Hayden & Ghosh 2012). It appears from the above results that the NF-B 
signalling pathway is associated with the neuroinflammation inhibitory activity of 
tiliroside in microglia. 
The p38 MAPK signalling play a critical role in controlling signalling events during 
neuroinflammation and contribute to the production of inflammatory mediators such 
as TNFα, IL-1β, iNOS and NO (Kim et al. 2004), (Jeong et al. 2013) and (Herlaar & 
Brown 1999). Therefore, small molecules that are capable of down-regulating MAP 
kinase signalling could potentially inhibit neuroinflammation (Xing et al. 2008) and 
(Okorji et al. 2015). Further experiments showed that tiliroside attenuated the 
phosphorylation of p38 MAPK in LPS/IFN-stimulated BV2 microglia. Also, tiliroside 
blocked the activation of p38 downstream substrate MK2 and upstream kinase 
MAPK kinase 3/6 (MKK3/6). Several studies have demonstrated that, compounds 
that inhibit LPS-activated MKK3/6 and MK2 proteins blocks the production of TNFα, 
IL-6 and IL-8 and other cytokines in the microglia (Duraisamy et al. 2008), (Corrêa et 
al. 2012), (Fyhrquist et al. 2010) and (Neininger et al. 2002). Collectively, these 
results seem to indicate that p38 MAPK signalling pathway is involved in the 
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inhibitory effect of tiliroside in the production of inflammatory mediators when 
stimulated with a combination of LPS and IFN in microglia. 
Studies have shown that inflammatory stimuli such as LPS initiate expression of pro-
inflammatory cytokines by binding to the membrane-bound toll-like receptor 4 
(TLR4). Results show that the combination of LPS and IFN significantly activated 
TLR4 in BV2 microglia. Furthermore, activated TLR4 culminates TRAF6 protein 
complex in the microglia. Activated TRAF6 complex has been shown to trigger the 
induction and nuclear translocation of NF-B via rapid phosphorylation of specific 
serine residues of IB by IKK complex along with p38 MAPK signalling (Karin & 
Gallagher 2009). Several studies have revealed that blocking TLR4 activation could 
culminate the production of NF-B and p38 MAPK associated inflammatory 
mediators such as iNOS, COX-2, IL-1β and NO (Lehnardt et al. 2003), (Takeda & 
Akira 2004) and (Xu et al. 2014). This study revealed that tiliroside at highest 
concentration blocked the activation of TLR4 in activated microglia. Production of 
various pro-inflammatory factors during neuroinflammation are shown to be 
mediated by activated TLR4 via induction of TRAF6 complex (Karin & Gallagher 
2009) and (Zhu et al. 2014). In addition to its TLR4 inhibitory activity, tiliroside also 
inhibited LPS and IFN-induced upregulation of TRAF6 expression in microglia 
showing that its activity is more pronounced at the level of TLR4/TRAF6. All these 
results seem to suggest that tiliroside alleviates LPS/IFN-induced 
neuroinflammation by inhibiting TLR4 mediated NF-B and p38 MAPK signalling in 
microglia. 
In the resting microglia, sirtuins especially SIRT1 were shown to inhibit NF-B 
transcriptional activity by deacetylation of p65 subunit in the nucleus (Herskovits & 
Guarente 2014) and (Donmez & Donmez 2012). In this study, the combination of 
LPS and IFN increased the levels of acetylated-NF-B-p65 in the microglia. 
However, tiliroside suppressed the expression of acetylated-NF-B-p65 in a 
concentration–dependant manner suggesting that the compound is capable of 
inhibiting neuroinflammation via promoting deacetylation of NF-B-p65 in microglia. 
Studies in the past have demonstrated that the binding of acetylated-NF-B to the 
promoter regions of COX-2, iNOS, TNFα, IL-1β and IL-6 expressing gene is required 
for the target gene transcription in activated microglia (Chen et al. 2001), (Kawai et 
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al. 2011) and (Guarente 2011). Compounds that target NF-B signalling during 
inflammation also exhibited inhibitory effects on acetylated-NF-B-p65 subunit in 
microglia (Kumar & Sharma 2010) and (Zhu et al. 2011).  
After confirming that tiliroside is capable of reducing the levels of acetylated-NF-B-
p65, further studies were conducted to investigate the effect of the compound on 
SIRT1 activation in microglia. Results show that tiliroside dose-dependently activated 
SIRT1 protein in the microglia. These data suggest that activation of SIRT1 by 
tiliroside probably results in the inhibition of acetylated-NF-B-p65 in the microglia. 
Neuroinflammation is known to influence the expression of SIRT1 in the microglia. 
Emerging evidence demonstrates that there is a strong link between acetylated-NF-
B-p65 and SIRT1 (Cho et al. 2015). Therefore, the effect of the compound against 
LPS/IFN-induced SIRT1 nuclear accumulation was investigated in microglia. Data 
revealed a significant decrease in the level of SIRT1 protein in LPS/IFN-treated 
microglia, which explains the high levels of acetylated NF-B-p65 during 
neuroinflammatory conditions. Studies have reported that inhibition of SIRT1 by LPS 
significantly increased the acetylation of RelA/p65 subunit and further enhanced NF-
B transcriptional activity in endothelial cells (Yang et al. 2012). Results from the 
current research suggest that the activation of LPS/IFN-induced SIRT1 protein by 
tiliroside probably results in the inhibition of NF-B signalling in the microglia.  
Tiliroside was shown to block LPS/IFN-induced neuroinflammation in the microglia, 
as well as supressed the expression of acetylated-NF-B-p65 and also activated 
SIRT1. It should be kind of interesting to investigate whether SIRT1 activation 
contributes to the neuroinflammation inhibitory effects of tiliroside in LPS/IFN-
treated microglia. This was achieved by using control and SIRT1 siRNA-transfected 
cells. Results show that in control siRNA-transfected cells, tiliroside inhibited the 
production of LPS/IFN-induced PGE2, nitric oxide and pro-inflammatory cytokines 
such as TNFα, IL-1β and IL-6. However, these inhibitory activities of the compound 
were not affected in SIRT1 siRNA-transfected cells. These results further suggest 
that LPS/IFN-induced neuroinflammation inhibitory actions of tiliroside are 
independent of SIRT1 activation. The efficiency of SIRT1 gene knockdown in BV2 
cells was assessed using western blotting experiments Results revealed that SIRT1 
gene was successfully knocked out in all these experiments. 
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Glial cells have been shown to produce different ROS in response to various 
inflammatory stimuli (Lee & Yang 2012) and (Zhang et al. 2016). This intracellular 
accumulation of ROS triggers the release of various inflammatory mediators through 
activation of downstream signalling pathways like MAPKs and NF-B in microglia 
(Rojo et al. 2014). Small molecules that exhibit inhibitory actions on intracellular 
signalling cascades involving NF-B and p38 MAPK, have also been shown to block 
ROS generation in LPS-treated microglia (Zeng et al. 2012) and (Lee et al. 2015). 
Since tiliroside has produced a remarkable inhibition of NF-B and p38 MAPK 
signalling, its effect on intracellular ROS production was assessed in LPS/IFN-
stimulated microglia. Results demonstrate that a combination of LPS and IFN 
significantly increased ROS production in BV2 microglia. Tiliroside dose-dependently 
blocked this intracellular ROS accumulation, suggesting that the compound possess 
inhibitory actions against ROS-mediated neuroinflammation in microglia. Glutathione 
(GSH) is a critical cellular antioxidant and has been shown to be involved in 
scavenging ROS and peroxynitrite produced during neuroinflammation 
(Roychowdhury et al. 2003) and (Barger et al. 2007). In this study, the combination 
of LPS and IFN inhibited the endogenous level of GSH in the microglia. This 
observation further confirms that glutathione levels will be affected in 
neuroinflammation. However, tiliroside dose-dependently increased the production of 
GSH in activated microglia suggesting that compound possesses strong anti-
inflammatory effects.  
Tiliroside inhibited neuroinflammation in BV2 microglia through a mechanism 
involving TLR4 receptor-mediated activation of NF-B and p38 MAPK signalling 
pathways. Also, the compound was shown to activate SIRT1 and inhibited the 
expression of acetylated- NF-B-p65 in LPS/IFN-treated microglia. However, further 
RNAi experiments revealed that neuroinflammation inhibitory activities of the 
compound are not SIRT1 mediated. 
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Figure 3.21 Proposed neuroinflammation inhibitory effects of tiliroside in 
microglia challenged with LPS and IFN. LPS: Lipopolysaccharide, IFN: Interferon 
gamma, TLR4: Toll-like receptor 4, TRAF6: TNF receptor associated factor 6, IKK: IκB 
kinase, MKK3/6: Mitogen-activated protein kinase kinase 3/6, MK2: MAP kinase-activated 
protein kinase 2, TNFα: Tumor necrosis factor alpha, IL-1β: Interleukin 1 beta, IL-6: 
Interleukin 6, COX: Cyclooxygenase, PGE2: Prostaglandin E2, iNOS: inducible Nitric oxide 
synthase, NO: Nitric oxide. 
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Chapter 4. Tiliroside inhibited neuroinflammation-induced neuronal 
toxicity 
4.1 Introduction 
In response to local injury, infection or harmful toxins, microglial cells become 
hyperactivated and exhibit chronic inflammatory responses by secreting 
inflammatory mediators like nitric oxide, PGE2, ROS/RNS and pro-inflammatory 
cytokines including IL-6 and TNFα (Peterson & Toborek 2014), (Spencer et al. 2012) 
and (Huang et al. 2015). Sustained activation of microglia consistently produces 
powerful neurotoxic mediators which can cause neuronal injury and thereby 
contribute to the progressive death of neurons in the CNS. Microglia-derived 
excessive cytotoxic factors and its associated chronic neuroinflammation have been 
recognised as important pathological events in several neurodegenerative diseases 
like Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis, and 
dementia (Zecca et al. 2004) and (Ray & Lahiri 2009). However, how these cytotoxic 
factors become more detrimental to neurons is yet to be investigated. 
In adverse neurological diseases, progressive loss of structure and function of 
neurons was observed, leading it to profound brain atrophy and cognitive deficit 
(Cobourne-Duval et al. 2016). Studies have shown that elevated levels of pro-
inflammatory cytokines and ROS-mediated oxidative stress play a vital role in 
inducing these adverse effects in neurons (Hamadi et al. 2016) and (Hwang et al. 
2009). Limited production of NO by active microglia is turned to be beneficial to 
adjacent neurons. However, recent research has shown that high levels of NO 
during chronic inflammation can induce neuronal death by causing selective 
inhibition of mitochondrial cytochrome C oxidase in neurons releasing high levels of 
ROS into the cytoplasm (Uttara et al. 2009) and (Watanabe et al. 2000). In addition 
to these effects, NO in excess reacts with superoxide from NADPH oxidase leads to 
the generation of peroxynitrite (ONOO−), which is a key regulator in driving the 
neurotoxic responses (Brown & Neher 2010). Compounds that are shown to inhibit 
neuroinflammation exhibited neuroprotective potential by blocking ROS-mediated 
neuronal death (Zeng et al. 2010). 
Interestingly, ROS accumulation within the neuronal cells has been linked to the 
disruption of calcium homoeostasis and its mediated induction and activation of pro-
apoptotic proteins such as p53, caspases, Bax and Bcl2 leading to a programmed 
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neuronal death resulting in neuronal toxicity (Mattson 2007) and (Pfeiffer et al. 2014). 
LPS-induced neuroinflammation has been shown to evoke calcium influx in the 
neuronal cells of the animal brain, while inhibition of excessive calcium appeared to 
be beneficial to the neurons (Hoffmann et al. 2013). This observation gives a hint 
that blocking neuroinflammation-induced ROS production and calcium increase in 
neuronal cells would be a useful therapeutic approach in the treatment of various 
neurodegenerative diseases. 
In addition to ROS, active microglia are shown to release various pro-inflammatory 
cytokines which have been reported to initiate morphological changes in the adjacent 
neurons (Lull & Block 2010). It has been demonstrated that inflammatory cytokines 
such as TNFα and IL-1β from hyperactive active microglia are capable of inducing 
redox imbalance and DNA strand breakage in neurons. These were considered as a 
common feature of many neurodegenerative conditions which cause neuronal death 
in hippocampal regions of the brain (Vauzour et al. 2015) and (Michelle L. Block et 
al. 2007). From this perspective, targeting neuroinflammation-mediated intracellular 
ROS accumulation and its associated DNA damage with suitable pharmacologically-
active compounds may help to reduce neuronal toxicity. 
Neurotoxic factors released during neuroinflammation can be studied in vitro by 
treating neuronal cells with conditioned culture medium collected from BV2 microglia 
that are stimulated using external stimuli such as LPS (Bevinahal et al. 2014) and 
(Gresa-Arribas et al. 2012). Tiliroside was shown to have neuroinflammation 
inhibitory effects; however, its neuroprotective potentials were not yet studied. In the 
current research, culture medium collected from BV2 microglia that were pre-treated 
with tiliroside (2-6 µM) before stimulation with LPS and IFN was investigated for its 
neuroprotective effects against HT22 neuronal toxicity induced by 
neuroinflammation. 
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4.2 Results 
4.2.1 Tiliroside inhibited neuroinflammation-mediated neurotoxicity in HT22 cells 
It is now well established that microglia-induced neuroinflammation is involved in 
neuronal damage in the brain causing neurodegenerative diseases like AD and PD 
(Michelle L. Block et al. 2007). The neurotoxic effects of conditioned medium 
collected from microglia that were stimulated with LPS and IFN was tested on HT22 
neuronal cells. Results of XTT assay showed that there was a marked reduction in 
the viability of HT22 neurons when exposed to conditioned medium from the 
microglia that were incubated with LPS and IFN for 24 hours. However, culture 
medium collected from BV2 cells that were pre-treated for 30 minutes with increasing 
concentrations of tiliroside (2-6 M) before the stimulation with LPS/IFN significantly 
(p< 0.01) inhibited neuronal toxicity induced by neuroinflammation. Microglia culture 
medium pre-treated with 2 M of the tiliroside increased the viability of HT22 neurons 
by ~1.5-fold, 4 M by ~ 1.9-fold and 6 M by ~2-fold (Figure 4.1).  
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Figure 4.1 Tiliroside inhibited microglial conditioned medium-induced neuronal death 
in HT22 neurons 
HT22 neurons were incubated with conditioned culture medium obtained from BV2 microglia that 
were stimulated with LPS and IFN. Subsequently, other wells containing HTT22 neurons were 
exposed to conditioned medium obtained from BV2 cells that were pre-treated with increasing 
concentrations of tiliroside (2-6 µM) prior to stimulation with LPS/IFN for 24 hours. XTT assay 
was carried out to assess the viability of HT22 neurons. Results showed that tiliroside reversed the 
neuroinflammation-induced HT22 neuronal death. All values are expressed as mean ± SEM for 
three independent experiments. Data were analysed using one-way ANOVA for multiple 
comparisons with post-hoc Student Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 compared 
with untreated control and *p<0.05, **p<0.01, ***p<0.001 compared to LPS/IFN. 
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4.2.2 Tiliroside inhibited neuroinflammation-induced calcium accumulation in HT-22 
neuronal cells 
Studies have shown that calcium ions are universal regulators that control various 
cellular processes such as cell death (Tran & Watanabe 2006). High levels of 
calcium were observed in neuronal cells during neuroinflammatory conditions 
(Hoffmann et al. 2013). Moreover, several lines of evidence reported that excess 
generation of ROS in neurons tend to induce calcium influx resulting in the death of 
neurons (Ye et al. 2013) and (McCoy & Tansey 2008). The addition of conditioned 
culture medium from BV2 cells that were stimulated with LPS/IFN to HT22 neurons 
induced high levels of calcium (~10-fold increase, p<0.001). However, incubation of 
HT22 cells with conditioned medium collected from BV2 cells that are pre-treated 
with tiliroside showed a minimal effect at concentrations of 2 and 4 µM. Surprisingly 
culture medium from BV2 cells pre-treated with 6 µM tiliroside significantly reduced 
(~1.8-fold reduction, p<0.01) neuroinflammation-induced calcium accumulation in 
HT22 neurons (Figure 4.2). 
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Figure 4.2 Tiliroside inhibited microglial conditioned medium-induced calcium 
accumulation in HT22 neuronal cells 
HT22 neurons were incubated with conditioned culture medium obtained from BV2 microglia 
that were stimulated with LPS and IFN. Subsequently, HT22 neurons in other wells were 
incubated with conditioned medium obtained from BV2 cells that were pre-treated with 
increasing concentrations of tiliroside (2-6 µM) and stimulated with LPS/IFN for 24 hours. 
After that, calcium accumulation assay was carried out in HT22 cells. Results show that 
microglia-induced neuroinflammation increased calcium levels in HT22 neurons. Culture 
medium from BV2 cells pre-treated with compound was shown to reduce calcium 
accumulation in HT22 neurons. All values are expressed as mean ± SEM for at least three 
independent experiments. Data were analysed using one-way ANOVA for multiple 
comparisons with post-hoc Student Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 
compared with the untreated control and *p<0.05, **p<0.01, ***p<0.001 in compared to 
LPS/IFN. 
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4.2.3 Tiliroside inhibited ROS production in HT-22 neuronal cells  
Reactive oxygen species from hyperactive microglia causes oxidative damage, 
induction of apoptosis and DNA fragmentation in adjacent neurons (Hsieh & Yang 
2013). Since conditioned culture medium from microglia treated with tiliroside and 
LPS/IFN was shown to inhibit calcium accumulation in HT22 neuronal cells, its 
effect on ROS generation was further investigated. Incubation of HT22 cells with 
conditioned culture medium collected from LPS and IFN stimulated BV2 cells 
significantly increased (~5-fold increase, p<0.001) intracellular ROS production 
compared to the cells that were incubated with culture medium collected from control 
BV2 microglia. Generation of ROS was significantly inhibited (p<0.01) when HTT22 
neuronal cells were incubated with conditioned culture medium obtained from 
microglia cells that were pre-treated with tiliroside 2 µM (~1.8-fold), 4 µM (~2.3-fold) 
and 6 µM (~1.8-fold) in a concentration-dependent manner (Figure 4.3). 
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Figure 4.3 Tiliroside inhibited microglial conditioned medium-induced ROS 
production in HT22 neurons 
HT22 neurons were exposed to conditioned culture medium obtained from BV2 microglia that 
were stimulated with LPS and IFN or to the medium from untreated microglia. At the same 
time, HT22 neurons were incubated with conditioned medium obtained from BV2 cells that 
were pre-treated with increasing concentrations of tiliroside (2-6 µM) before stimulation with 
LPS and IFN for 24 hours. Later, ROS production in HT22 neurons was determined by using 
DCFDA-assay kit. Results showed that tiliroside dose-dependently reduced ROS generation in 
HT22 neurons. All values are expressed as mean ± SEM for at least three independent 
experiments. Data were analysed using one-way ANOVA for multiple comparisons with post-
hoc Student Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 as compared with untreated 
control and *p<0.05, **p<0.01, ***p<0.001 in compared to LPS/IFN.. 
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4.2.4 Tiliroside inhibited neuroinflammation-mediated DNA fragmentation of HT22 
neuronal cells 
Inflammatory cytokines released by activated microglia were shown to induce 
apoptosis that leads to the damage and death of adjacent neurons (Thornton et al. 
2006). In general, cleavage of chromatin DNA into fragments is considered as an 
essential hallmark of neuronal apoptosis (Koh et al. 2008). The effect of conditioned 
medium obtained from BV2 microglia that were stimulated with the combination of 
LPS and IFN on HT22 neuronal DNA fragmentation was determined. Results in 
Figure 4.4 show that conditioned medium from BV2 cells that were stimulated with 
LPS and IFN significantly increased (p<0.001) DNA fragmentation in HT22 neurons. 
Neuroinflammation increased DNA fragmentation of HT22 neurons by ~2.9-fold 
compared to neurons treated with culture medium collected from control BV2 cells. 
Interestingly, conditioned medium from microglial cells that were pre-treated with 
tiliroside 2 M has no significant inhibitory effect on DNA fragmentation, however at 
4 and 6 M showed a dose-dependent reduction (~1.2-fold, p< 0.001 and ~1.6-fold, 
p< 0.001) in the DNA fragmentation of HT22 neuronal cells. 
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Figure 4.4 Tiliroside inhibited neuroinflammation-induced DNA fragmentation of 
HT22 neuronal cells 
HT22 neurons were exposed to conditioned culture medium obtained from BV2 microglia that 
were stimulated with LPS and IFN. Subsequently, other wells with HT22 neurons were 
incubated with conditioned medium obtained from BV2 cells that were pre-treated with 
increasing concentrations of tiliroside (2-6 µM) prior to treat with LPS and IFN for 24 hours. 
Later, DNA fragmentation assay was performed using ELISA based DNA fragmentation assay 
kit. Results showed that tiliroside (2-6 µM) reduced neuroinflammation-induced DNA 
fragmentation of HT22 neurons. All values are expressed as mean ± SEM for three 
independent experiments. Data were analysed using one-way ANOVA for multiple 
comparisons with post-hoc Student Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 in 
comparison with untreated control and *p<0.05, **p<0.01, ***p<0.001 compared to LPS/IFN. 
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4.2.5 Tiliroside reduced MAP2 expression in microglial conditioned medium-induced 
HT22 neuronal death 
In the brain, active neuronal cells have been shown to express high levels of 
microtubule-associated protein 2 (MAP2) (Strauss et al. 2000). Studies have shown 
that neurotoxic mediators along with pro-inflammatory cytokines influence the 
structure and synaptic plasticity of neurons in the CNS (Brown & Neher 2010). 
Notably, microglia-mediated neuroinflammation was shown induce neuronal toxicity, 
where the expression of MAP2 is typically reduced (Hwang et al. 2009). The 
conditioned medium obtained from BV2 microglia that were stimulated with LPS/ 
IFN was tested against MAP2 protein expression in HT22 neurons. Western blotting 
results show that when HT22 neurons were incubated with culture medium from 
microglia that were stimulated with LPS and IFN significantly reduced (~4.1-fold 
reduction, p<0.001) the expression of MAP2 protein compared to neurons that were 
treated with culture medium collected from control BV2 cells. Surprisingly, at 2 M 
the effect of the compound was minimal on the neuroinflammation-induced MAP2 
protein expression (Figure 4.5a). However, conditioned medium from the microglia 
that were pre-treated with tiliroside significantly increased (4 M, ~3.1-fold, p<0.001 
and 6 M, ~3.9-fold, p<0.001) MAP2 protein expression. Immunofluorescence 
experiment was done to further confirm the effect of microglia-induced 
neuroinflammation on the expression of MAP2 protein in HT22 neurons. Figure 4.5b 
shows that MAP2 protein expression was reduced in neurons incubated with culture 
medium obtained from BV2 cells that were stimulated with LPS and IFN compared 
to neurons that were incubated with culture medium collected from control BV2 
microglia. Interestingly, conditioned culture medium from BV2 cells that were pre-
incubated with tiliroside (2-6 M) was shown to increase the expression of MAP2 
protein in HT22 neurons. 
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Figure 4.5 Tiliroside reversed neuroinflammation-induced MAP2 expression in 
HT22 cells 
HT22 neurons were incubated with conditioned culture medium obtained from BV2 microglia 
that were stimulated with LPS and IFN. Subsequently, HT22 neurons in other wells were 
incubated with conditioned medium obtained from BV2 cells that were pre-treated with 
increasing concentrations of tiliroside (2-6 µM) and stimulated with LPS/IFN for 24 hours. (a) 
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Cytoplasmic lysates were collected and subjected to western blotting to assess the expression 
of MAP2 protein. Results showed that tiliroside dose-dependently increased MAP2 protein 
expression in HT22 neurons. (b) Immunofluorescence experiments were done to investigate 
the effects of microglia-induced neuroinflammation on the expression of MAP2 protein. HTT22 
neuronal cells were treated with microglial conditioned medium for 24 hours. Later, cells were 
fixed, blocked and stained with MAP2 antibody for overnight. The following day, cells were 
washed and incubated with secondary antibody for 2 hours in the dark. Cells were 
counterstained with DAPI and fluorescence images acquired with an EVOS® FLoid® cell 
imaging station (scale bar=100 μm) and processed using image J. Results revealed that 
tiliroside increased the expression of MAP2 protein in HT22 neurons. All values are expressed 
as mean ± SEM for three independent experiments. Data were analysed using one-way 
ANOVA for multiple comparisons with post-hoc Student Newman-Keuls test. &p<0.05, 
&&p<0.01, &&&p<0.001 compared with untreated control and *p<0.05, **p<0.01, ***p<0.001 
compared to LPS/IFN. 
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4.3 Discussion 
During neuroinflammation, microglia becomes hyperactivated and release high 
amounts of neurotoxic factors that are detrimental to adjacent neurons. Studies have 
shown that pro-inflammatory cytokines such as IL-1β, IL-6, IL-12, IL-18 and TNFα 
released by microglia are critically involved in promoting neurotoxicity (Ye et al. 
2013). The primary purpose of this study was to evaluate HT22 neuronal toxicity 
when treated with microglial conditioned medium that was previously collected from 
microglia that were stimulated with the combination of LPS and IFN. Also, to further 
investigate the neuroprotective effects of the culture medium obtained from BV2 
microglia that were pre-treated with various concentrations of tiliroside before 
treatment with LPS/IFN. 
In the CNS, microglia promotes inflammatory responses following bacterial invasion 
or local injury by consistently producing pro-inflammatory cytokines, interleukins and 
chemokines. However, in neuroinflammation, high levels of these neurotoxic factors 
released by microglia have been shown to influence surrounding neurons (Michelle 
L. Block et al. 2007). Cell viability results revealed that microglia-mediated 
neuroinflammation induced toxicity in HT22 neurons when treated with conditioned 
culture medium from BV2 cells that were stimulated with LPS/IFN. However, culture 
medium from microglia that were pre-incubated with tiliroside protected neurons from 
neuroinflammation-induced toxicity. Results from several other animal models 
revealed that neuroinflammation is closely associated with the risk of inducing 
neuronal death via releasing excess pro-inflammatory cytokines in 
neurodegenerative diseases like AD and PD (Kumar & Sharma 2010) and (Lee et al. 
2010). These results seem to suggest that neurotoxic mediators that are released 
into microglial conditioned media may contribute to HT22 neuronal death. While 
culture medium collected from microglia that were pre-treated with tiliroside was 
shown to block neuroinflammation-mediated neuronal death, suggesting the 
neuroprotective potential of the compound. 
Relatively high levels of intrinsic calcium accumulation was observed in adjacent 
neurons during neuroinflammation (Pfeiffer et al. 2014) and (Mattson 2007). HT22 
neuronal calcium levels were significantly increased when exposed to conditioned 
culture medium obtained from BV2 cells that were stimulated with LPS/IFN. 
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Surprisingly, culture medium collected from BV2 cells pre-incubated with increasing 
concentrations of tiliroside was shown to reduce calcium accumulation in the HT22 
neurons. Studies have shown that microglial TNFα during neuroinflammation 
induces calcium influx in neurons by binding to TNFR1 receptor (Olmos & Llad 
2014). Possibly, this leads to the excessive accumulation of Ca2+ in neurons which 
will further induce neuronal death by increasing the excitatory synaptic strength (Yu 
et al. 2002). In addition to TNFα, IL-1β secreted by hyperactive microglia was shown 
to induce neurotoxicity through high glutamate production in neurons (Ye et al. 
2013). A different set of studies revealed that excess calcium in the neurons also 
tends to release high levels of free radicals and ROS, which will further damage DNA 
by inducing apoptosis cascades (McCoy & Tansey 2008).  
Excessive generation of ROS in neurons is considered as an important hallmark in 
neuroinflammation-induced neurotoxicity (Mitra et al. 2015) and (Mattson 2007). 
Therefore, production of ROS in HT22 neuronal cells was measured after incubated 
with conditioned culture medium obtained from BV2 microglia that were challenged 
with LPS and IFN. Results revealed that conditioned culture medium collected from 
BV2 cells that are challenged with the combination of LPS and IFN increased ROS 
production in HT22 neuronal cells. Interestingly, neuroinflammation-induced 
intracellular ROS accumulation was prevented when HT22 neurons were incubated 
with culture medium collected from microglia that were pre-treated with tiliroside 
before stimulation with LPS/IFN. In previous studies, compounds that possess 
neuroprotective effects were shown to block neuroinflammation-mediated calcium 
and ROS accumulation in neuronal cells (Zeng et al. 2010), (Bisht et al. 2010) and 
(Ishige et al. 2001). In SH-SY5Y neuronal cells, dietary flavonoid kaempferol 
inhibited rotenone-induced ROS production at a concentration of 30 µM and further 
blocked neurodegeneration (Filomeni et al. 2012). In the current research, tiliroside, 
a derivative of kaempferol blocks neuroinflammation-induced ROS generation at a 
concentration of 6 µM. These overall results tend to suggest that conditioned culture 
medium collected from microglia that were pre-incubated with tiliroside and 
stimulated with LPS/IFN was shown to inhibit HT22 neuronal toxicity by blocking 
calcium and ROS accumulation. 
Activated microglia produces pro-inflammatory cytokines and chemokines along with 
ROS have been implicated in neuronal apoptosis and also shown to be linked to the 
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pathogenesis of neurodegenerative diseases (Ishige et al. 2001) and (Hamadi et al. 
2016). Also, it is evident from several studies that when neurons were stimulated 
with inflammatory cytokines such as TNFα or IL-1β, they undergo apoptosis, which 
suggests that neuroinflammation will induce neuronal apoptosis (Bevinahal et al. 
2014) and (Wiese et al. 2006). Neurons that undergo apoptosis release DNA 
fragments into the cytoplasm (Zhou et al. 2014) and (Koh et al. 2008). When the 
conditioned culture medium from microglia stimulated with LPS/IFN incubated with 
HT22 neuronal cells, an increase in the DNA fragmentation was observed. This 
observation further suggests that conditioned culture medium collected from BV2 
microglia that were stimulated with combination of LPS and IFN was neurotoxic. 
However, data from the results show that the conditioned medium from BV2 cells 
that were pre-treated with various concentrations of tiliroside significantly inhibited 
neuroinflammation-mediated HT22 neuronal DNA fragmentation. 
After observing the effects of conditioned medium on neuronal DNA fragmentation, 
its effect on MAP2 protein expression was next investigated. MAP2 belongs to 
microtubule-associated family and are thought to be involved in the assembly of the 
neuronal microtubules (Strauss et al. 2000). It is a neuronal marker and was shown 
to highly express in healthy neuronal cells. Results show that conditioned medium 
that contained neurotoxic factors was shown to reduce the expression of MAP2 
protein. However, conditioned medium collected from BV2 cells that were pre-treated 
with tiliroside significantly increased the expression of MAP2 protein in HT22 
neurons. It appears from the results that neuroprotective potentials of culture 
medium obtained from BV2 microglia that were pre-treated with tiliroside inhibited 
neuroinflammation-induced HT22 neuronal death via blocking neurotoxic cellular 
events such as DNA fragmentation, ROS production, calcium accumulation and 
partly by increasing MAP2 protein expression. 
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Chapter 5. Anti-neuroinflammatory effects of tiliroside are Nrf2 
mediated 
5.1 Introduction 
Several studies indicate that neuroinflammation is a double-edged sword that 
executes both beneficial and detrimental effects on the adjacent neurons in the brain 
(Tang & Le 2014). This execution depends on the functional phenotype of the 
microglia, which ranges from pro-inflammatory M1 phenotype to immunosuppressive 
M2 phenotype. Hyperactive microglia that induces inflammatory cytokines such as 
TNF-α, IL-1β, IL-6, as well as superoxide, ROS, NO and NF-B pathways are termed 
as M1 microglia. On the other hand, M2-microglia have been shown to inhibit 
inflammatory responses by releasing anti-inflammatory cytokines such as IL-4, IL-13, 
IL-10, and TGF-β (Tang & Le 2016) and (Zhou et al. 2012). Studies have also shown 
that M2-microglia could suppress the production of pro-inflammatory cytokines, 
neurotoxic factors and reduce NO release, which collectively blocks LPS-induced 
neuroinflammation (Ledeboer et al. 2000) and (Park et al. 2005). Further research on 
M2-microglia revealed that several antioxidant and cytoprotective genes, which are 
under control of transcription factor nuclear factor erythroid 2 related factor 2 (Nrf2) 
are activated to inhibit neuroinflammation in the brain (Jazwa et al. 2011). Novel 
findings also indicate that Nrf2-deficient mice showed increased levels of 
neuroinflammatory M1 markers (COX-2, iNOS, IL-6, and TNF) and reduced levels of 
M2 markers (ARG1, and IL-4) in response to neurotoxin (Rojo et al. 2010) and 
(Jazwa et al. 2011). Also, other studies have suggested that NF-B is considered as 
a master regulator of M1 phenotype, while Nrf2 may be a regulator of the M2 
phenotype (Rojo et al. 2014). 
In this regard, activating intracellular anti-inflammatory mechanisms such as Nrf2 
signalling could be a popular strategy to prevent inflammation-mediated neuronal 
toxicity. Nrf2 is a critical regulator of endogenous inducible defence systems in the 
brain and is actively produced by microglia in response to oxidative stress. Under 
normal conditions, Nrf2 is bound to cysteine residues of repressor protein Kelch-like 
ECH-associated protein 1 (Keap-1), in the cytoplasm. When countered with oxidative 
or nitrosative stimuli, these cysteine residues get modified enabling translocation of 
Nrf2 into the nucleus, where it will bind to cis-acting antioxidant responsive element 
(ARE). And further initiate the activation of ARE-dependent detoxifying genes such 
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as, heme oxygenase-1 (HO-1), NADPH quinine oxidoreductase (NQO1), γ-glutamyl 
synthase , γ-glutamylcysteine synthase (GCS), glutathione reductase (GR), 
superoxide dismutase’s (SODs), UDP-glucuronosyl transferases (UGTs) and 
glutathione S-transferase (GST) (Johnson et al. 2008) and (Buendia et al. 2016). 
Recently, several studies have suggested the relevance of these antioxidant proteins 
in the immunomodulation of microglia (Pan et al. 2012) and (Kim et al. 2012). 
Notably, HO-1 and NQO1 are considered to be critical cytoprotective mediators in 
the cellular response to nitrosative and oxidative stress during neuroinflammation. 
Two types of heme oxygenase isoforms (HO-1 and HO-2) are ubiquitously 
expressed in microglia. HO-1 is considered as rapidly inducible protein which is 
under control of transcription factor Nrf2 and HO-2 is a constitutive protein that is 
expressed under normal conditions. Out of two isoforms, HO-1 has been shown to 
degrade heme to generate iron, carbon monoxide (CO) and bilirubin, which exert an 
important implication in limiting neuroinflammation (Sawle et al. 2005) and (Syapin 
2008). Notably, HO-1 induced iron is involved in maintaining the structure of the glial 
cells, which was inhibited during inflammation in the brain (Gu et al. 1998). (Gu et al. 
1998). Also, heme generated iron plays a critical role in DNA synthesis, 
mitochondrial respiration, oxygen transportation, myelin synthesis, and 
neurotransmitter synthesis, in contrast, dysregulation of iron homoeostasis can 
cause neurotoxicity (Zecca et al. 2004). Surprisingly, deprived HO1 expression and 
its generated final by-products were observed in neurodegenerative conditions like 
AD, PD and ALS (Lee & Suk 2007). On the other hand, its activation has been 
shown to suppress LPS-induced inflammation in mouse peritoneal macrophages and 
microglial cells in the brain (Li et al. 2008), (Kang, Kim, et al. 2013) and (Y. Li et al. 
2015). Therefore, activation of HO-1 could be a better therapeutic strategy for the 
treatment of neuroinflammatory conditions. 
Under conditions of neuroinflammation, activation of NQO1 was shown to protect 
hyperactive microglia from highly reactive quinone by catalysing them to redox-
stable hydroquinone (Nioi & Hayes 2004). Also, increase in ROS are detrimental to 
normal cell function as this condition can facilitate the damage of DNA, however, the 
presence of high levels of NQO1 has been shown to modulate this DNA damaging 
stimuli by stabilising the endogenous p53 (Nioi & Hayes 2004) and (Wakabayashi et 
al. 2010). From this perspective, targeting Nrf2/HO-1/NQO1-antioxidant axis with 
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suitable pharmacologically-active compounds may help to reduce neuroinflammation 
and its associated neurodegeneration. 
NF-B has been shown to attenuate Nrf2 signalling and its mediated antioxidant 
genes (Liu et al. 2008). It appears that NF-B communicate with Nrf2 at the 
transcriptional level in neuroinflammation. These two transcription factors have been 
shown to compete against co-activator CREB binding protein (CBP/p300) at DNA 
level. Transcription factor NF-B binds to CBP/p300 and facilitate the transcription of 
inflammatory genes such as c-Fos, c-jun, Arc, Fosb and brain-derived neurotrophic 
factors (BDNF), which has shown to induce neuroinflammation in microglia (A. 
Cuadrado et al. 2014) and (Krasnova et al. 2016). Previous studies have suggested 
that pharmacological activation of Nrf2 might inhibit NF-B binding capacity to 
CBP/p300 and thus block neuroinflammation (Beaumont et al. 2012) and (Didonato 
et al. 2012). Studies in the past showed that during neuroinflammation, high levels of 
ROS, nitrosative stress and upstream kinases like MAPKs, initiate the activation of 
Nrf2 leading it to translocate to the nucleus and compete with NF-B at the 
transcriptional level (Surh & Na 2008) and (Kawai et al. 2011). However, activation of 
NF-B has been shown to attenuate the transcription of antioxidant genes like HO-1 
and NQO1 that are under the control of Nrf2 (Cuadrado et al. 2014). Also, studies in 
various animal models had illustrated that when Nrf2 gene was knocked out, 
increase in the NF-B-mediated neuroinflammation was observed (Boyanapalli et al. 
2014) and (Ichimura et al. 2013). Interestingly, dietary flavonoids that activate Nrf2 
signalling were shown to inhibit neuroinflammation in various cell cultures and animal 
models (Lee et al. 2011), (Y. Li et al. 2015), (Onasanwo et al. 2016) and (Foresti et 
al. 2013). Taken together, there appears to be a crosstalk between two transcription 
factors NF-B and Nrf2 in neuroinflammation which needs to be further investigated.  
Tiliroside has been shown to have neuroinflammation inhibitory effects in LPS/IFN-
induced BV2 microglia, however, the effect of the compound on Nrf2 signalling is not 
known. Therefore, the effect of tiliroside on Nrf2/HO-1/NQO1-antioxidant axis was 
assessed in BV2 microglia. 
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5.2 Results 
5.2.1 Tiliroside increased the levels of HO-1 and NQO-1 proteins in BV2 microglia  
Microglia has been shown to trigger the activation of repair mechanisms that are 
involved in the protection of microglia during sustained neuroinflammation by 
inducing Nrf2 expression and its mediated inducible detoxifying antioxidant proteins 
such as HO-1 and NQO1 (Foresti et al. 2013). These two antioxidant proteins have 
been reported to be involved in the resolution of neuroinflammation (Gill et al. 2014) 
and (Lee et al. 2015). As a result, the ability of tiliroside to activate these antioxidant 
proteins was investigated in BV2 microglia. Western blot experiments revealed that 
increasing concentrations of tiliroside produced a significant increase in the 
expression of HO-1. Activation of HO-1 by the compound was not effective at 2 M, 
however at 4 M tiliroside increased the expression by ~1.8-fold (p<0.01) compared 
to control BV2 cells. Tiliroside at 6 M increased the expression of HO-1 protein by 
~2.3-fold (p<0.001) compared to untreated control microglia. Besides, tiliroside was 
shown to activate NQO1 protein expression (4 M, ~1.4-fold increase, p<0.01 and 
6 M, ~1.8-fold increase, p<0.01) at 24 hours compared to untreated microglial cells 
(Figure 5.1). 
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Figure 5.1 Tiliroside increased levels of HO-1 and NQO1 proteins in BV2 microglia 
cells 
BV2 microglia were treated with various concentrations of tiliroside for 24 hours. Cytoplasmic 
lysates were collected and analysed for (a) HO-1 and (b) NQO1 protein expression using 
western blot. Tiliroside significantly increased protein levels of HO-1 and NQO1 in the 
microglia. All values are expressed as mean ± SEM for three independent experiments. Data 
were analysed using one-way ANOVA for multiple comparisons with post hoc Student 
Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 compared with untreated control. 
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5.2.2  Tiliroside activated Nrf2/ARE antioxidant protective mechanism in BV2 
microglia 
After confirming that both HO-1 and NQO1 were strongly activated by tiliroside, its 
effect on Nrf2 activation was next examined. Firstly, Nrf2-DNA binding activity of 
tiliroside in the microglia was done using EMSA assay. Results show that the 
compound (2-6 µM) produced a dose-related increase (2 µM, ~2.4-fold, p<0.05, 
4 µM, ~3.8-fold, p<0.01 and 6 µM, ~6-fold, p<0.001) in the DNA binding of Nrf2 
compared to untreated cells (Figure 5.2b). Later, a luciferase reporter gene assay 
was performed to verify whether the effects of the drug were mediated through 
activation of the antioxidant responsive elements, which is under the control of a 
promoter containing the ARE consensus. As shown in Figure 5.2c, tiliroside (2-6 µM) 
produced a significant and dose-dependent increase in the ARE-luciferase activity in 
BV2 microglia. Notably, at 6 µM, tiliroside significantly increased (p<0.001) ARE-
luciferase activity by ~6.6-fold compared to untreated cells, while at 2 µM ~5.6-fold 
and at 4 µM by ~3.3-fold increase was observed.  
Based on the tiliroside effect on ARE-luciferase activity and Nrf2-DNA binding further 
experiments were carried out to determine whether tiliroside could activate nuclear 
Nrf2 in BV2 microglia. Western blot results showed that treatment of BV2 microglia 
with increasing concentrations of tiliroside resulted in a significant and dose-
dependent increase (4 µM, ~2.3-fold, p<0.01 and 6 µM, ~2.6-fold, p<0.01) in the 
accumulation of Nrf2 protein in the nucleus (Figure 5.2a). Immunofluorescence 
experiments were conducted to further assess the effect of tiliroside in microglia 
cells. As shown in Figure 5.2d, relatively low levels of Nrf2 were detected in the 
untreated cells. The expression of Nrf2 was upregulated after treatment with 
increasing concentrations of tiliroside (2-6 µM), suggesting that the compound is 
capable of activating Nrf2 signalling in microglia. 
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(d) 
 
Figure 5.2 Tiliroside increased Nrf2 protein expression in BV2 microglia. 
Microglia were treated with tiliroside for 24 hours. After that, nuclear lysates were collected and 
analysed for the activation of Nrf2 using western blot and DNA binding assay. (a) Tiliroside 
upregulated the protein expression of Nrf2 when incubated for 24 hours in microglia. (b) Tiliroside 
produced a dose-related increase in DNA binding of Nrf2 to immobilised ARE consensus binding 
site in microglia. (c) Tiliroside activated ARE-luciferase activities transfected with ARE construct in 
BV2 cells using luciferase reporter gene assay. Microglia cells were transfected with ARE-reporter 
construct for 18 hours. Thereafter, cells were treated with tiliroside for 8 hours and luciferase 
activity was further measured. (d) Immunofluorescence experiments were carried out to detect Nrf2 
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activation by tiliroside. Nrf2 protein was not detected in untreated control cells; however, increasing 
concentrations of tiliroside activated Nrf2 protein. Cells were counterstained with DAPI and 
fluorescence images acquired with an EVOS® FLoid® cell imaging station (scale bar=100 μm) and 
processed using image J. All values are expressed as mean ± SEM for at least 3 independent 
experiments. Data were analysed using one-way ANOVA for multiple comparisons with post-hoc 
Student Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 compared with untreated control. 
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5.2.3 Anti-neuroinflammatory effects of tiliroside are dependent on Nrf2 activity in 
LPS/IFN-activated BV2 microglia 
In earlier experiments, tiliroside inhibited LPS/IFN-induced neuroinflammation by 
blocking the production of pro-inflammatory cytokines such as IL-1β, IL-6 and TNFα 
in microglia. It is possible that Nrf2 antioxidant protective mechanisms may partly 
mediate these suppressive effects. Therefore, experiments were conducted to 
investigate whether the anti-neuroinflammatory effects of the tiliroside were 
dependent on Nrf2 activation in the microglia. To achieve this, control siRNA and 
Nrf2 siRNA-transfected BV2 microglia were pretreated with an effecient 
concentration of tiliroside (6 μM) and stimulated with LPS (100 ng/ml)/IFN (5 ng/ml) 
for 24 hours. As shown in Figure 5.3a LPS/ IFN produced high levels of IL-1β, IL-6 
and TNFα in control siRNA cells, while in Nrf2 siRNA cells a significant increase in 
the cytokines production was observed, which proves that absence of Nrf2 gene 
increases cytokine induction in LPS/IFN-treated microglia. However, tiliroside 
(6 μM) produced a significant reduction in LPS/IFN-induced IL-1β production in 
control siRNA-transfected cells. In contrast, the IL-1β inhibitory effects of the 
compound were significantly reversed in Nrf2 siRNA-transfected cells. Also, tiliroside 
inhibited LPS/IFN-induced IL-6 and TNFα production in control siRNA cells, when 
compared with Nrf2 siRNA-transfected BV2 cells, these inhibitory effects were 
significantly abolished (Figure 5.3b and c). 
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Figure 5.3 Inhibitory actions of tiliroside on pro-inflammatory cytokine are 
dependent on Nrf2 activity  
Both Nrf2 siRNA and control siRNA transfected BV2 cells were incubated with tiliroside (6 µM) 
prior to stimulation with LPS and IFN for 24 hours. Subsequently, culture supernatants were 
analysed to detect the levels of IL-1β (a), IL-6 (b) and TNFα (c) using ELISA. Inhibition of IL-
1β, IL-6 and TNFα was observed in control siRNA transfected microglia; however, these 
inhibitory actions were disappeared in Nrf2 knockout cells. All values are expressed as mean ± 
SEM for at least three independent experiments. Data were analysed using one-way ANOVA 
for multiple comparisons with post-hoc Student Newman-Keuls test. ᶿp< 0.05, ᶿᶿp<0.01, 
ᶿᶿᶿp<0.001 as compared within the groups of the untreated control. $p< 0.05, $$p<0.01, 
$$$p<0.001 as compared within the groups stimulated with LPS/IFN and #p<0.05, ##p<0.01, 
###p<0.001 as compared within the groups pre-treated with tiliroside (6 μM). 
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5.2.4 Inhibitory actions of tiliroside on iNOS and COX-2 protein expressions and its 
mediated NO and PGE2 production was dependent on Nrf2 activation in BV2 microglia  
Encouraged by the outcome of the effects on tiliroside in Nrf2 silenced LPS/IFN-
induced cytokines, its effect on nitrites and iNOS protein expression in Nrf2 knockout 
microglia were investigated. This was achieved by transfecting BV2 cells with control 
siRNA and Nrf2 siRNA, followed by pre-incubation with tiliroside (6 μM) for 30 
minutes and stimulated with the combination of LPS (100 ng/ml) and IFN (5 ng/ml) 
for 24 hours. Results show that tiliroside significantly inhibited nitrite production in 
LPS/IFN-stimulated control siRNA-transfected cells. Interestingly, in Nrf2 silenced 
BV2 cells, these inhibitory effects of the compound were significantly reversed in 
comparison with control siRNA cells (Figure 5.4a). Similar results were observed 
from the western blot experiments conducted to assess iNOS protein expression. 
Tiliroside inhibited LPS/IFN-induced iNOS protein in control siRNA-transfected cells, 
however, these inhibitory actions of the compound were significantly reversed in Nrf2 
siRNA-transfected microglia (Figure 5.4b).  
Tiliroside has been shown to inhibit COX-2 protein expression and PGE2 production 
in LPS/IFN-activated microglia. Further investigation was done to find out whether 
inhibitory effects of the compound on PGE2 production and COX-2 protein 
expression have depended on Nrf2. This was achieved by transfecting cells with 
control siRNA and Nrf2 siRNA, followed by pre-incubation with tiliroside (6 μM) for 30 
minutes and stimulated with LPS (100 ng/ml)/IFN (5 ng/ml) for 24 hours. As 
expected, PGE2 production was abrogated by tiliroside in LPS/IFN-treated control 
siRNA cells, while in Nrf2 siRNA cells this inhibitory effect was significantly reversed 
(Figure 5.5a). Western blot experiments for COX-2 protein expression show that, in 
control siRNA cells, tiliroside (6 μM) significantly inhibited the upregulation of COX-2 
protein expression. However, in the absence of Nrf2 protein, this inhibitory effect was 
significantly reversed (Figure 5.5b). 
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Figure 5.4 Nrf2 knockout in BV2 microglia reversed suppressive effects of 
tiliroside on LPS/IFN-induced iNOS and nitrite production 
BV2 microglia were transfected with Nrf2 siRNA and control siRNA. After that, cells were 
treated with tiliroside (6 µM) prior to LPS and IFN stimulation for 24 hours. Subsequently, 
supernatants and cytoplasmic lysates were analysed for nitrite production and iNOS protein 
expression. (a) Inhibition of nitrite production and (b) iNOS protein expression was observed in 
control siRNA transfected microglia; however, these inhibitory actions were disappeared in 
Nrf2 knockout cells. All values are expressed as mean ± SEM for at least three independent 
experiments. Data were analysed using one-way ANOVA for multiple comparisons with post-
hoc Student Newman-Keuls test. ᶿp< 0.05, ᶿᶿp<0.01, ᶿᶿᶿp<0.001 as compared within the 
groups of the untreated control. $p< 0.05, $$p<0.01, $$$p<0.001 as compared within the 
groups stimulated with LPS/IFN and #p<0.05, ##p<0.01, ###p<0.001 as compared within the 
groups pre-treated with tiliroside (6 μM). 
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Figure 5.5 Nrf2 mediates the inhibitory effects of tiliroside on COX-2 protein 
expression and PGE2 prodcution in LPS/IFN-treated microglia  
Nrf2 siRNA and control siRNA transfected BV2 cells were pre-treated with tiliroside (6 µM) 
before stimulation with LPS and IFN for 24 hours. Later, supernatants and cytoplasmic 
lysates were analysed for PGE2 production and COX-2 protein expression. (a) Tiliroside 
inhibited PGE2 production and (b) COX-2 protein expression in control siRNA transfected 
microglia; however, these inhibitory actions were disappeared in Nrf2 knockout cells. All 
values are expressed as mean ± SEM for at least three independent experiments. Data were 
analysed using one-way ANOVA for multiple comparisons with post-hoc Student Newman-
Keuls test. ᶿp< 0.05, ᶿᶿp<0.01, ᶿᶿᶿp<0.001 as compared within the groups of the untreated 
control. $p< 0.05, $$p<0.01, $$$p<0.001 as compared within the groups stimulated with 
LPS/IFN and #p<0.05, ##p<0.01, ###p<0.001 as compared within the groups pre-treated with 
tiliroside (6 μM). 
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5.2.5 NF-B inhibitory actions of tiliroside are Nrf2 mediated in LPS/IFN-stimulated 
microglia 
After observing that inhibitory effects of tiliroside on cytokines, NO, PGE2, iNOS and 
COX-2 were reversed in the absence of Nrf2 gene in microglia, the inhibitory activity 
of the compound on NF-B signalling in Nrf2-silenced BV2 microglia was further 
investigated. Cells were transfected with control siRNA and Nrf2 siRNA, followed by 
pre-incubation with tiliroside (6 μM) for 30 minutes and stimulated with LPS/IFN for 
60 minutes. Later, nuclear lysates were collected and subjected to ELISA based 
EMSA. As shown in Figure 5.6a, in control siRNA cells, tiliroside significantly 
inhibited DNA binding of NF-B. Interestingly, this DNA binding inhibitory activity of 
the compound was reversed in Nrf2 siRNA-transfected cells. To assess the 
transfection efficiency of Nrf2 siRNA, western blot experiments were done using 
nuclear extractions. Results show that, in control siRNA cells, a combination of LPS 
and IFN upregulated phosphorylation of p65 which was significantly inhibited by 
tiliroside. However, in Nrf2 siRNA-transfected cells, inhibitory actions of the 
compound were completely abolished (Figure 5.6b). 
To determine whether the anti-neuroinflammatory effect of tiliroside was dependent 
on Nrf2 activity, control siRNA and Nrf2 siRNA-transfected BV2 cells were pre-
treated with tiliroside (6 μM) and incubated with LPS/IFN for 24 hours. Later, 
nuclear lysates were collected and subjected to western blotting. Results showed 
that BV2 microglia transfected with control siRNA expressed nuclear Nrf2 protein. 
However, following transfection of BV2 microglia with Nrf2 siRNA, there was a 
marked deletion of nuclear Nrf2 protein in the cells (Figure 5.7). Tiliroside (6 μM) has 
upregulated Nrf2 expression in control cells, while there was a marked reduction of 
Nrf2 protein was observed in Nrf2 gene silenced cells. These experiments show that 
Nrf2 gene was significantly knocked down at the nuclear level when treated with Nrf2 
siRNA compared to control siRNA in microglia. 
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Figure 5.6 Inhibitory actions of tiliroside on NF-B were dependent on Nrf2 activity in activated 
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BV2 microglia. 
Nrf2-silenced BV2 cells were pre-treated with tiliroside prior to stimulation with LPS/IFN for 24 hours. 
Subsequently, nuclear and cytoplasmic lysates were collected and subjected to (a) ELISA based EMSA and 
(b) western blot. Tiliroside inhibited NF-B DNA-binding and phosphorylation of p65 in BV2 microglia that 
were transfected with control-siRNA. However, these inhibitory effects of the compound were disappeared in 
the absence of Nrf2. All values are expressed as mean ± SEM for at least three independent experiments. 
Data were analysed using one-way ANOVA for multiple comparisons with post-hoc Student Newman-Keuls 
test. ᶿp< 0.05, ᶿᶿp<0.01, ᶿᶿᶿp<0.001 as compared within the groups of the untreated control. $p< 0.05, 
$$p<0.01, $$$p<0.001 as compared within the groups stimulated with LPS/IFN and #p<0.05, ##p<0.01, 
###p<0.001 as compared within the groups pre-treated with tiliroside (6 μM). 
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Figure 5.7 Western blot experiment show Nrf2 knockout efficiency in BV2 microglia 
Control siRNA and Nrf2 siRNA-transfected BV2 microglia were treated with tiliroside 6µM before 
stimulation with a combination of LPS and IFN for 24 hours. Nuclear lysates were collected and 
assessed for Nrf2 protein expression using western blot. Nrf2 protein expression was significantly 
knocked down compared to control siRNA in the microglia. All values are expressed as mean ± 
SEM for at least 3 independent experiments. Data were analysed using one-way ANOVA for 
multiple comparisons with post-hoc Student Newman-Keuls test. &p<0.05, &&p<0.01, &&&p<0.001 
in comparison with untreated control. 
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5.3 Discussion 
The transcription factor Nrf2 protects microglia from cellular stress by activating 
cytoprotective proteins such as HO-1 and NQO1. Moreover, several in vivo and in 
vitro disease models revealed that activation of Nrf2 antioxidant mechanism provides 
protection against neuroinflammation and oxidative stress (Gan & Johnson 2014), 
(Na et al. 2008) and (Kim et al. 2012). Consequently, activation of microglial Nrf2 
was thought to be a right approach in resolving neuroinflammatory conditions. 
Increased consumption of dietary supplements and fruits are associated with the 
prevention of neuroinflammatory conditions and its mediated neurodegenerative 
diseases. Tiliroside, a dietary compound inhibits LPS/IFN-mediated 
neuroinflammation and ROS production in microglia. However, its effect against Nrf2 
signalling in BV2 microglia is yet to be investigated. 
The role of microglial Nrf2 signalling in neuroinflammation is well documented 
(Turpaev 2013), (Luo et al. 2011) and (W. Li et al. 2008). Hyperactive microglia 
tends to release excess pro-inflammatory cytokines, interleukins, as well as ROS 
and nitrogen species, that leads to demyelination of neuronal axons and neuronal 
death (Pan et al. 2012). However, activating natural antioxidant mechanisms like 
Nrf2 signalling could prevent this hyper activation of microglia. Antioxidant proteins 
such as HO-1 and NQO1 are known to play a crucial role in inhibiting 
neuroinflammation and its mediated neuronal loss (Gill et al. 2014). Results show 
that tiliroside (6 μM) significantly increased endogenous levels of antioxidant proteins 
HO-1 and NQO1 in the microglia. These results suggest that the compound is 
capable of activating Nrf2 signalling in microglia. In several in vitro studies, activation 
of HO-1 was shown to be beneficial against neuroinflammation by inhibiting NADPH 
oxidase, the primary enzyme responsible for microglial ROS release, and TLR 4 
signalling activation (Nakahira et al. 2006) and (Sandberg et al. 2014). Furthermore, 
HO-1 is involved in the metabolism of heme into Fe2+, biliverdin and carbon 
monoxide that eventually get converted to bilirubin (Sawle et al. 2005) and (Zecca et 
al. 2004). These by-products of HO-1 were shown to limit neuroinflammation in 
microglia (Lee & Suk 2007). In addition to HO-1, tiliroside was shown to activate the 
expression of NQO1. Excessive NQO1 production was shown to protect hyperactive 
microglia from reactive quinones by reducing them to stable hydroquinone (Nioi & 
Hayes 2004) and (Wakabayashi et al. 2010).  
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There have been some studies investigating the effects of natural dietary flavonoids 
on Nrf2 activation in neuroinflammation that exhibited some promising results (Na et 
al. 2008), (Kim et al. 2012), (Wakabayashi et al. 2010) and (Liu et al. 2008). Also, 
studies in the past showed that the compounds activate Nrf2 signalling in microglia 
blocked the production of pro-inflammatory cytokines and other neurotoxic mediators 
associated in neuroinflammation (Lastres-Becker et al. 2014), (Onasanwo et al. 
2016) and (Pan et al. 2012). Expression of HO-1 and NQO1 are predominantly 
regulated by the transcription factor Nrf2 (Kim et al. 2012) and (Huang et al. 2013). 
After observing the effects of tiliroside on HO-1 and NQO1 protein expression, its 
activity on Nrf2 activation was investigated next. Results show that tiliroside at 6µM 
increased nuclear accumulation of Nrf2. Further experiments revealed that tiliroside 
significantly enhanced Nrf2 DNA-binding activity. Also, the compound was shown to 
increase the transcriptional activity of the cis-acting antioxidant responsive element 
(ARE), which means that tiliroside is acting at the transcriptional level of Nrf2 to 
induce expression of antioxidant proteins HO-1 and NQO1 in the microglia. These 
results further encouraged to investigate the effects of the compound on Nrf2 
transactivation in microglia. Results show that tiliroside significantly increased Nrf2-
driven luciferase expression, suggesting that compound activates Nrf2 signalling in 
microglia. It, therefore, appears from the above results that tiliroside inhibit 
neuroinflammation probably by activating Nrf2/HO-1/NQO1 axis in BV2 microglia. 
Tiliroside inhibited neuroinflammation that was induced by the combination of LPS 
and IFN in microglia. Studies have revealed that Nrf2 activation might inhibit 
neuroinflammation via modulating NF-B-mediated inflammatory mediators in 
microglia (Lee et al. 2015) and (Jazwa et al. 2011). Also, compounds that inhibit NF-
B activation have been shown to activate Nrf2 (Surh & Na 2008). For instance, the 
antimalarial drug artemether inhibited LPS-induced neuroinflammation via Nrf2 
signalling and those inhibitory effects were lost in the absence of Nrf2 in microglia 
(Okorji et al. 2015). Moreover, Nrf2 gene knockout experiments showed that 
microglia tends to generate excess amounts of inflammatory mediators when 
stimulated with LPS compared to control, highlights the protective role of Nrf2 (Na et 
al. 2008), (Rojo et al. 2010) and (Lee et al. 2011). Results of Nrf2 knockout 
experiments show that in control siRNA-transfected cells, tiliroside inhibited pro-
inflammatory cytokines such as IL-1β, IL-6 and TNFα production in LPS/IFN-
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stimulated microglia. However, these inhibitory activities of tiliroside were 
significantly abolished in Nrf2 siRNA-silenced cells, suggesting that 
neuroinflammation inhibitory effects of the compound are Nrf2 mediated in microglia. 
Western blot results revealed that Nrf2 gene was successfully knocked down in all 
Nrf2 siRNA experiments. 
Similar observations were made in other mechanistic studies conducted by other 
researchers. For example, kolaviron, a biflavonoid was shown to inhibit LPS-induced 
NF-B signalling in BV2 microglia and also activated Nrf2. Further experiments 
demonstrated that Nrf2 was required for kolaviron to exhibit neuroinflammation 
inhibitory effects in microglia (Onasanwo et al. 2016). Also, Licochalcone E 
attenuated LPS-induced inflammatory responses in BV2 microglia by a mechanism 
involving Nrf2 activation and upregulation of its downstream antioxidant proteins, and 
its effects were reversed in Nrf2 siRNA cells (Kim et al. 2012). In addition to the 
inhibitory effects of tiliroside on pro-inflammatory mediators, it was observed that 
compound inhibited iNOS mediated NO production and COX-2 induced PGE2 
production in control siRNA cells. The inhibitory effects of tiliroside on iNOS, nitric 
oxide, COX-2 and PGE2 were reversed in the absence of Nrf2 protein in the 
microglia, highlighting that transcription factor Nrf2 plays a critical role in mediating 
the anti-inflammatory action of tiliroside.  
Studies in various experimental models revealed that several redox-sensitive factors 
regulate Nrf2 and NF-B and lack of Nrf2 shown to increase nitrosative and oxidative 
stress leading to upregulation of cytokine production (Yerra et al. 2013) and 
(Cuadrado et al. 2014). To further understand the relation between Nrf2 and NF-B 
in microglia, Nrf2 gene was knocked out using siRNA-transfection and stimulated 
with a combination of LPS and IFN. Results show that tiliroside significantly 
inhibited LPS/IFN-induced NF-B DNA-binding and protein expression in control 
siRNA-transfected microglia and as expected these inhibitory effects of the 
compound were significantly reversed in Nrf2 silenced cells. These results suggest 
that transcription factor Nrf2 mediates the neuroinflammation inhibitory actions of 
tiliroside in LPS/IFN-stimulated microglia. Interestingly, p-NF-B-p65 was highly 
expressed in Nrf2 siRNA transfected cells when treated with LPS and IFN 
compared to control cells. This observation explains the excessive generation of pro-
inflammatory cytokines in the absence of Nrf2 protein. Studies on Nrf2−/− deficient 
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mice showed that IKKβ activity was upregulated suggesting that this step will further 
enhance phosphorylation of IBα and releasing NF-B into the nucleus 
(Thimmulappa et al. 2006). In contrary to these observations, studies conducted by 
Yu et al. revealed that NF-B activity could negatively regulate Nrf2-mediated ARE 
expression. However, this modulatory action is cell dependent (Yu et al. 2011). 
Collectively, all these results seem to suggest that tiliroside attenuated LPS/IFN-
induced neuroinflammation in BV2 microglia and these inhibitory actions of the 
compound are reversed in the absence of Nrf2. 
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Figure 5.8 The neuroinflammation inhibitory activity of tilrioside is Nrf2 mediated 
in activated microglia . LPS: Lipopolysaccharide, IFN: Interferon gamma, TLR4: Toll-like 
receptor 4, TRAF6: TNF receptor associated factor 6, IKK: IκB kinase, Nrf2: nuclear factor 
erythroid 2 related factor 2, HO-1: Heme oxygenase 1, NQO1: NAD(P)H dehydrogenase 
[quinone] 1, ARE: antioxidant response element.  
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Chapter 6. General discussion and conclusion 
Tiliroside is a natural polyphenolic glycoside found in various dietary supplements. 
Several studies have demonstrated anti-inflammatory activity of tiliroside in different 
models of inflammation (Goto et al. 2012), (Rao et al. 2005), (Sala et al. 2003) and 
(Qiao et al. 2011). However, there is no report to date demonstrating inhibition of 
neuroinflammation by the compound. This study evaluated the anti-
neuroinflammatory effects of tiliroside in BV2 microglia which were stimulated with a 
combination of LPS and IFN. 
Inflammatory mediators released by activated microglia are believed to be a major 
target for anti-inflammatory compounds. This study established that tiliroside inhibits 
the production of TNFα, IL-1β and IL-6 in BV2 microglia stimulated with LPS/IFN. 
On the other hand, tiliroside increased the levels of IL-10 in the activated microglia. 
Tiliroside also inhibited neuroinflammation by blocking iNOS protein expression and 
nitric oxide production in the microglia. In addition, tiliroside reduced the expression 
of COX-2 and its mediated PGE2 production in LPS/IFN-stimulated microglia, 
suggesting that the compound possesses strong neuroinflammation inhibitory 
activities. All these observations demonstrate that tiliroside produces a marked 
inhibition of neuroinflammation in activated BV2 microglia. Previously, tiliroside was 
reported to exhibit anti-inflammatory activity through the inhibition of phospholipase 
A2-induced paw oedema, TPA-induced ear inflammation, and leukocyte migration in 
mice (Sala et al. 2003). In addition, a study conducted by Rao et al. showed that 
tiliroside inhibits LPS/IFN-induced TNFα, NO production and iNOS protein 
expression in mouse macrophages (Rao et al. 2005).Results from the current study 
appears to be consistent with the previous observations made by Rao and co-
workers.  
Tiliroside is a 3-O-β-D-(6″-O-coumaroyl) glucopyranoside derivative of kaempferol. 
Previous studies have reported that tiliroside was synthesised by condensation of a 
coumaroyl residue at the (6″) carbon of the kaempferol glucose moiety (Vermes et al. 
1981). Kaempferol was reported to block LPS-induced TNFα, IL-1β and IL-6 
production in BV2 microglia and J774.2 murine macrophages. In addition, 
kaempferol reduced the expression of iNOS and COX-2 proteins in activated 
microglia and J774.2 murine macrophages (Park et al. 2011) and (Kowalski et al. 
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2005). In the current research, tiliroside exhibited neuroinflammation inhibitory 
effects in LPS/IFN-treated BV2 microglia at much lower concentrations compared to 
kaempferol.  
The activation of NF-B signalling in microglia is a pre-requisite for the transcription 
of pro-inflammatory genes. Pharmacological inhibition of NF-B signalling has been 
shown to reduce neuroinflammation (Shih et al. 2015), (Xu et al. 2014) and (Jeong et 
al. 2013). In the microglia, inflammatory stimuli like LPS induce phosphorylation of 
IKKα. This results in phosphorylation of IB followed by NF-B-p65 translocation 
into the nucleus. NF-Bp-65 subunit in the nucleus undergoes phosphorylation and 
acetylation, thereby binding to the promoter sequences of the target DNA. This 
binding results in the expression of target genes including pro-inflammatory 
cytokines such as TNFα, IL-1β IL-6, iNOS and COX-2. This study demonstrated that 
tiliroside inhibits LPS/IFN-induced phosphorylation, nuclear translocation and 
binding of NF-B to the consensus DNA sequence. In addition, tiliroside blocked the 
phosphorylation of IKKα and IB in the activated microglia. From these 
observations, it appears tiliroside directly targets NF-B signalling to prevent 
LPS/IFN-induced neuroinflammation in microglia. However, there is a possibility that 
the compound might be blocking upstream signalling pathways that activate NF-B 
signalling. Studies by Jin et al. showed that tiliroside extracted from Agrimonia pilosa 
Ledeb (Rosacea) exhibited strong anti-inflammatory effects in LPS-treated RAW 
264.7 macrophages (Jin et al. 2016). However, inflammation inhibitory effects of 
tiliroside were not mediated by NF-B signalling. The differences in the effect of 
tiliroside on these cells might be related to differences in the molecular signatures of 
macrophages and microglia, which are brain-resident macrophages.  
Acetylation of nuclear NF-B-p65 subunit regulates various functions of NF-B such 
as DNA binding affinity and transcriptional activation of pro-inflammatory genes. In 
the nucleus, SIRT1 deacetylates NF-B subunit and blocks the binding of acetylated-
NF-B-p65 to the promotor regions of the DNA. Previous studies demonstrated that 
compounds which activate SIRT1 will reduce the acetylation of NF-B-p65 and 
further inhibit the transcription of inflammatory mediators in neuroinflammation (Cho 
et al. 2015), (Haigis & Sinclair 2011) and (Ye et al. 2013). In this research, tiliroside 
increased the expression of SIRT1 in the microglia. In addition, tiliroside inhibited the 
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acetylation of NF-B-p65 in LPS/IFN-stimulated microglia, suggesting that there is a 
possibility that this compound inhibits NF-B signalling via accelerating deacetylation 
of NF-B-p65. However, further research in this study demonstrated that 
neuroinflammation inhibitory actions of tiliroside are not SIRT1 mediated. This 
observation suggests that SIRT1 activation may not be involved in the inhibition of 
acetylated-NF-B-p65 by tiliroside in the microglia. A study conducted by Zhu et al. 
revealed that resveratrol, a potent SIRT1 activator inhibits NF-B-mediated 
inflammation in TNF α-induced NIH/3T3 fibroblast cell line (Zhu et al. 2011). 
However, knockdown of SIRT1 gene reduced anti-inflammatory effects of 
resveratrol. This observation is in contrast to the current outcome, suggesting that 
there might be an involvement of other signalling pathways in SIRT1 activation to 
block neuroinflammation in the microglia. 
The p38 MAPK signalling has been shown to be critical for the expression and 
production of proinflammatory cytokines in the CNS (Cuadrado et al. 2010) and 
(Kaminska 2005). Several studies have demonstrated that pharmacological 
modulation of p38 MAPK signalling in LPS-stimulated microglia decreases the 
production of inflammatory cytokines and attenuates neuroinflammation (Zeng et al. 
2010) and (Herlaar & Brown 1999). LPS is known to trigger the activation of p38 
MAPK signalling in microglia through activation of MKK3/6. This results in the 
phosphorylation of p38α and further activates mitogen-activated protein kinase 
(MAPK)-activated protein kinases 2 (MK2). Activated MK2 is involved in regulating 
the production of TNFα, IL-6 and IL-1β and other cytokines in microglia. This study 
established that tiliroside inhibits LPS/IFN-induced MKK3/6 and p38α in the 
microglia. In addition, tiliroside reduced phosphorylation of MK2 in activated 
microglia. These observations suggest that tiliroside targets p38 MAPK signalling to 
inhibit neuroinflammation in LPS/IFN-stimulated microglia. Tiliroside isolated from 
Agrimonia pilosa Ledeb inhibits LPS-induced inflammation by blocking p38 MAPK 
signalling in RAW 264.7 macrophages (Jin et al. 2016). These results are consistent 
with observations from the current study showing that tiliroside reduced p38 
signalling in LPS/IFN-treated BV2 microglia.  
The toll-like receptor 4 (TLR4) plays a critical role in the induction of 
neuroinflammatory responses in the microglia (Takeda & Akira 2004). Excessive 
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activation of TLR4 leads to the accumulation of cytotoxic factors and pro-
inflammatory cytokines. Membrane-bound TLR4 could be activated by inflammatory 
stimuli such as bacterial lipopolysaccharide (LPS). Following TLR4 activation, the 
TRAF6 complex becomes activated. This activated TRAF6 further culminates in the 
activation of the p38 MAPK and NF-B signalling pathways. This study established 
that tiliroside prevents the activation of TLR4, suggesting that tiliroside interferes with 
TLR4-mediated neuroinflammatory signalling in the microglia. This study also 
showed that tiliroside reduced the activation of TRAF6 in LPS/IFN-stimulated BV2 
microglia. Earlier, kaempferol was reported to exhibit anti-neuroinflammatory activity 
through the inhibition of LPS-induced TLR4/NF-B and p38 MAPK signalling in 
microglia (Park et al. 2011).  
Activation of the intrinsic antioxidant and anti-inflammatory mechanisms in the 
microglia is crucial in the downregulation of neuroinflammation (Foresti et al. 2013) 
and (Wakabayashi et al. 2010). The Nrf2 signalling is one of the important 
antioxidant pathways in the microglia (Innamorato et al. 2008) and (Pan et al. 2012). 
In normal conditions, Nrf2 is bound to cysteine residues of Keap-1 protein in the 
cytoplasm. In response to oxidative stress, these cysteine residues get modified 
enabling translocation of Nrf2 into the nucleus, where it will bind to cis-acting 
antioxidant responsive element (ARE). This initiates the activation of ARE-dependent 
detoxifying genes such as HO-1 and NQO1. In this study, tiliroside increased 
endogenous expression of HO-1and NQO1 in the microglia. In addition, tiliroside 
increased nuclear translocation and DNA binding of Nrf2 to the ARE-dependent 
genes in BV2 microglia. This study also showed that Nrf2 activation is required for 
tiliroside to inhibit pro-inflammatory cytokines and NF-B activity in activated 
microglia. These observations suggest that tiliroside might be directly activating Nrf2 
protein or may be targeting Nrf2/Keap1 interaction in the cytoplasm to inhibit 
neuroinflammation. This is the first report linking the neuroinflammation inhibitory 
property of tiliroside in LPS/IFN-activated microglia to Nrf2 activity. 
Neuroinflammation-related neurotoxicity contributes to the development of 
neurodegenerative diseases like AD, PD, HD and ALS (Block et al. 2007). Pro-
inflammatory mediators such as TNFα, IL-1β and IL-6 released by activated 
microglia are shown to induce damage to adjacent neurons. TNFα released by 
activated microglia promotes neuronal damage by inhibiting cell survival 
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mechanisms such as PI3K/AKT pathway and further activates Bcl-2 family members 
Bad, Bax, and caspase-9 (Takeuchi et al. 2006). Also, treatment with IL-1β induced 
activation of caspases and other apoptosis signalling cascades leading to the death 
of neurons via increasing the generation of ROS and DNA fragmentation (Thornton 
et al. 2006) and (Barzilai & Yamamoto 2004). These observations further indicate 
that inflammatory mediators from activated microglia lead to neuronal death. In 
theory, compounds that are shown to inhibit the production of pro-inflammatory 
cytokines like TNF-α, IL-1β and IL-6 would be expected to confer protection against 
neurotoxicity. This study demonstrated that inhibition of pro-inflammatory mediator 
release by tiliroside in the activated microglia increased the viability of HT22 neurons 
by reducing calcium accumulation, ROS generation and DNA fragmentation. From 
this observation, it appears that tiliroside indirectly protects HT22 neurons by 
blocking the inflammatory responses in the activated microglia. Similar results were 
obtained in studies conducted by Lee et al., which revealed that tiliroside isolated 
from Agrimonia eupatoria (Rosaceae) exhibits neuroprotective activity against 
glutamate-induced toxicity in HT22 neurons. 
In the current research, pharmacologically relevant doses were used to assess the 
neuroinflammation inhibitory actions of tiliroside against activated BV2 microglia. 
However, these doses may not be physiologically achievable in in vivo experiments 
due to various reasons. For example, the concentrations of a compound that cells 
are exposed to in vivo depends on diverse factors including the pharmacodynamic 
and pharmacokinetic properties of that compound. Also, the efficacy of the 
compound in in vivo depends on the bioavailability, first pass effect and how well the 
compound crosses the blood-brain barrier. On the other hand, it is merely impossible 
to convert pharmacological doses (ex: micro molar) to physiologically achievable 
doses (ex: mg/kg). The only way to investigate the activity of the compound in in vivo 
is to perform a wide range of efficacy dose selection experiments such as rodent 
toxicity studies by following some strict guidelines. 
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Figure 6.1 Proposed mechanism of actions of tiliroside in BV2 microglia that were 
stimulated with the combination of LPS and IFN. LPS: Lipopolysaccharide, IFN: 
Interferon gamma, TLR4: Toll-like receptor 4, TRAF6: TNF receptor associated factor 6, IKK: 
IκB kinase, MKK3/6: Mitogen-activated protein kinase kinase 3/6, MK2: MAP kinase-
activated protein kinase 2, TNFα: Tumor necrosis factor alpha, IL-1β: Interleukin 1 beta, IL-
6: Interleukin 6, COX: Cyclooxygenase, PGE2: Prostaglandin E2, iNOS: inducible Nitric 
oxide synthase, NO: Nitric oxide, Nrf2: nuclear factor erythroid 2 related factor 2, HO-1: 
Heme oxygenase 1, NQO1: NAD(P)H dehydrogenase [quinone] 1, ARE: antioxidant 
response element. 
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Conclusion 
Tiliroside protected BV2 microglia from LPS/IFN-induced neuroinflammation by 
targeting NF-B and p38 MAPK signalling. In addition, tiliroside activated Nrf2 
antioxidant mechanisms in the microglia, an effect which may be contributing to the 
anti-neuroinflammatory activity of the compound. This study also established that 
tiliroside protects HT22 neurons from neuroinflammation-induced toxicity. 
Suggestions for the future studies 
So far, this study answered several research questions regarding the anti-
neuroinflammatory potentials of tiliroside. However, further mechanistic studies are 
required to explore the novel actions of tiliroside against neuroinflammation.  
Activated TLR4 signalling triggers PI3K/AKT signalling in the microglia, indicating 
that its induction might increase neuroinflammatory responses. This study 
established that tiliroside inhibits TLR4 signalling in the activated microglia. 
Therefore, it would be useful to determine the effects of the compound on PI3K/AKT 
signalling pathway in activated microglia. 
Neuroinflammation-related neurotoxicity contributes to the development of 
neurodegenerative diseases like Alzheimer’s diseases. Tiliroside exhibited 
neuroprotective effects by blocking neuroinflammation-mediated toxicity in HT22 
neurons. Further experiments are needed to explore possible effects of tiliroside on 
critical targets of amyloidogenesis, tauopathies and synucleinopathies using various 
animal models.  
It is evident that BBB represents a major obstacle for the compounds to enter CNS. 
Therefore, it is crucial to investigate the capability of tiliroside to cross BBB using in 
vitro models such as Human Brain Endothelial Cell Line (HCMEC/D3) cell line. 
Current research revealed the neuroinflammation inhibitory effects of tiliroside in 
various cellular models of the brain. However, a very limited information is available 
regarding the pharmacokinetic and pharmacodynamic profile of tiliroside in humans 
or animals. Therefore, further in vivo experiments are needed to assess the 
metabolism, absorption, distribution and elimination of tiliroside. For instance, male 
Sprague-Dawley rats will be administered with tiliroside. The metabolised and 
distributed aglycones can be measured from blood, plasma and urine samples.  
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